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Increasing knowledge exists about the mechanisms involved in the pathogenesis of B-
cell chronic lymphoproliferative disorders (B-CLPD). Generally, tumor cell survival and/or 
proliferation depend both on the genetic abnormalities of neoplastic cells and the tumor 
microenvironment. Therefore, the development and widespread of molecular techniques for 
the characterization of both tumor cell genetic alterations and B-cell receptor (BCR) features, 
have been pivotal in the understanding of B-CLPD. As a consequence, chronic lymphocytic 
leukemia (CLL) is now considered as the prototype for several B-cell diseases where 
microenvironmental interactions, rather than a specific genetic abnormality, are critical in the 
onset, expansion and even progression of the disease, in at least a fraction of cases. Thus, a 
biased repertoire of the immunoglobulin heavy chain variable region (IGHV) genes with a 
particular mutational status, or even closely homologous antigen (Ag) binding sites among 
otherwise unrelated cases (“stereotyped” BCR), is generally considered as evidence for the 
involvement of a limited set of Ags, superantigens or both, in the development of CLL, 
fostering research about the early phases of the disease, e.g. monoclonal B-cell lymphocytosis 
(MBL). In this regard, flow cytometry has facilitated the identification of MBL cases with 
(MBLhigh) or without (MBLlow) absolute B-lymphocytosis which precedes most CLL cases, 
allowing the investigation of potential mechanisms involved in the transition from such MBL 
precursor states to overt CLL. Since tumorigenesis is a multi-step process, the first 
transforming events may occur at earlier stages, either directly in the normal counterpart of a 
CLL cell or perhaps, even in the hematopoietic stem cell compartment of CLL patients.  
In order to address this issue, in the present doctoral thesis we investigated multiple 
phenotypic and BCR features of clonal B-cells and their microenvironment in a relatively large 
series of MBL, CLL/B-CLPD clones, from both monoclonal and multiclonal cases. In order to 
explore whether particular Ag could be involved in specific cytogenetic pathways during early 
oncogenesis, we first investigated the potential association between unique cytogenetic 
profiles and specific IGHV repertoires. In a second step, we compared the BCR and cytogenetic 
features of B-cell clones from monoclonal vs. multiclonal cases to determine whether or not 
the latter were associated with a higher BCR homology, potentially reflecting occurrence of B-
cell mediated immune responses. Finally, we compared the features of stereotyped vs. non-
stereotyped MBL and CLL cases.   
Overall, we detected three major groups of clones with distinct but partially 
overlapping patterns of IGHV gene usage, mutational status and cytogenetic alterations: 1) a  
group enriched in MBLlow clones expressing specific IGHV genes (e.g. VH3-23) with no or 
isolated good-prognosis cytogenetic alterations; 2) a group which mainly consisted of MBLhigh 
and advanced stage CLL with a skewed, but different, IGHV gene repertoire (e.g. VH1-69), 
Abstract 
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often associated with complex karyotypes and poor-prognosis cytogenetic alterations, and; 3) 
a group with intermediate features, prevalence of mutated IGHV genes and higher numbers of 
del(13q)+ clonal B-cells. Altogether, these results suggest that BCR features of CLL-like B-cell 
clones may modulate the type of cytogenetic alterations acquired by the transformed cell, 
their rate of acquisition, and potentially also, their clinical consequences.  
As referred above, recent findings support the existence of underlying chronic B-cell 
stimulation by a restricted set of epitopes in CLL. In line with this, expansion of ≥2 B-cell clones 
has been frequently reported in B-CLPD, mainly in MBL, which could be an epiphenomenon of 
a chronic and persistent antigenic stimulation. Thus, we hypothesized that multiclonality could 
be associated with particular BCR features indicating a greater probability of interaction with 
shared immunological determinants. Comparative analysis of CLL-like and non-CLL-like B-cell 
clones from multiclonal vs. monoclonal MBL, CLL/B-CLPD cases showed clonotypic BCR of 
multiclonal cases have a slightly higher degree of HCDR3 homology, together with unique 
hematological and cytogenetic features, which are typically associated with earlier disease 
stages. Among these cases a subgroup of phylogenetically related (coexisting) B-cell clones 
which displayed unique molecular and cytogenetic features, was identified. Altogether, these 
results would support the Ag-driven nature of such multiclonal B-cell expansions and the 
potential involvement of multiple epitopes in promoting the development of MBL and favor 
their progression into full disease (e.g. CLL). However, the scenario in which these events 
occur, remains unknown.  
In order to gain insight into the above scenario in the last part of our work we further 
investigated the potential relationship between an altered/clonal hematopoiesis and antigenic 
driving forces, during the expansion of stereotyped vs. non-stereotyped CLL and CLL-like MBL 
clones. Overall, former cases more frequently used IGHV1 rather than IGHV3 genes, together 
with longer HCDR3 and unmutated IGHV sequences. The overall size of the stereotyped B-cell 
clones in peripheral blood (PB) did not appear to be associated with their cytogenetic profile 
but it was more closely related to presence of myelodysplasia-associated immunophenotypes 
on PB myeloid cells. Such unique association suggests that the emergence and/or expansion of 
CLL-like B-cell clones in these stereotyped cases could be favored by an underlying altered 
hematopoiesis. 
In conclusion, our results highlight the potential involvement of different Ag-driven 
pathways in the early stages of development of MBL and transformation to CLL, where BCR 
recognition of multiple epitopes together with the co-existence or not of an underlying altered 
hematopoiesis, would modulate further patterns of acquisition of cytogenetic alterations in 
the pathway to CLL, through different transitional stages from multiclonal MBL to monoclonal 
CLL clones carrying more complex cytogenetic profiles. 
  
 
 5 
 
 
 
 
Hoje o conhecimento dos mecanismos envolvidos na patogenia das doenças 
linfoproliferativas crónicas de célula-B (B-CLPD) assume uma importância crescente. De forma 
geral, a sobrevivência e/ou proliferação da célula tumoral depende tanto das anomalias 
genéticas das células neoplásicas como do microambiente tumoral. Neste sentido, o 
desenvolvimento generalizado de técnicas moleculares para a caracterização quer das 
alterações genéticas presentes nas células tumorais, quer das características do recetor das 
células B (BCR), mostrou-se fundamental. Como consequência, a leucemia linfocítica crónica 
(CLL) é hoje considerada como o protótipo para várias doenças de células B em que as 
interações com o microambiente, mais que a presença de uma anomalia genética específica, 
são cruciais no surgimento, expansão ou mesmo na progressão da doença, em pelo menos 
uma fração dos casos. Neste sentido, a existência de um repertório de genes da região variável 
da cadeia pesada da imunoglobulina (IGHV) tendencioso juntamente com um estado 
mutacional particular e a recente identificação em casos não relacionados de locais de ligação 
ao antigénio (Ag) praticamente homólogos (BCR “estereotipados") é, regra geral, indicativo do 
envolvimento de um conjunto limitado de Ags, superantigénios ou ambos, no 
desenvolvimento da doença, fomentando a investigação das fases iniciais da mesma, p.e., 
através do estudo da linfocitose monoclonal de células B (MBL). Por isso, a citometria de fluxo 
veio facilitar a identificação de casos de MBL com (MBLhigh) ou sem (MBLlow) linfocitose B 
absoluta, a qual precede a maioria dos casos de CLL, permitindo assim a investigação de 
potenciais mecanismos envolvidos na transição de tais estados precursores tipo MBL, para CLL. 
Uma vez que a tumorigénese consiste num processo em várias etapas, os primeiros eventos 
transformantes podem ainda ocorrer em etapas mais precoces, quer diretamente na 
contrapartida normal da célula de CLL ou talvez, mesmo no compartimento de células 
estaminais hematopoiéticas de doentes com CLL. 
Para resolver esta questão, na presente tese de doutoramento investigámos múltiplas 
características fenotípicas e do BCR de células B clonais assim como do seu microambiente, 
numa série relativamente ampla de clones MBL, CLL/B-CLPD, tanto de casos monoclonais 
como multiclonais. De forma a explorar se determinados Ags poderão estar envolvidos em vias 
citogenéticas específicas durante as fases inicias do processo oncogénico, na primeira parte do 
estudo, focámos o nosso interesse na potencial associação entre determinados perfis 
citogenéticos e repertórios IGHV específicos. Num segundo passo, foram comparadas as 
características do BCR e as alterações citogenéticas dos clones de células B de casos 
monoclonais vs. casos multiclonais para determinar neste último grupo de doentes, a possível 
existência de uma maior homologia nos BCR que fosse potencialmente indicadora da 
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ocorrência de respostas imunes mediadas por células B. Por fim, comparámos as 
características dos casos com clones MBL e CLL estereotipados vs. não estereotipados. 
De uma forma geral, foram detetados três grupos principais de clones com padrões 
distintos, mas parcialmente sobrepostos, relativamente ao uso dos genes IGHV, ao estado 
mutacional desses genes e às alterações citogenéticas: 1) um grupo enriquecido em clones 
MBLlow expressando genes IGHV específicos (p.e. VH3-23) sem alterações citogenéticas ou com 
alterações isoladas de bom prognóstico; 2) um grupo principalmente constituído por clones 
MBLhigh e estágios avançados de CLL com um repertório IGHV restrito, mas diferente (p.e., 
VH1-69), muitas vezes associado com cariótipos complexos e alterações citogenéticas de mau 
prognóstico, e; 3) um grupo com características intermédias, com prevalência de genes IGHV 
mutados e com números mais elevados de células clonais B del(13q)+. Estes resultados 
sugerem que as características do BCR de clones de células B com fenótipo de CLL podem 
modular o tipo de alterações citogenéticas adquiridas pela célula transformada, a sua taxa de 
aquisição, e eventualmente também, as suas consequências clínicas. 
Tal como referido anteriormente, os resultados recentes apoiam a existência em 
doentes com CLL, de uma estimulação crónica subjacente das células B por um conjunto 
restrito de epítopos. Neste sentido, expansões de ≥ 2 clones de células B têm sido 
frequentemente relatadas em B-CLPD, principalmente na MBL, a qual parece constituir um 
epifenómeno de estimulação antigénica crónica e persistente. Assim, foi colocada a hipótese 
de a multiclonalidade se encontrar associada com características particulares do BCR indicando 
uma maior probabilidade de interação com determinantes imunológicos partilhados. A análise 
comparativa de clones de células B com fenótipo de CLL e com fenótipo não-CLL de casos de 
MBL, CLL/B-CLPD multiclonais vs. monoclonais mostrou que, nos casos multiclonais o BCR 
clonotípico apresenta um grau ligeiramente maior de homologia de HCDR3, juntamente com 
características hematológicas e citogenéticas únicas, que estão tipicamente associadas com os 
estágios iniciais da doença. De entre estes casos foi ainda identificado um subgrupo de clones 
de células B (coexistentes) filogeneticamente relacionados que exibiam características 
moleculares e citogenéticas únicas. No seu conjunto, esses resultados apoiariam a natureza de 
tais expansões de células B multiclonais associada ao Ag e o potencial envolvimento de 
múltiplos epítopos em promover o desenvolvimento da MBL e favorecer a sua progressão para 
doença (p.e., LLC). No entanto, o cenário no qual podem ocorrer esses eventos permanece 
desconhecido. 
De forma a ganhar um maior conhecimento acerca deste cenário, na última parte do 
nosso trabalho, investigamos ainda a potencial relação entre uma hematopoiese alterada/ 
clonal e o estímulo antigénico durante a expansão dos clones de CLL e MBL estereotipados vs. 
não estereotipados. No geral, os casos estereotipados exibiam mais frequentemente genes 
IGHV1 em vez de IGHV3, juntamente com sequências HCDR3 mais longas e genes IGHV não 
mutados. O tamanho dos clones de células B estereotipados no sangue periférico (PB) não 
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mostrou estar relacionado com o seu perfil citogenético, mas sim com a presença de 
imunofenótipos associados com mielodisplasia em células mielóides do PB. Tal associação 
particular sugere que o surgimento e/ou expansão de clones de células B de CLL nestes casos 
estereotipados pode ser favorecido por uma hematopoiese alterada subjacente. 
Em conclusão, os nossos resultados destacam o potencial envolvimento de diferentes 
vias induzidas pelo Ag nos estágios iniciais de desenvolvimento da MBL e de transformação 
para CLL, onde o reconhecimento de múltiplos epítopos pelo BCR, juntamente com a 
coexistência ou não de uma hematopoiese alterada subjacente, poderão modular os padrões 
de aquisição de alterações citogenéticas na patogénese da CLL, através de diferentes vias de 
transição desde os estágios de MBL multiclonal até aos clones de CLL monoclonal com perfis 
citogenéticos mais complexos. 
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Chapter 1 INTRODUCTION 
B-cell chronic lymphoproliferative disorders (B-CLPD) are a heterogeneous group of 
diseases with a highly variable clinical course.1 Despite the well-defined clinical, biological and 
histopathological features of the distinct World Health Organization (WHO) clinical entities, the 
specific factors associated with the ontogeny of these disorders still remain largely elusive.  
As in other tumors, chromosomal and molecular/genetic alterations, particularly those 
genetic mutations and chromosomal translocations involving the immunoglobulin (Ig) heavy 
chain genes and to a lower extent also the light chain gene loci, and their distinct partnering 
proto-oncogenes, are a hallmark of many types of B-cell lymphoma.2 In recent years, 
important progress has been made as regards the identification of oncogenic mutations – e.g. 
BRAF and MyD88 gene mutations in hairy cell leukemia (HCL)3 and lymphoplasmacytic 
lymphoma (LPL),4 respectively – and chromosomal translocations – e.g. t(11;14) in mantle cell 
lymphoma (MCL)5 –. However, for other B-CLPD such as B-cell chronic lymphocytic leukemia 
(CLL), despite extensive research has been done, no universal oncogenic alteration has been 
identified thus far.6 In this regard, several factors other than genetic/chromosomal alterations 
have also been associated with the ontogenesis of specific subtypes of B-CLPD. Concerning 
this, tumor cells from most chronic B-cell leukemias and non-Hodgkin B-cell lymphomas (B-
NHL) express a unique B-cell receptor (BCR) molecule and in several B-cell malignancies, 
antigen (Ag) activation of tumor cells through BCR signaling seems to be an important factor in 
the pathogenesis of the disease.7 For example, It has been hypothesized that chronic antigenic 
stimulation could drive CLL development,8,9 as it has also been proposed for indolent B-cell 
lymphomas that are supposed to derive from the marginal zone – e.g. gastric lymphomas of 
mucosa-associated lymphoid tissue (MALT) –. The latter lymphomas are commonly associated 
with chronic antigenic stimulation either as a result of infection (e.g. Helicobacter pylori in the 
stomach) or autoimmune responses/disease in other MALT lymphomas (e.g. Sjögren syndrome 
and salivary glands lymphoma).10  
Immunogenetic analyses of the tumor cell BCR have provided new insights into the 
ontogenic relationship between B cell malignancies and Ags that they might interact with 
within their tissue of origin.11,12 Thus, a biased IG gene repertoire is seen as evidence for an 
underlying selection of progenitor cells by Ag in diseases such as CLL or marginal zone 
lymphoma (MZL). Additional evidence is provided by the differential prognosis of cases with 
distinct mutational status of the clonotypic BCR in CLL, and the existence of subsets of patients 
with highly-selected or even quasi-identical (e.g stereotyped) BCR, which account for up to 
around one-third of all CLL cases.13 These observations have been instrumental in shaping the 
notion that the ontogeny and progression of CLL are functionally driven and dynamic, rather 
than a simple stochastic process.  
 14 
 
Chapter 1 INTRODUCTION 
Interestingly, a precursor condition for B-CLPD, particularly for CLL, has been identified 
as a premalignant state: monoclonal B-cell lymphocytosis (MBL) with (MBLhigh; high count MBL) 
or without (MBLlow; low count MBL) absolute B-lymphocytosis in PB.14 Extensive research 
performed in recent years in MBL has also contributed to a better understanding of the 
mechanisms involved in the genesis of lymphoma/leukemia and the identification of those 
factors involved in the transition from a B-cell lymphoma/leukemia precursor state to an overt 
lymphoproliferative disorder. Thus, most MBL cases are characterized by the presence of 
circulating monoclonal B-cells, which have an immunophenotypic profile that fully overlaps 
with that of CLL (CLL-like MBL).15,16 At present, the precise factors and the likelihood of MBL to 
progress to CLL over time are still largely unknown. In this regard, the overall prevalence of 
MBL, which is significantly greater than that of CLL, is consistent with the expectation that 
most MBL will not progress to CLL; even more, for MBLlow, progression appears very unlikely,17 
while for MBLhigh the risk of progression to CLL requiring therapy is of approximately 1% per 
year.16,18 In turn, it has also been shown that many MBL are oligoclonal based on interphase 
fluorescence in situ hybridization (iFISH) but also on single cell Ig sequence analyses;15,19 in 
contrast, only around 5% of the B-CLPD display two phenotypically distinct populations of 
clonally unrelated B lymphocytes coexisting in the same patient, either simultaneously or at 
different time points during follow-up.20,21 Such particularly high prevalence of multiclonality at 
the earliest stages of MBL (≥20% vs. 5%), would further support the potential reactive nature 
of MBL among individuals with normal lymphocyte counts, prior to stepwise acquisition of 
genetic alterations and progression to MBLhigh and CLL;22-24 such a model could be similar to 
that occurring in other cancers, indicating that development of CLL might be initiated at a 
polyclonal B-cell population, one clone progressively taking over. Consequently, the evolution 
from a reactive to a neoplastic expansion of MBL clones, and their transformation to CLL, 
might provide a model for the development of CLL, where analyses of IG genes and the 
associated cytogenetic profiles can assist in better understanding the precise mechanisms 
leading to the genesis of the tumor and its malignant transformation. 
In this section, we will first review the BCR structure and repertoire, along the B-cell 
differentiation; afterward, we will focus on the major features of distinct WHO subtypes of B-
CLPD, particularly of CLL and MBL, and their monoclonal vs. multiclonal nature. 
 
  
 15 
 
Chapter 1 INTRODUCTION 
1. B-CELL ANTIGEN RECEPTOR 
  
1.1. Basic structure of the B-cell receptor 
 
The BCR for Ags consists of two monomeric molecules: the Ig responsible for Ag 
binding and CD79 which delivers intracellular signals for B-cell activation. Igs are heterodimer 
molecules composed of two heavy (H) and two light (L) chains (Figure 1).25,26 Each H and L 
chain consists of a variable (V) domain, which binds to the Ag, and between one and four 
constant (C) domains, which carry out the effector function of that chain. Diversity is 
asymmetrically distributed within the V domain, each V domain containing three segments of 
higher variability which form those loops recognizing the Ag termed complementarity 
determining regions (CDR); CDR are separate one from each other and from the external 
sequences by  four conserved sequences, known as the framework regions (FR) (Figure 1).27 
Two of the CDR loops are encoded by the V genes (CDR1 and CDR2) whereas the third, and 
most polymorphic one, is encoded by the junction between the rearranged V, (D) and J genes. 
The four FR of both the H and L Ig chains fold to form the scaffold that brings together the 
three H chain and the three L chain CDRs to create the Ag binding site in the 3-dimensional 
structure.26 
Through the transmembrane and intracellular domains of their H chains, Igs are linked 
in the B-cell membrane to CD79a and CD79b, to form the functional BCR. CD79 is a disulphide-
linked transmembrane heterodimer which belongs to the immunoglobulin superfamily and 
that is responsible for the transduction of BCR signals, upon Ag recognition by B cells. 
Figure 1. Schematic diagram of the structure of the genetic loci of the immunoglobulin heavy and light (λ and κ) 
chain genes [adapted from Zakharova et al.
28
]. 
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1.2. The B-cell receptor repertoire 
 
Signaling through the BCR is required throughout B cell development, as well as during 
peripheral B-cell maturation and for the selection of the B-cell repertoire. Additionally, the 
avidity and the context in which Ag is encountered will determine both cell fate and 
differentiation in the periphery, once the Ig genes are further diversified during immune 
responses.29,30 Consequently, the study of the BCR repertoire by sequence analysis of Ig heavy 
and light chain gene transcripts can refine the categorization of B cell subpopulations and can 
shed light on the selective forces that act during aging, immune responses (e.g. infections) or 
immune dysregulation that result from B-CLPD.31,32 In contrast to nearly all other proteins, the 
components of Ig molecules are not encoded by germline DNA. The genetic elements in the Ig 
loci, the Variable (V), Diversity (D) and Joining (J) genes, need to be rearranged to encode a 
functional protein essentially through processes of V(D)J recombination, exonuclease trimming 
of germline genes, and the random addition of nucleotides that are not encoded in a DNA 
template. In the IGH locus, one of each V, D and J genes are randomly coupled to form a 
functional exon while similar rearrangements are initiated between one V and one J gene 
segment in the IGK and IGL loci.33,34  
While somatic point mutations have given B cell studies a major focus on variable 
(IGHV, IGLV, and IGKV) genes, D genes identified in BCR VDJ rearrangements allowed the 
processes and elements that contribute to the incredible diversity of the Ig heavy chain CDR3 
(HCDR3) to be analyzed in detail. Such diversity is in contrast with that of the light chain where 
a small number of polypeptide sequences dominate the repertoire.35 
 
1.2.1. Germline immunoglobulin genes and lymphocyte diversity 
 
The variable locus of the IG gene consists of multiple genes which have evolved 
through gene duplication in order to generate a diverse germline repertoire.36 Analysis of 
homology among the V gene segments has revealed that these can be grouped in discrete V 
gene families,37,38 which can further be regrouped in clans39 which reflect the earliest events of 
gene duplication in the evolution of the IG locus.40,41 The organization in multiple copies of 
variable genes, plus the somatic processes of recombination and hypermutation, allow the 
immune system to generate an antibody repertoire of great diversity. Moreover, selective 
pressures have shaped the evolution of the germline genes of the Ig. The nature of these 
selective forces is still a matter of controversy.42  
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Analysis of nucleotide and amino acid (aa) substitutions at the coding region of the V 
genes has shown that the regions involved in the interaction with the Ag present high 
variability, in contrast to the remaining relatively conserved FRs, pointing out that different 
selective forces act over these two regions.36,42,43 Evaluation of other aspects like 
polymorphisms,36,44,45 sequence variability46,47 and phylogeny39,40,48 has provided additional 
evidence of selective forces acting over V genes in order to shape their variability. In fact, 
current knowledge about the germline genes is far from being complete; this is due in part, to 
the complexity of the loci, where numerous highly similar genes are thought to have evolved 
via gene conversion,49 duplication and divergence,50 and further interspersed with many 
pseudogenes and repetitive elements. 
IGHV genes are by far the longest of the recombining IGH genes, and they are the main 
targets of the mutational machinery.51,52 As it is necessary to be certain of the germline origin 
of mutated sequences, the complete and accurate definition of the set of germline IGHV genes 
and allelic variants should remain clear. The official human IGHV germline gene dataset, 
created by the ImMunoGeneTics (IMGT) group (www.imgt.org), includes 129 functional genes, 
open reading frames (ORF), and pseudogenes, as well as over 200 allelic variants which have 
increased in recent years, as 40 new allelic variants have been reported since 2005.53-56 In turn, 
the 27 human IGHD genes include 25 functional genes, 23 of which are unique.57 The IGHJ 
locus includes 6 functional genes, which are all found downstream of the IGHD locus in a single 
cluster.  
 
1.2.2. Biases in combinatorial and junctional diversity and shaping of the BCR 
repertoire  
 
Many BCR repertoire studies which have utilized different sets of primers, and 
amplified different source materials, are surprisingly consistent with the occurrence of strong 
gene utilization biases. Some data show that segments in the V3 family are most frequently 
used (namely the IGHV3-23 gene), followed in descending order by V4, V1, V5, V2, V6, and 
lastly V7.58 Different IGHV genes are used at frequencies that range from 0.1% to more than 
10% of all rearrangements in an individual’s naïve B-cell repertoire, their relatively frequency 
also varying between alleles.59,60  
 Frequencies of usage of some IGHV families are surprisingly constant among different 
individuals (e.g. IGHV1-46, IGHV3-21 and IGHV3-49),61 while IGHV1-69 varies at frequencies 
that range from 3.1 to 9.1% (average 6.2%).59 Biased gene usage is not confined to the IGHV 
genes since IGHD gene usage also varies from < 1% (e.g. IGHD4-4/11) to > 15% (e.g. IGHD3-22) 
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of total rearrangements.62 For each D segment, there is one reading frame (RF) encoding 
predominantly hydrophilic aa residues (specially tyrosine and serine; RF1), followed by a 
hydrophobic RF (RF2), and lastly, a third RF that often encodes a stop codon (RF3). Thus, the 
RF3 can be used only if either somatic mutations or nucleotide losses during VDJ 
recombination delete the germline stop codon. Finally, there is also considerable variation 
between the frequencies of usage of IGHJ genes (e.g. IGHJ4 gene is present in approximately 
45–50% of rearrangements, IGHJ6 accounts for 20–25% of VDJ rearrangements63,64 and IGHJ1 
is only used by 1% of all rearrangements).65 
In a similar way, analysis of IGK rearrangements from sequence databases also showed 
a preferential gene usage with under- and over-utilization of the different JK gene segments,66 
while the IGLV usage is strongly skewed toward a limited number of the functional V segments 
with 3 of the 30 IGLV accounting for > 50% of the expressed rearrangements.67 Only four of the 
seven IGLJ are considered functional68 and their frequencies range from almost 55% of the 
expressed B-cell repertoire for IGLJ7, to just 5.5% for IGLJ1.69 
On the other hand, variations in the recombination signal sequences (RSS) also 
influence the frequencies of BCR gene usage, while they cannot explain all differences in allele 
utilization.70-72 In addition to the underlying biases in utilization of germline genes, a final bias 
has been identified that affects the contribution of recombination frequencies to repertoire 
diversity. For reasons that still remain unclear, the analysis of 6,500 IGH VDJ sequences 
collected from public databases appears to confirm pairing preferences for some IGHD and 
IGHJ genes that increase the frequency of particular IGHD-IGHJ pairs within the repertoire (i.e. 
IGHD2-2 and IGHD3-3 with IGHJ6, and of IGHD3-22 with IGHJ3).64,73 In addition, biases in the 
pairing of germline heavy and light chain genes have been also described in early studies;74 
however, such germline heavy and light chain gene pairing preferences were not supported by 
later studies,75,76 including a recent study that applied high-throughput sequencing to generate 
thousands of linked heavy and light chain gene sequences.77 
On top of all the above, at present it is also well established that N (non-germline 
encoded) nucleotides contribute significantly to the diversity of the BCR repertoire.78 Non-
template encoded N-additions are intrinsically biased owing to the nucleotide preferences of 
the terminal deoxynucleotidyl transferase (TdT) enzyme toward the incorporation of guanine 
(G) nucleotides; such TdT preference by G nucleotides ensures that the germline gene-
encoded regions of the CDR3 are frequently flanked by small aa encoded by G-rich codons 
such as glycine, that promote flexibility of the CDR3 loop.79 Exonuclease trimming which 
results in the loss of nucleotides from the coding ends of the genes during rearrangement is 
perhaps the least understood process that contributes to the BCR repertoire, but a number of 
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features of the process have been described, and intrinsic biases have been identified.80 In this 
regard, it seems that sequences enriched in adenine (A)/thymine (T) might be more 
susceptible to nucleotide loss, while G/cytosine (C) enriched sequences would be more 
resistant to processing.81-84 The gene sequence ends that remain after exonuclease processing 
provide a final bias that shapes the repertoire. 
Without the added diversity that comes from D genes, the kappa and lambda 
repertoires would be strongly shaped by biased gene usage and minimal processing giving rise 
to repertoires with a surprisingly limited diversity. 
 
 
2. B-CELL ONTOGENY 
 
B cells are generated throughout life from long-lived and self-renewing hematopoietic 
stem cells (HSC) in the bone marrow (BM). B-cell maturation occurs in two clearly defined 
stages which are localized in different tissues: Ag‑independent precursor B‑cell differentiation 
from an HSC to naïve mature B-lymphocytes occurs in the BM,85 whereas Ag-dependent B-cell 
maturation to memory B-cells and effector plasma cells takes place mostly in secondary 
lymphoid tissues, e.g. lymph nodes (LN), MALT, BM and spleen (Figure2).86 
Figure 2. Antigen-independent B-cell differentiation occurs in the bone marrow, whereas Ag-dependent B-cell 
differentiation occurs in the periphery. The immunophenotypic profile of the distinct human B-cell differentiation 
stages including V(D)J recombination bars are shown for both the BM and peripheral B-cell differentiation pathways  
 [adapted from Vinuesa, et al.
87
 and Perez-Andres, et al.
88
]. 
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2.1. Antigen independent B-cell differentiation in the bone marrow  
 
Differentiation of B cells from early committed progenitors to mature B-lymphocytes is 
a multistep maturation process that can be monitored by the coordinated acquisition and loss 
of leukocyte differentiation Ags and the status of rearrangement of the IGH and IGL genes 
(Figure 2). The major goal of precursor B-cell differentiation to mature B-lymphocytes is to 
generate a functional Ig receptor via an ordered V(D)J recombination of the genes encoding 
the Ig heavy (IgH) and the Ig light (Igk or Igʎ) chains. Double stranded (ds)DNA breaks at the V, 
D and J gene segments are induced by the recombinase activating gene proteins products 1 
and 2 (RAG1 and RAG2) that specifically recognize short conserved DNA sequences termed 
RSS.89 The first gene rearrangements that occur during precursor B-cell differentiation involve 
D to J rearrangements in the IGH locus.90,91 These rearrangements are generally initiated in 
parallel on both IGH alleles.92 Subsequently, only one of the alleles starts complete V to DJ 
rearrangements, whereas the second one only rearranges V to DJ when the first allele is not 
successful, e.g. if there is no functional IgH protein. In the majority of precursor B cells, V to J 
gene rearrangements in the IGK and IGL loci are initiated only after a functional IgH protein is 
formed. Still, it has been demonstrated that a minor fraction of pro-B cells can rearrange IGL 
genes before the assembly of a productive IGH.93,94 
Based on the order of IG gene rearrangements, precursor B-cells are classified into 
distinct stages of maturity (Figure 2). Thus, pro-B-cells represent the first committed B-cell 
precursors,95,96 which can be distinguished from pre-pro-B-cells by surface expression of CD19, 
upon expression of Pax5.97 In these cells, the Igα–Igβ heterodimer (CD79a/CD79b) is expressed 
on the cell surface in association with calnexin and potentially also other chaperone 
molecules.98 
D to J rearrangement in the IGH locus is initiated in the pre-pro-B-cells and continues 
with V to DJ rearrangement at the pro-B cell stage. The pre-BCR is not required for lineage 
commitment and the initiation of recombination but, this is rather dependent upon the 
intrinsic expression of two main transcription factors, E12 and E47,99 and the transcription 
factor EBF (early B-cell factor),100 which have been shown to up-regulate expression of the B-
cell-specific genes λ5, VpreB, Igα/CD79a and Igβ/CD79b, as well as of the lymphoid-specific 
RAG-1 and RAG-2, and the B-cell-specific transcription factor Pax5 or BSAP (B-cell-specific 
activator protein).101-103 Lineage commitment is enforced at the pro-B-cell stage by Pax5, which 
both activates B-cell-specific genes (including BLNK, CD19 and Igα/CD79a) and represses the 
expression of other non-B-lineage genes (including Notch1).104,105 
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Early B-cell development is not entirely intrinsically regulated by the future B-cell 
precursor, as signalling through the interleukin-7 (IL-7) receptor is required to generate pro-B-
cells.106 IL-7 signalling also induces pro-B-cells to proliferate and expand, and it has been 
shown to up-regulate expression of CD19 and Pax5.107,108 
Surface expression of a signalling-competent pre-BCR, containing an in-frame V(D)J 
rearrangement of the Ig heavy chain, allows progression from the pro-B-cell to the pre-B-cell 
stage; the pre-B cell stage is the first stage at which BCR signalling becomes required. 
Appropriate pre-BCR signalling results in allelic exclusion at the heavy-chain locus, at the same 
time it leads to parallel changes in the phenotype of developing B-cells;109 cells become larger 
as they undergo a proliferative burst of two to five cycles and become more responsive to IL-
7.110,111 After proliferation, cells enter the small pre-B stage, where they down-regulate HSA 
(heat stable Ag), CD43 and IL-7R, becoming IL-7 unresponsive. Then, they begin the process of 
light chain rearrangement, first at the kappa locus and then at the lambda locus.112 
Upon light-chain rearrangement, heavy and light chains are co-expressed on the cell 
surface, in association with Igα/CD79a and Igβ/CD79b, to form a functional Ig receptor; 
subsequently, the new B cell will be positively selected and will become an immature B-
lymphocyte. The new IgM+ IgD– immature B-lymphocytes frequently carry autoreactive or 
polyreactive receptors, which need to be removed from the immune repertoire through a BCR 
receptor-mediated negative selection process. These cells are assumed to either undergo 
apoptosis/deletion in response to high-avidity ligands, to become anergic if they encounter 
lower-avidity ligands and unresponsive to Ig receptor crosslinking, or to modify the reactivity 
of the Ig receptor by initiation of a secondary Ig gene rearrangement (receptor editing).113-115 
Of note, short-lived anergic cells down-regulate surface IgM expression and exhibit a 
characteristic intracellular signalling signature in association with a unique gene expression 
profile116 that appears to be maintained throughout chronic engagement of the BCR with low-
avidity ligands. Which of these three tolerance mechanisms is invoked depends on many 
different factors, including receptor affinity, receptor expression levels, developmental stage 
and site of encounter (e.g. ligation of the immature BCR in a BM environment results in 
receptor editing, whereas ligation in a splenic environment induces B-cell deletion).117,118 
Negative selection of cells with polyreactive and autoreactive BCR takes place during 
two checkpoints. Thus, a central checkpoint occurs in the BM and results in the removal of 
cells with both autoreactive and polyreactive BCR. Consequently, the frequencies of 
autoreactive (≈75%) and polyreactive (≈55%) BCR in early immature B-cells decrease to ≈45% 
and <10% among immature B-cells, respectively.119 In turn, a second peripheral checkpoint 
occurs upon B cell migration from the BM to the periphery, and it is mainly directed against 
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the remaining autoreactive BCR which often display long (>20 aa) and positively charged IGH-
CDR3 regions,119 reducing their frequency to ≈20% among naïve mature B-cells.  
 
2.2. Antigen dependent B-cell maturation in the periphery 
 
Following successful Ag-independent differentiation in the BM, B cells migrate to 
peripheral lymphoid organs and recirculate in blood. The cells require external signals for 
survival, which thereby ensure stable homeostasis of the total B-cell pool.86,120 Only those cells 
that recognize their cognate Ag initiate further differentiation and generate memory B-cells 
and antibody-producing plasma cells.86 The maturation pathways will differ depending on the 
anatomic localization of the response (e.g. LN vs. gut, lung or splenic marginal zone) and the 
type of Ag (e.g. protein vs. polysaccharide). 
 
2.2.1. Peripheral distribution and maturation of immature to naïve B cells 
 
Recent BM emigrants are functionally immature, i.e. they do not respond to BCR 
stimulation. Immature B-lymphocytes, also referred as transitional B cells, represent ≈5–10% 
of all B cells in blood of healthy adults and have a characteristic phenotype which includes 
expression of surface membrane (Sm)IgM and SmIgD, CD21, CD22, CD5 and high expression 
levels of CD24 and CD38.121-123 Of note, B lymphocytes leaving the BM consist of cells at 
different maturation stages between the immature and naïve mature B-cell compartments; 
therefore, they typically show heterogeneous features; these cells have unmutated IGHV 
genes, express phenotypic features of immature B-cells, show a lower ability to proliferate and 
differentiate to Ab-secreting cells after in vitro stimulation when compared to naïve mature B-
cells together with a higher κ/λ ratio vs. other PB B-cell subsets.121-124 Of note, the frequency of 
these immature B-lymphocytes in PB seems to increase in autoimmune diseases and other 
immunological diseases (e.g. systemic lupus erythematosus, common variable 
immunodeficiency, X-linked lymphoproliferative disease), as well as during BM regeneration 
after transplantation,125 in parallel to decreased numbers of memory B-cells.121-123 
Maturation into pre-naïve B-cells is accompanied by downregulation of CD38 and CD24 
which makes them partially responsive to BCR stimulation and CD40 ligation. Upon subsequent 
downregulation of CD5, pre-naïve B cells finally become naïve B-cells, which are fully 
responsive to Ag. Naïve B-cells are a relatively frequent B cell compartment in the PB and 
comprise about 60–70% of circulating B-cells; they simultaneously co-express IgM and IgD and 
display unmutated IGV sequences. 
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2.2.2. T-cell dependent and T-cell independent B-cell responses to antigen 
 
B cells respond to Ags which are specifically recognized by their BCR. Upon binding to 
its cognate Ag, the BCR induces downstream signaling through the same pathways as the pre-
BCR, to initiate target gene transcription. The CD19-complex, consisting of CD19, CD21, CD81 
and CD225, is necessary for sufficiently strong signaling.126,127 
In addition to Ag recognition via the BCR and CD19 signaling, B cells require a second 
signal to become activated. Activated T cells can provide such a signal via CD40L that interacts 
with CD40 on B cells. T cell-dependent (TD) B-cell responses are characterized by germinal 
center (GC) formation. In the GC, B lymphocytes undergo extensive proliferation, affinity 
maturation and Ig class switch recombination (CSR).128 Thus, after the GC reaction, high-affinity 
memory B-cells and Ig-producing plasma cells are formed. 
Alternatively, B cells can respond to T cell-independent (TI) Ags that either activate 
them via the BCR and another (innate) receptor (TI type 1 response) or via extensive cross-
linking of the BCR due to the repetitive nature of the Ag (TI type 2 response). The Ags 
triggering TI B-cell responses can be both lipid and carbohydrate structures;129 similarly, the co-
stimulatory receptors include various types of receptors particularly pattern recognition 
receptors, such as Toll-like receptors (TLR) and nucleotide oligomerization domain-like 
receptors (NLR) that have been implicated in TI responses.130,131 Usually, TI responses are 
directed against blood-borne pathogens in the splenic marginal zone and in mucosal tissues 
(reviewed in 132,133). Among other proteins and molecules, the B-cell activating factor (BAFF) 
and the proliferation-inducing ligand (APRIL) protein must likely support TD and TI, as well as 
induction of affinity maturation and Ig CSR.134,135 
 
2.2.3. Somatic hypermutation and Ig class-switch recombination 
 
The Ig variable regions of activated B cells are targets for somatic hypermutation 
(SHM). In this process of SHM, the activation-induced cytidine deaminase (AID) enzyme is a key 
player. AID initiates deamination of cytidine to uracil (U) on single-stranded (ss)DNA through 
preferentially targeting of RGYW and WRCY DNA motifs where R are purine nucleotides, Y are 
pyrimidines, and W is either A or T.136,137 Although SHM can be introduced through the entire 
Ig variable regions, mutations in post-GC cells are preferentially found in the CDR sequences. In 
part, this is due to overrepresentation of AID-targeted RGYW and WRCY DNA motifs in the Ig 
CDR138,139 vs. the FR and other Ig regions,140,141 and results on selection of GC B-cells with higher 
affinity for the target Ag, which will therefore have preferentially mutated CDR3. AID-
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associated mutations in the DNA sequence of the IG gene can either be silent (S) mutations 
with no effect on the aa composition, or replacement (R) mutations which lead to aa 
substitutions. R mutations in the FR regions are likely to impair the Ig structure, and cells that 
acquired these mutations are most frequently removed from the repertoire. In turn, R 
mutations in the CDR regions can have either positive or negative effects on the recognition 
and affinity of the BCR for the Ag. Hypermutated B cells that cannot recognize the Ag undergo 
apoptosis, while those that carry mutations which increase their affinity for the Ag will survive 
and proliferate. In general, a high ratio of R vs. S mutations (R/S ratio) in the IGHV CDR is 
regarded as a molecular sign of an underlying affinity maturation.142 
 AID does not only play a crucial role in the generation of SHM, but it is also involved in 
the process of CSR, which leads to changes in the Ig receptor effector functions.136 In this 
regard, it should be noted that the IGH locus contains multiple constant region-encoding genes 
downstream of IGHM. In precursor and naïve mature B-cells, these regions are not used, and 
rearranged VDJ exons are spliced to the IGHM and IGHD exons. During the GC response, the B 
cell is capable of rearranging the Ig switch region upstream of IGHM with one of the switch 
regions upstream, resulting in the deletion of the intervening DNA and splicing of VDJ exons to 
the exons of an IGHC other than IGHM. 
The process of CSR does not affect the Ag specificity and/or the affinity of the BCR, but 
it influences the effector functions of the antibodies the cell will eventually produce, due to 
differential recognition of Ig subclasses (e.g. isotypes) by Fc receptors on immune cells and by 
soluble proteins (e.g. complement proteins). Also the type of Ig subclasses has an impact on 
the avidity of the Ig, since the ability of IgM and IgA antibodies to form polymers also increases 
their avidity.143,144 
IgG is the predominant Ig class in human serum, and can act locally in the tissues. All 
IgG subclasses are involved in neutralization of pathogens, but only IgG1 and IgG3 are potent 
activators of the complement system and inducers of antibody-dependent cell-mediated 
cytotoxicity (ADCC).145 Complement activation is also the predominant function of IgM, while 
the two IgA subclasses act as neutralizing antibodies with different susceptibility to digestion 
by bacterial proteases.146,147 Finally, IgE is involved in mast cell and basophil sensitization and it 
is the mediator of allergic responses and of responses to parasitic infections.148 
 
2.2.4. Circulating human memory B cells and their diversity 
 
A substantial fraction of B cells in adults (≈20–30% of all PB B-cells) are Ag-experienced 
and shows hallmarks of memory B-cell. One of these hallmarks is an increased responsiveness 
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which results from upregulation of co-stimulatory and activation molecules (i.e. CD80, CD86, 
CD180, TACI), and downregulation of Ig signaling inhibitors (i.e. CD72, LAIR1).149-151 Moreover, 
these Ag-experienced cells may display SHM within their IGHV and IGLV regions and around 
half of them have also undergone Ig CSR,152,153 as reflected by surface membrane expression of 
a switched IgH (e.g. to SmIgG or SmIgA); (23% ± 10% and 21% ± 9% of adult PB memory B-cells 
express SmIgG and SmIgA, respectively). Meanwhile, the other half of memory B-cells still 
coexpress SmIgM and SmIgD (52% ± 15% of memory B-cells), or potentially SmIgM or SmIgD 
only. Even considering that Ig class switching specializes the future effector function of the 
antibodies that will be produced by Ag-specific B-cells, through replacement of the IgM and 
IgD gene exons (Cµ and Cδ) by the IgG (Cγ), IgA (Cα), or IgE (Cε) exons via genetic 
recombination, it should be noted that a small percentage of B-cells (1%–3%) actually class 
switch from Cµ to Cδ at the genetic level using cryptic switch regions between the Cµ and Cδ 
exons; this results in an SmIgM–SmIgD+ memory B-cell phenotype. Recently the presence of 
very low numbers of SmIgE+ memory B-cells has also been described in PB;154 murine studies 
suggest that IgE-secreting plasma cells could be generated both indirectly via CSR to memory 
SmIgE+ B-cells and directly from IgG1 memory B-cells,
155 although the latter possibility remains 
controversial.156 
Until recently, human memory B-cells have been defined based on the expression of 
the CD27 protein on their surface membrane.157 However, recent studies have demonstrated 
that memory B-cells are a more complex and heterogeneous group of B cells than originally 
thought, and that they can also be CD27–; such heterogeneity of memory B-cells probably 
reflects the fact that they consist of multiple different and diverse subsets originated from 
functionally distinct types of immune responses.154,158 
The majority of circulating memory B-cells in healthy adult PB derives from TD 
responses in the GC. Thus, CD27+SmIgG+ and CD27+SmIgA+ GC-derived memory B-cells have 
typically undergone the highest rate of proliferation and SHM; this supports the notion that at 
least part of the CD27+SmIgG+ and CD27+SmIgA+ B-cell subsets in healthy adults, occur later in 
the course of an immune response and/or have undergone multiple immune responses.128,159 
Interestingly, despite these two memory B-cell subsets share selection mechanisms, 
CD27+SmIgA+ B-cells display a clearly higher frequency of IGHV gene mutation vs. CD27+SmIgG+ 
B-cells. A potential explanation for such difference might be the different localization of the 
immune responses which generate most of the CD27+SmIgA+ vs. CD27+SmIgG+ memory B-cells, 
since IgA class switching mostly occurs in MALT, while IgG is typically predominant in other 
lymphoid tissues such as the LN.160 Compared to CD27+SmIgA+ and CD27+SmIgG+ memory B-
cells, CD27+SmIgM+ memory B-cells contain less SHM but show molecular footprints of (early) 
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GC emigrants that did not undergo CSR161 and participate in IgM responses initiated early in 
primary infection. Interestingly, in contrast to these CD27+(SmIgM+SmIgD−) “IgM-only” cells, 
CD27+SmIgM+SmIgD+ “natural effector” B-cells are present in patients with CD40 or CD40L 
deficiency, indicating that at least part of this subset can be generated independently of T cell 
help outside of the GC.131,159 Furthermore, natural effector B-cells resemble prediversified 
marginal zone populations that can be generated independently of functional GC and that 
have a limited replication history compared to GC B-cells (both centroblasts and centrocytes) 
and CD27+SmIgD− memory B-cells.128,159 Thus, CD27+SmIgM+SmIgD+ natural effector B-cells 
probably consist of a mixed population of GC-derived and splenic marginal zone-derived 
memory B-cells. Moreover, these cells more frequently use a subset of Ig variable region genes 
which have long been associated with autoreactivity, at the same time, they also show 
evidences of receptor editing during B-cell development,162-164 which suggests that these 
memory B-cells are either generated by a mechanism of immune tolerance or that they evade 
immune tolerance. 
Regarding IgD-only B-cells, at present it is known that these cells have undergone a Cμ 
deletion due to a non-canonical CSR event, they typically express Igλ, contain extremely high 
levels of SHM and show a strongly biased IGHV3-30 gene usage that can be also seen in some 
malignant B-cell disorders.165 
In addition to all above subsets of memory B-cells, there are three other minor 
populations of IgG, IgA and IgE class-switched B-cells which lack CD27 expression (21% ± 10%, 
9% ± 6% and <1% of all memory B-cells, respectively), which are present in the PB of healthy 
individuals.166 The specific origin of these cells and their relationship to the CD27+ memory B-
cell subsets remain currently unknown; overall, these CD27– memory B-cells show a lower 
frequency of SHM.154,158 In addition, CD27−SmIgG+ B-cells are derived from primary GC-
dependent responses and compared to their CD27+ counterparts, they show dominant usage 
(> 90%) of the IGHM-proximal IGHG1 and IGHG3 genes, which are potent activators of the 
complement system and inducers of ADCC, revealing their potential role in autoimmunity.167 
The CD27−SmIgA+ memory B-cell subset is a smaller population and can be derived 
independently from T cell help, through TI IgA responses in the splenic marginal zone and 
locally in the gastrointestinal system.135 The nature of CD27−SmIgE+ memory B-cells still 
remains to be elucidated.154 
Taking all these findings in consideration, 8 different subsets of antigen-experienced B 
cells have been described. They all exhibit an activated phenotype but different molecular 
signs of Ag experience (i.e. levels of SHM of rearranged Ig genes and participation in primary 
vs. secondary phases of GC responses).  
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2.2.5. Terminal B-cell differentiation to plasmablasts and plasma cells 
 
Very low numbers of CD20-/+ SmIg+ CD19+ CD27high CD38high CD43+ CD138– CD45+ HLA-
class II+ plasmablasts/plasma cells newly generated in the LN and which are derived from 
activated B cells following a different transcriptional program than memory B-cells, are found 
in steady state PB of healthy adults.168 These circulating plasmablasts/plasma cells are induced 
to circulate for a short period until they reach a niche in the BM, spleen, MALT, LN or 
chronically inflamed tissues. They ensure regulation of normal Ig production in view of the 
competition of newborn plasmablasts generated after Ag immunization with older plasma cells 
for binding to a niche, inducing the old plasma cells to recirculate.168 In the plasma cells niches, 
early plasma cells encounter all factors they require to survive and further differentiate into 
long-living mature (CD20− SmIg− CD138+) plasma cells. Overall, circulating plasmablasts/plasma 
cells only represent about 1–3% (1–5 cells/μL) of all PB B-cells in healthy adults under steady 
state conditions, although they can be found at higher frequencies of all circulating B-cells in 
specific disease conditions associated with active immune responses (e.g. acute infection).88 
Since plasma cells progressively loose membrane BCR expression while maturing, they depend 
on other mechanisms for long-term antibody production and survival in the BM.169  
In contrast to memory B-cells, the most represented subset of plasmablasts/plasma 
cells in PB is that of circulating SmIgA+ plasmablasts/plasma cells (49% ± 12% of all PB 
plasmablasts/plasma cells); SmIgM-only plasmablasts/plasma cells represent around 18% ± 
12% and SmIgG+ cells are about 13% ± 11% of all PB plasmablasts/plasma cells. The remaining 
14% ± 12% of circulating plasmablasts/plasma cells do not express any SmIg.168,170 
Interestingly, presence of circulating IgD+IgM- plasmablasts/plasma cells (<5% of 
plasmablasts/plasma cells) has been recently reported in the PB of healthy adults,168 being 
specifically associated with immune responses involving the upper respiratory tract.171,172 
 
 
3. B-CELL CHRONIC LYMPHOPROLIFERATIVE DISORDERS 
 
B-CLPD consist of a heterogeneous group of clonal/neoplastic conditions associated 
with the accumulation of variable numbers of mature-appearing clonal B-lymphocytes blocked 
at distinct stages of B-cell differentiation from transitional/immature B-lymphocytes to plasma 
cells. The expanded neoplastic B-cells typically combine features of their normal B-cell 
counterpart, with aberrant characteristics. Whereas the former features reflect the maturation 
stage and tissue homming profile of equivalent normal B-cells, the latter are frequently related 
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to primary genetic and molecular alterations occurring during either the early stages of 
malignant B-cell transformation (e.g. derailment and oncogenic V(D)J gene rearrangements) or 
during antigen-driven GC reactions in lymphoid tissues,173-175 and/or to secondary genetic 
events associated with disease progression.  
Since expanded B-CLPD lymphocytes are clonal and (frequently) aberrant, at the same 
time they accumulate in one or more “easily” accessible tissues, such as PB, BM and lymphoid 
tissues, morphologic and multiparameter flow cytometry (MFC) analyses of B-CLPD have 
emerged with the years as the most well-suited approaches for the specific identification, 
enumeration and phenotypic characterization of the expanded tumor cells. In this regard, in 
recent years, MFC has become particularly relevant because it has proven to be a highly 
sensitive and specific method for discriminating between normal and leukemic B-cells and the 
recognition of B-CLPD-phenotypes associated with distinct disease categories, even when the 
neoplastic B-cells are present at very low frequencies among a major population of normal 
hematopoietic cells and therefore, may go undetected with conventional microscopic-based 
morphologic and histologic techniques. Furthermore, MFC requires single cell suspensions, 
which can be easily obtained from PB samples, LN biopsies and fine needle aspirates, as well as 
BM aspirated samples. 
In contrast to most normal and reactive B-cell populations, expanded mature B-cells 
from B-CLPD typically display (mono)clonal features including identical V(D)J gene 
rearrangements and Ig light chain expression restricted to Igk or Igʎ.176 In addition, these cells 
also display aberrant cell Sm and/or intracellular (Cy) protein expression profiles.177 Altogether, 
these features allow for a highly specific and sensitive identification of mature neoplastic B-
cells and their distinction from normal cells by MFC.  
In the above sections of this introduction chapter we have already described in detail 
the normal B-cell phenotypes. In turn, in B-CLPD four major types of aberrant phenotypes have 
been described so far, which include: i) crosslineage Ag expression (e.g. expression of T-/NK-
cell-associated markers such as CD2 on neoplastic B-cells); ii) asynchronous expression of 
markers associated with distinct maturation stages (e.g. Bcl2 high expression on CD10+ GC-like 
B-cells); and expression of either iii) abnormally high amounts (e.g overexpression of CD305 on 
hairy cells) or; iv)  abnormally low levels – e.g. decreased intensity of staining for CD19 and 
CD20 in follicular lymphoma (FL) and CLL B-cells, respectively – of B-lineage associated 
markers.178 In practice, detailed characterization of mature B-cell-associated aberrant 
phenotypes, contributes both to the discrimination between normal and neoplastic B-cells, as 
well as to a more accurate classification of the disease, including the screening for specific 
genetic alterations for fast subsequent molecular studies.179  
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The current WHO classification of B-CLPD is based on combined assessment of 
cytomorphological/histopathological, immunophenotypic, and genetic/molecular features of 
tumor B-cells, together with the clinical characteristics of the disease.180,181 Thus, in the WHO 
2008 classification of hematopoietic and lymphoid neoplasias, B-CLPD are identified as 
neoplastic conditions of mature lymphoid B-cells, and they are stratified into three major 
groups of diseases which are mostly related to the pattern of tissue infiltration, including: i) 
peripheral blood involvement (peripheral/mature chronic B-cell leukemias); ii) infiltration of 
secondary lymphoid tissues (peripheral/mature B-cell lymphomas) and; iii) BM (and also other 
non-lymphoid tissues) involvement (neoplastic plasma cell disorders) (Table 1).181 Of note, 
within each multiple diagnostic disease categories of these three groups of B-CLPD, those 
showing common genetic events – e.g. t(11;14) in MCL or CMYC gene rearrangements in 
Burkitt lymphoma – are included together with other genetically heterogeneous disorders that 
display either a uniform immunophenotype (e.g. CLL) or a similar pattern of tissue involvement 
(e.g. MZL). In addition, the WHO 2008 classification has also drawn attention for the first time 
to pre-malignant B-cell neoplasias related to peripheral/mature lymphoid leukemias/ 
lymphomas, such as MBL14,182 and both in situ FL183,184 and in situ MCL (Table 1).5 Although such 
cases might share many biologic features with their malignant counterparts, they usually 
display a benign clinical course with relatively low rates of malignant transformation. 
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Table 1. List of the distinct subgroups of mature B-cell neoplasias and their major features, as 
defined in the WHO 2008 classification [adapted from Campo et al.181]. 
MATURE B-CELL NEOPLASMS 
Peripheral / Mature chronic B-cell leukemias 
Monoclonal B-cell lymphocytosis (MBL) 
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) 
B-cell prolymphocytic leukemia (PLL) 
Hairy cell leukemia (HCL) 
Peripheral / Mature B-cell lymphomas 
In situ follicular lymphoma  
In situ mantle cell lymphoma 
Splenic marginal zone lymphoma (SMZL) 
Splenic lymphoma/leukemia, unclassifiable* 
Lymphoplasmacytic lymphoma (LPL) 
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 
Nodal marginal zone B-cell lymphoma (NMZL) 
Follicular lymphoma (FL) 
Primary cutaneous follicle center lymphoma 
Mantle cell lymphoma (MCL) 
Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) 
DLBCL associated with chronic inflammation 
Lymphomatoid granulomatosis 
Primary mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 
Primary cutaneous DLBCL, leg type 
ALK+ large B-cell lymphoma 
Plasmablastic lymphoma 
Primary effusion lymphoma 
Burkitt lymphoma (BL) 
Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt 
lymphoma 
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical 
Hodgkin lymphoma 
Neoplastic plasma cell disorders 
Heavy chain disease 
Monoclonal gammopathy of undetermined significance (MGUS) 
Plasma cell myeloma 
Solitary plasmacytoma of bone 
Extraosseous plasmacytoma 
ALK, anaplastic lymphoma kinase; HHV8, human herpes virus 8.*This histologic type is a provisional entity for which the WHO 
Working Group felt there was insufficient evidence to recognize as distinct diseases at this time. 
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In the following sections of the introduction chapter we will review the most relevant 
biological as well as clinical features of the major subtypes of B-CLPD, particularly focusing on 
CLL-like MBL and CLL. 
 
3.1. Monoclonal B-cell lymphocytosis 
 
3.1.1. Diagnostic criteria for MBL and its subtypes 
 
Several hospital-based and population-based flow cytometry immunophenotypic 
studies have been reported, in which the presence of relatively small (usually CLL-like) B-cell 
clones has been demonstrated in PB from a substantial fraction of otherwise healthy adults 
classified as with or without increased B-cell counts; MBLlow or MBLhigh, respectively.15,16,185 
In most MBL cases (85%), clonal B-cells display an immunophenotype which is similar 
to that of CLL cells (CLL-like MBL) consisting of CD5+, CD19+, CD20low, CD23+, SmIglow and 
CD79blow clonal B-lymphocytes (Table 2).14,182,186 In turn, in a small fraction of CD5+ MBL cases 
(atypical-CLL-like MBL) and in a minor proportion of cases corresponding to CD5– MBL (non-
CLL-like MBL), clonal B-cells display variable phenotypes which are distinct from those typically 
found on CLL cells (e.g. CD23+, CD20low, CD79blow and SmIglow); such phenotypes frequently 
overlap with those of MZL cells (Table 2).14 Since clonal B cells of individuals with CLL-like 
MBLlow, CLL-like MBLhigh, and CLL share an identical immunophenotypic profile and overlapping 
cytogenetic alterations, at present the distinction between the two MBL subgroups and CLL is 
mostly based on the absolute count of B-lymphocytes in PB. Therefore, while diagnosis of CLL 
requires the presence of ≥ 5,000 B-cells/µl, MBL includes only those cases with < 5,000 B-
cells/µl in the absence of organ infiltration (Table 2).14 Among MBL cases, there is consensus as 
regards the usage of a threshold of 500 B-cells/µl to distinguish between MBLlow (< 500 B-
cells/µl) and MBLhigh (≥ 500 B-cells/µl) cases. However, it should be noted that such cutoff for 
the definition of MBLlow vs. MBLhigh still deserves confirmatory approval in the coming WHO 
classifications of mature B lymphoid neoplasias. Despite this, in all cases it is mandatory to 
actively exclude an underlying (e.g. BM, LN, splenic) mature-B-cell neoplasm other than MBL, 
particularly among non-CLL-like subjects and in atypical CLL-like MBL cases with circulating 
CD5– or CD5+CD23– monoclonal B-cells at levels below 5x109/L clonal B-cells, through e.g. BM 
cytomorphological/histopathological and imaging techniques (e.g. computerized tomography 
and/or magnetic resonance imaging). 
At present, the precise significance of MBL B-cell clones, particularly of the MBLlow 
ones, still remains controversial. Thus, it has been hypothesized that expanded clonal B-cells 
 32 
 
Chapter 1 INTRODUCTION 
circulating in the PB of MBL subjects might either result from a transient and/or chronic 
activation of the immune system during e.g. infection,187 or they may represent premalignant 
states of CLL and NHL.5,184 So far, most reported data has focused on CLL-like MBL, while there 
is very limited information concerning individuals with CD5– non-CLL-like MBL.188  
 
Table 2.Diagnostic criteria and nomenclature for MBL [adapted from Shanafelt et al.185] 
Diagnostic criteria for MBL 
1. Documentation of one or more clonal B-cell population
1
 by ≥1 of the following criteria:  
a) Light chain restriction: kappa: lambda ratio >3:1 or <0.3:1, or 
 > 25% B-cells lacking SmIg or expressing SmIg
low
  
b) Monoclonal IGHV gene rearrangement 
2. Presence of a B-CLPD disease-specific immunophenotype
2
 
3. Absolute B-cell lymphocyte count <5x10
9
/L 
4. No other clinical features compatible with a lymphoproliferative disorder: a) absence of B 
symptoms, b) normal physical examination (no lymphadenopathy or organomegaly), c) no 
autoimmune/infectious disease 
 Subclassification of MBL: 
CLL-like MBL 
● CLL phenotype: CD5
+
CD19
+
CD20
low
CD23
+
sIg
low
CD79b
low
 
● Light chain restriction with SmIg
low
 
3
 
Atypical CLL-like MBL 
● CD5
+
CD19
+
, but CD23
- or low
 and/or CD20
high
, and/or SmIg
high
 and/or CD79b
high 
● Light chain restriction with moderate to bright SmIg expression
3
 
● Exclude t(11;14) to rule out mantle cell lymphoma 
Non-CLL-like MBL 
● CD5
-
CD19
+
CD20
+ 
B-cells 
● Light chain restriction with moderate to bright SmIg expression
3
 
1
Where possible, repeated assessment(s) should also demonstrate that the monoclonal B-cell population is stable 
over a 3-month period. 
2
In the absence of a disease-specific immunophenotype, a highly skewed kappa:lambda ratio may result from a 
reactive process/immune response. 
3
Very small MBL clones may be oligoclonal and thus not light chain restricted. 
 
3.1.2. Prevalence of MBL 
 
The prevalence of MBL in the general population varies substantially (from 0.6% to up 
to 20% of cases) depending on the population-cohorts investigated and the sensitivity of the 
MFC immunophenotypic approach used.15,16,185 Thus, in the general population, MBL is more 
commonly detected among males, its frequency increasing with age, similarly to what is 
observed in CLL.15,189 Reports on more limited series of first degree relatives of CLL patients 
also suggest familial aggregation and consequently, a genetic predisposition/ inheritance.190,191 
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The prevalence of MBL in the general population appears to be very rare under the age 
of 40.16,186 Thereafter, it increases from 5.1% of adults with 40–49 years and 5.3% of adults 
aged 50 to 59 years, to much higher rates: 17.5%, 21.7%, 27.3% and 75% among the 60–69, 
70–79, 80–89 years and >89 years age groups, respectively.15 In turn, the risk for MBL appears 
to be increased by 4-fold in first-degree relatives of CLL patients.190,191 Conversely, there is 
almost no data about the prevalence of MBL among first-degree relatives of individuals with 
MBL. 
Regarding non-CLL-like MBL, controversial results have been reported in the literature 
with respect to the age at onset of the underlying B-cell clones. Ghia et al.186 suggested that 
non-CLL-like MBL clones are already detectable in the general population in sizeable amounts 
among individuals younger than 40 years and that their frequency is only marginally affected 
by age. Thus, based on the observations of Ghia et al.186 it could be hypothesized that while 
CLL-like MBL could be related to physiologic immune senescence-associated mechanisms, this 
would not explain the observation of other non-CLL-like MBL cases. However, it should be 
noted that, in contrast to what occurs in CLL-like MBL, currently there are no highly sensitive 
assays for the identification of non-CLL-like B-cells in PB, which weaknesses the potential 
conclusions about the exact prevalence (and even phenotypes) of non-CLL MBL. In addition, 
Nieto et al.192 found a progressively higher frequency of non-CLL-like MBL cases in the general 
population with increasing age, the frequencies observed ranging from 0.4% among subjects 
aged 40–59 years to 5.4% among individuals over 80 years; such findings, suggest a similar 
behavior in the general population for non-CLL-like and CLL-like MBL, as regards its prevalence 
and distribution per age. 
 
3.1.3. Risk factors for progression from CLL-like monoclonal B-cell lymphocytosis to 
chronic lymphocytic leukemia 
 
The strong association reported between CLL-like MBL and increasing age, has 
promoted the hypothesis that MBL could be one of many signs of “immunosenescence”.193 
Immunosenescence is a physiological process which involves an impaired function of immune 
cells. Among B-cells, immunosenescence is associated with accumulation of B cell populations 
producing polyreactive and autoreactive antibodies, lower incidence of SHM, and a more 
limited IGHV gene usage together with the emergence of oligo and even (mono)clonality, 
including the presence of detectable (mono)clonal component peaks in the serum.194-196 
Actually, presence of tiny numbers of clinically indolent (mono)clonal B cells with a CLL or 
other B-CLPD associated phenotype, is a rather common finding at the very early phases of 
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most mature B-cell neoplasms. The most well-recognized example of such early events is 
monoclonal gammopathy of undetermined significance (MGUS), which shows an incidence of 
around 1% in the general population older than 50 years, such frequency increasing thereafter 
to up to 10% among subjects older than 75 years.197 Of note independent studies198,199 have 
demonstrated that in most multiple myeloma (MM) patients, the disease is preceded by MGUS 
with a malignant transformation rate of MGUS to MM of between 1% and 2% cases per 
year.200 More recently, a similar behavior and relationship has been identified for CLL-like MBL 
and CLL5,184 as discussed below.  
Population-based screening for CLL-like MBL has shown that MBLlow is more commonly 
associated with oligoclonality than CLL (20% of MBL vs. 5% of CLL) and MBLlow is enriched for 
lower risk CLL markers, such as mutated IGHV sequences (around 87% of MBLlow clones have 
mutated Ig genes vs. around 50% of CLL cases).20 These findings suggest that the acquisition of 
a CLL-like cell surface immunophenotype does not necessarily go along with the emergence of 
a single clone, but it might more likely reflect a functional state potentially associated with 
prolonged/chronic B-cell stimulation, activation and/or immunesenescence, similarly to what 
has been  previously described for T cells in the aging population, where chronic and persistent 
viral infections induce the emergence of oligoclonal and even monoclonal expansions of 
CD4+CD8+ T lymphocytes, under the influence of a specific genetic background (e.g. HLA-class II 
haplotypes).201,202 In this regard, it should be noted that preliminary investigations of IGHV 
gene usage in CLL-like MBLlow based on highly-sensitive single cell purification techniques, have 
shown that clonal B-cells from MBLlow cases less frequently use VH CDR3 stereotypes (see 
definition in section 3.2.3.2.), their restricted IGHV repertoire (e.g. the IGHV4–59 and IGHV4–
61 families are more frequently used than others) being also distinct from that detected in 
both mutated and unmutated CLL cases.15,20,203 Overall, the above biological differences 
observed between expanded clonal B-cells in CLL-like MBLlow vs. CLL suggest that detection of 
CLL-like MBL in an otherwise healthy subject is not always equivalent to a preleukemic state, 
because specific BCR configurations are more prone than others for disease transformation. In 
line with this hypothesis, it has been recently shown in a cross-sectional epidemiological study 
that in the general population, MBLlow is significantly associated with a personal history of 
pneumonia and meningitis and infectious diseases among their children, while it was less 
commonly observed among subjects vaccinated against pneumococcus and influenza; these 
results suggest that exposure to infectious agents leads to serious  clinical manifestations in 
the patients or their relatives and that they may more frequently trigger immune events 
leading to MBL.204 
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In contrast to what has been described for MBLlow, in MBLhigh cases the biology of the 
expanded CLL-like B-cell clone more closely mimicks what is also seen in good-risk CLL: it 
shows molecular features similar to good-prognosis CLL (e.g. a bias toward mutated and 
clinically favorable BCR) different from those that are more frequently found in MBLlow.16 For 
example, recent investigations203,205 indicate that Ig genes commonly expressed in CLL (IGVH1–
69 and IGVH4–34) are also frequently used in CLL-like MBLhigh (IGVH4–34 and IGVH3–23), but 
rarely observed in MBLlow. 
In line with what has been described above for the IGHV repertoire of MBL, 
cytogenetic analysis of clonal B-cells from CLL-like MBL subjects has also demonstrated 
alterations – typically restricted to del(13q) and trisomy 12 – in about 40% of cases vs. >50% of 
CLL patients.16,206 These abnormalities are usually seen in only a fraction of all abnormal cells, 
such fraction increasing from MBLlow cases to CLL.20 Despite MBLlow does not show poor-
prognosis cytogenetic/molecular alterations – e.g. del(17p), del(11q) or NOTCH1 mutations – 
currently there is no cytogenetic marker which identifies MBL individuals who are likely to 
develop progressive disease.203,206 Of note, in some MBLlow cases, cytogenetic alterations are 
observed even when the number of circulating MBL cells is extremely small, once again, in the 
absence of any evidence of progression to MBLhigh and CLL.187 Overall, these findings mimick 
what has been previously reported also for most MGUS cases, where the (mono)clonal plasma 
cells frequently bear overlapping chromosomal abnormalities and cytogenetic profiles with 
symptomatic MM;207,208 at the same time, it may also contribute to explain why cells carrying 
the t(14;18) translocation (the cytogenetic hallmark of FL) can be found in the PB of 
approximately 50% of healthy persons in the absence of evidence for disease progression.209 In 
more detail, del(13q14) can be detected in approximately an equal proportion of CLL-like MBL 
and CLL, particularly among IGHV mutated clones, independent of the absolute number of 
circulating CLL cells.210,211 Once again, these observations highlight the fact that development 
of very small CLL clones with “good risk” cytogenetic and biological features is a common 
finding in the elderly and it may be a consequence of the ageing of immune system more than 
an actual oncogenic event; at the same time, they indicate that additional factors are required 
to drive small CLL clones to expand. In contrast to del(13q) cytogenetic abnormalities which 
are associated with poor prognosis CLL, such as del(17p13), del(11q22) and NOTCH1 
mutations, have not been reported in MBLlow and they are only occasionally seen in CLL-like 
MBLhigh.15,16,18 These observations, together with the restricted but different, IGHV repertoire 
detected in MBLlow vs. MBLhigh, suggest that in addition to the occurrence of specific genetic 
alterations, specific BCR signaling would be also required for the expansion of CLL-like MBL 
cells and for the transformation of MBL to symptomatic CLL, at least in a fraction of the cases.  
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In this regard, it has been recently shown that CLL is always preceded by an MBL 
state,212 similarly to what occurs with MM and MGUS. In turn, this is also consistent with the 
fact that most MBL cases will not progress to CLL, particularly among MBLlow subjects, where 
progression appears to be very unlikely.213 Due to the arbitrary cutoffs used for the distinction 
between MBL and CLL Rai stage 0, at present it is well-accepted that it is more appropriate to 
define the risk of MBL progression as the risk for developing CLL requiring treatment, than just 
the risk to develop CLL. Based on such criteria, follow-up studies of large series of MBLhigh cases 
have found an annual risk of progression of MBLhigh to CLL requiring treatment of between 1 
and 2% vs. 5 to 7% for CLL Rai stage 0 patients.16,18,214 Today, the only prognostic factor known 
to predict progression of MBL to CLL is the actual number of clonal B lymphocytes in PB.16,18 
However, other prognostic markers that are informative within CLL might also be applied to 
CLL-like MBL, to predict which cases might progress to CLL and eventually require treatment. 
Therefore, established risk factors for CLL, such as the IGHV mutational status, 
cytogenetic/molecular aberrations, expression of specific phenotypic markers (e.g. ZAP-70, 
CD38 and CD49d), are potentially also adverse prognostic factors among CLL-like MBL subjects, 
their precise value deserving further investigations.  
Other factors that might contribute to understand the pathogenesis of MBL and 
predict transformation of MBL into CLL include an altered homeostasis and functionality of 
both NK- and/or T-cells, which have been suggested to influence survival of CLL B-cells and 
progression of the disease.19,215 In this regard, recent studies have shown that in MBL subjects, 
CD4+CD8+ double-positive T-cells are significantly reduced in absolute numbers while CD8+CD4– 
T-cells are increased, supporting the notion that an impaired immunosurveillance function may 
favor the emergence of MBL clones.216 Moreover, presence of MBL clones in healthy subjects 
is associated with reduced counts of normal circulating PB B-cells, mainly at the expense of 
immature and naive B-cells, such decrease being more pronounced as the number of MBL cells 
increases.216 Based on these observations, it could be hypothesized that the reduced PB counts 
of normal B-cells at the expenses of recently produced B-cell subsets in MBLlow, could depend 
on the size of the B-cell clone in the BM, suggesting a potential suppressive effect of the MBL 
clone on normal B-lymphopoiesis. Whether these abnormalities occur before or after the 
emergence of the MBL clone(s), and whether this reduction derives from immune-suppression 
or it may reflect a decrease in B-cell production at BM niches due to MBL-cell competition, 
requires further investigations. 
Altogether, the above observations raise the question about whether there is a time-
dependent pipeline of unavoidable events leading from MBLlow to MBLhigh and also to CLL, or 
MBLlow simply represents one of many features of immunesenescence, while (clinical) MBLhigh 
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is already a pre-malignant CLL state. At present, further research is still required to elucidate 
this question. However it should be noted that the understanding of the molecular and 
biological features underlying the risk of progression of MBL to CLL may significantly modify 
the currently used strategies for the follow-up of MBL, leading to a more refined management 
of CLL premalignant states and a better follow-up of MBL cases at risk of progression, for early 
adoption of measures that would potentially block or delay malignant transformation. 
 
3.2. Chronic lymphocytic leukemia 
 
3.2.1. Definition and diagnostic criteria for CLL 
 
CLL is the most common leukemia in adults in the Western world.217,218 It is a chronic 
incurable disease which is characterized by progressive accumulation of B cells in the PB, BM, 
and/or lymphoid tissues.219 When the disease mostly involves the PB and BM, it is called CLL, 
while when LN or other tissues are preferentially infiltrated by tumor cells with identical 
morphologic and immunophenotypic features to CLL, in the absence of the typical leukemic 
manifestations of the disease, it is called small lymphocytic lymphoma (SLL). In the WHO 2008 
classification,180,181 these two entities (CLL and SLL) are simply considered as different clinical 
manifestations of the same disease. Current diagnostic criteria for typical CLL requires the 
presence of at least 5,000 B lymphocytes/µl of PB with a CLL immunophenotype, or LN 
involvement by CLL cells in case of SLL.220 BM involvement is typically present, infiltrating CLL 
cells usually represent more than 30% of all nucleated cells in the aspirated BM sample. 
Despite a remarkable phenotypic homogeneity, CLL is characterized by an extremely 
variable clinical course with very heterogeneous responses to treatment; thus, while some 
patients do not require therapy for rather long periods of time after diagnosis or they reach 
complete and prolonged remissions after treatment, others relapse early and need several 
lines of treatment and frequently die from the disease.221 Such clinical heterogeneity most 
likely reflects the underlying molecular and cellular heterogeneity of the disease.22 In fact, 
several lines of research have demonstrated that CLL can be subdivided into multiple 
subgroups with distinct biological features, based on underlying genomic features, 
cytogenetic/molecular aberrations and/or the immune signaling pathways that can be 
activated via cell surface and/or intracellular receptor molecules of both the innate (e.g. TLRs) 
and adaptive (e.g. BCR) immune system.22,222,223 
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3.2.2. Immunophenotypic features of CLL cells 
 
The typical immunophenotypic profile of CLL small lymphocytes includes coexpression 
of CD5 and CD23 in the absence of FMC7 and low expression levels of SmIg (often IgM with or 
without IgD);224 in addition, the levels of expression of several other B-cell-associated cell 
surface membrane molecules like CD20, CD22, CD79b and CD81 are also significantly 
decreased compared to those found on normal mature B-lymphocytes.225 CLL cells also 
coexpress CD43 and CD200 which may provide further information in differentiating CLL from 
other B-cell NHL and chronic lymphoid leukemias such as FL (e.g. CD43 is positive in CLL but 
usually negative in FL) and MCL (e.g. CD200 is consistently expressed in CLL whilst it is negative 
or very weakly expressed in MCL).226 Moreover, CLL cells are usually positive for CD21, CD24, 
CD25, CD27, CD39, CD40, CD45RA, CD62L and CXCR5 (CD185). In turn, CD11c, CD38, CD45RO, 
CD49d, CD80, CD95, CD124, CD126, CD130, ZAP-70 and other markers that recognize adhesion 
molecules, are expressed at variable levels in a fraction of all CLL/SLL cases.  
 
3.2.3. Molecular features of CLL cells  
 
3.2.3.1. Immunoglobulin heavy chain variable region gene usage in CLL 
 
In recent years, several studies have confirmed that the IGHV gene repertoire of CLL is 
restricted and different from that of normal IgM+ B-cells;227-229 thus, several IGHV genes are 
clearly over-represented in CLL (e.g. the IGHV1-69, IGHV4-34, and IGHV3-7 genes).227 Similarly, 
a restricted usage of specific IGHD and IGHJ genes has also been described in CLL.13 In this 
regard, only five IGHD genes are used by almost half of all CLL cases, the IGHD3-3 gene being 
the most frequently selected; in turn, the IGHJ gene repertoire of CLL cells is characterized by a 
preferential usage of the IGHJ4 and IGHJ6 genes.230,231 Such restricted IGH gene repertoire 
leads to the predominant usage of specific IGHV, IGHD and IGHJ gene combinations. For 
example, IGHV1-69 gene rearrangements are strongly biased toward the usage of the IGHD3-3 
and the IGHJ6 genes; in contrast, no significant (or minor) biases are noted for cases 
expressing other IGHV genes, particularly IGHV4-34, IGHV3-7 and IGHV3-23.230,232 
Furthermore, the imprint of SHM is not uniform across different IGHV genes in CLL; thus, the 
IGHV1-69 gene most frequently carries very few or no mutations, as opposed to the IGHV3-7, 
IGHV3-23 and IGHV4-34 genes, which are mutated in a relatively significant proportion of 
cases.227  
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3.2.3.2. Stereotyped B-cell receptors in CLL 
 
Immunogenetic studies of the BCR repertoire of CLL cells has revealed the presence of 
homologous BCR in a significant proportion of cases, suggesting that recognition of common 
epitopes or classes of structurally similar epitopes is likely involved in the selection of CLL 
clones.233-235 Overall, different types of homologous BCR have been defined, enabling different 
cases to be grouped into subsets based on common sequence features of the BCR, particularly 
the homology of their VH CDR3 sequences. These highly similar BCR have been referred as 
“stereotyped” BCR.233 So far, more than 200 different subsets of cases carrying stereotyped 
BCR have been defined, 8 of such subsets accounting for ≈30% of all stereotyped CLL cases.236 
In 2007, a set of criteria was proposed for the definition of stereotyped BCR based on 
the specific underlying IGH V(D)J gene rearrangements;237 these criteria include: 1) a VH CDR3 
aa identity ≥60%, in line with established bioinformatic concepts for evaluating sequence 
conservation in protein sequences; 2) usage of the same IGHV/IGHD/IGHJ germline genes or 
different IGHV genes, as long as the above criterion for VH CDR3 sequence conservation is 
met; 3) usage of the same IGHD gene RF.  
Based on this clustering approach for stereotyped BCR in CLL, it has been shown that 
the frequency of BCR Ig stereotypes in CLL can exceed 25% of the entire CLL patient cohort;13 
although BCR Ig stereotypes exist among both mutated and unmutated CLL, they are 
significantly more frequently observed in the latter group.233,238 Of note, different versions of 
BCR Ig stereotypes can be defined based on shared VH CDR3 aa sequence patterns, which are 
distinct for each subset.239 Interestingly, the relative size of each subset differs markedly, from 
just two to large numbers of cases with homologous BCR, since individual genes show a 
markedly different susceptibility to be used in stereotyped rearrangements in CLL. Hence, 
while the frequency of stereotyped rearrangements has been shown to exceed 30% of the 
cases for some IGHV genes (e.g. IGHV3-21, IGHV1-69, IGHV1-2, IGHV1-3, IGHV4-39, IGHV3-48), 
it is rather low (<5%) for other IGHV genes (e.g. IGHV3-7, IGHV3-74).237 In addition, individual 
subsets of cases with stereotyped VH CDR3 are often characterized by restricted Ig light chain 
gene usage and CDR3 features.237,240,241 On top of all the above, specific subsets of stereotyped 
CLL cases may be also associated with distinct clinical/phenotypic features including a different 
outcome (see section 3.2.5.2. below), raising the possibility that a particular Ag binding site can 
be critical in determining clinical presentation and potentially also even disease 
prognosis.237,242 Finally, although BCR stereotypes have also been found in other B-CLPD, those 
observed in CLL are frequently different from the ones reported in other B-cell malignancies 
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such as splenic MZL (SMZL) and MCL, alluding to distinct disease-biased, selective and 
ontogenetic processes.243,244 
Based on the above observations it might be concluded that depending on the BCR 
repertoire, CLL actually consists of two major different categories which show important 
biological and ontogenetic differences;13 the first includes cases with heterogeneous BCR (non-
clustered cases), while the second is characterized by a remarkably high frequency of BCR 
stereotypy (clustered cases). The biological significance of BCR stereotypy still remains to be 
fully understood.  
 
3.2.3.3. Recognition of conserved epitopes by CLL cells 
 
Detailed dissection of the potentially relevant antigenic epitopes recognized by the 
BCR in CLL, indicates that these might probably correspond to molecular structures usually 
involved in eliminating cellular debris, scavenging apoptotic cells and apoptotic bodies, and/or 
providing a first line of defense against pathogenic bacteria.245-247 For instance, non-muscle 
myosin heavy chain IIA (MYHIIA), which is expressed on a subpopulation of apoptotic cells 
(called myosin-exposed apoptotic cells or MEAC), emerged as the antigenic target of CLL 
monoclonal antibodies (mAbs) from a subset of cases expressing IGHV1-69/IGHD3-16/IGHJ3 
stereotyped BCR, as well as of several other CLL mAbs.246 Other Ags recognized by CLL cells 
have been functionally associated with specific bacterial infections – e.g. molecular mimicry 
driven by Streptococcus pneumoniae capsular polysaccharides, Gram-positive, Gram-negative 
bacterial strains and oxidized low-density lipoprotein (LDL) –.248 Viral infections have also been 
suggested to drive subgroups of BCR stereotyped CLL cases; accordingly, persistent infection 
by Epstein–Barr virus (EBV) and cytomegalovirus (CMV) has been correlated with a 
stereotyped IGHV4-34 subset249 and hepatitis C virus (HCV) has been recently associated with 
stereotyped IGHV4-59/IGKV3-20 CLL mAbs, albeit indirectly, since such CLL mAbs can exhibit 
rheumatoid factor activity.250 Interestingly, the existence of rheumatoid factor with restricted 
Ig gene sequences in various conditions (e.g. CLL, SMZL, myoepithelial sialadenitis in primary 
Sjogren’s syndrome, mixed cryoglobulinemia type II) may allude to cross-reactivity or 
molecular mimicry of the antigenic elements which are involved in the selection of the 
clonogenic B-cell progenitors involved in distinct pathologic conditions.250 
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3.2.4. Genomic aberrations in CLL 
 
Genomic aberrations can be identified in around 50-80% of CLL cases by iFISH analysis 
of CLL cell nuclei with a disease-specific probe set.251,252 The most common chromosomal 
abnormalities in CLL are del(13)(q14), trisomy 12, del(11)(q22–23), del(17)(p13) and 
del(6)(q21).222 Del(13q14) followed by trisomy 12 are the two most frequent cytogenetic 
alterations in CLL, being present in between 8% and 60% and between 10% and 25% of all 
cases, respectively.222,252,253 In turn, del(17p13) and del(11q23.3-q23.1) are detected in a 
significantly lower proportion of cases, ranging between 5% and 16% and between 5% and 
15% of all CLL cases, respectively.222,252,253 In common, these cytogenetic abnormalities, and a 
number of other chromosomal defects, are known to target genes that play a key role in the 
regulation of cell proliferation, survival, and/or DNA repair, such as the tumor protein p53 
(TP53), retinoblastoma (RB), ataxia telangiectasia mutated (ATM), CYCLIN D2, cyclin-dependent 
kinase 4 (CDK4), and E3 ubiquitin-protein ligase (MDM2) genes. Despite the high frequency of 
both del(13q14) and trisomy 12 and the fact that they have been suggested to play a primary 
and central role in the transformation process in CLL,254 the pathogenic role of del(13q) and 
trisomy 12 in CLL is not fully understood. In this regard, at present it is known that the deleted 
chromosome 13q region, always comprises the locus coding for two microRNA (miRNA), 
miRNA-16-1 and miRNA-15a, which have been suggested to act as tumor suppressor genes in 
the pathogenesis of CLL via down-regulation of expression of the antiapoptotic Bcl2 
protein;255,256 in turn, in a fraction of cases carrying del(13q), larger deletions that include the 
region coding for the RB1 gene occur, such larger deletions being associated with a poorer 
clinical outcome, potentially due to an altered control of cell proliferation and survival.257-259 
Besides its relevance in the pathogenesis of CLL, miRNA expression profiles may also 
be relevant prognostic markers in CLL. In this regard, it should be noted that critical processes 
of the B-cell physiology, including immune signaling through the BCR and/or TLR, are targeted 
by miRNA and, changes on the expression of specific miRNA (e.g. upregulation of miRNA-150, 
miRNA-29c, miRNA-143 and miRNA-223 and downregulation of miRNA-15a) which are 
differentially expressed among mutated vs. unmutated CLL cases and in certain CLL 
stereotypes (e.g downregulation of miRNA-101 in subset 1), may also modulate the biological 
and clinical behavior of CLL clones.260 As an example, miRNA-101 regulates the expression 
levels of the enhancer of zeste homolog 2 (EZH2) protein; consequently, its overexpression is 
associated with more aggressive CLL.260  
Recent studies devoted to whole CLL genome sequencing have shown the presence of 
more than one thousand distinct mutations across CLL patients. However, the frequency at 
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which such mutations were found in CLL was relatively low, except for a few genes.6,261,262 The 
recently identified genes, included the Notch 1 (NOTCH1, 12.3%), splicing factor 3b subunit 1 
(SF3B1, 9.0%), TP53 (7.1%), exportin 1 (XPO1, 3.4%), F-box and WD repeat domain containing 7 
(FBXW7, 2.5%), myeloid differentiation primary response gene 88 (MyD88, 1.5%) and the 
kelch-like family member 6 (KLHL6, 1.8%) genes, apart from those that had been previously 
described.6,263 Since, some of these mutations can also emerge during the clinical course of 
CLL,264 future studies are required to clarify how this might influence treatment strategies, as 
data suggest that therapy may disrupt the interclonal equilibrium and lead to evolution of 
subclones with driver mutations such as SF3B1, NOTCH1 or TP53 mutations.265 Furthermore, a 
recent cohort study has shown that different subgroups of CLL can be defined according to co-
occurrence of distinct patterns of genetic alterations for some of these mutations: 1) 
mutations in SF3B1 gene are frequently associated with del(11q); 2) mutations in the NOTCH1 
and the FBXW7 genes are associated with trisomy 12, whereas these two mutations and SF3B1 
mutations were nearly mutually exclusive, and; 3) mutations in the MYD88 gene are mainly 
found in combination with isolated del(13q), while NOTCH1, FBXW7 and SF3B1 mutations are 
rarely found in this cytogenetic subgroup of CLL.263 Thus, the combination of molecular 
markers with discrete cytogenetic subgroups may hint at distinct ways of CLL pathogenesis and 
may explain the clinical heterogeneity of the disease.  
 
3.2.5. Outcome and prognosis of CLL patients 
 
As discussed above, CLL is a clinically and biologically heterogeneous disease, with a 
highly variable outcome. During the last decades, several clinical and biological variables, 
including the immunogenetic profiles of CLL cells, have been related with the prognosis of the 
disease. 
 
3.2.5.1. Clinical and biological prognostic factors  
 
The standard clinical procedures to estimate prognosis in CLL are based on the staging 
systems developed by Rai et al.266 and reformulated latter on by Binet et al..267 These systems 
(Table 3) define early (Rai 0, Binet A), intermediate (Rai I/II, Binet B) and advanced (Rai III/IV, 
Binet C) stage disease with, median estimated overall survival rates of >10 years, 5-7 years, 
and only 1-3 years, respectively. Because most patients present early or intermediate stage 
disease and a heterogeneous course of disease occurs for individual patients within the same 
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disease stage, additional markers are needed to stratify patients who are at increased risk of 
disease progression with a potentially decreased survival, within individual disease stages.  
A relatively high number of prognostically relevant markers have long been identified 
in CLL. Among other, these include clinical characteristics (e.g. patient age, gender, and 
performance status) in addition to the stage of the disease, as well as laboratory parameters 
reflecting the tumor burden and/or activity of the disease, (e.g. lymphocyte count, BM 
infiltration pattern or lymphocyte doubling time) (Table 4).268 More recently, prognostic 
markers related to the biology of the tumor have been also identified, including serum 
parameters, immunophenotypic markers and cytogenetic/molecular characteristics of CLL 
cells, such as the mutational status of the IGHV genes (Table 4) that will be specifically 
discussed in the following section of this chapter.222,269-271 
 
 Table 3. Rai et al. and Binet et al. staging systems for the prognostic classification of CLL.  
 
At present, it is widely accepted that chromosomal aberrations are one of the most 
relevant prognostic factors in CLL, being associated with different clinical and prognostic 
features of the disease. Thus, in general a normal karyotype and presence of isolated del(13q) 
are both associated with a significantly better outcome, whereas trisomy 12 confers an 
intermediate prognosis associated with atypical CLL, and both del(11q) and del(17p) are 
associated with a particularly poorer outcome.222,252,272 Despite this, recent studies have shown 
that there is a significant heterogeneity in the outcome of patients with isolated del(13q),273-276 
Staging 
System 
Stage Definition Median survival 
Rai et al. 
staging 
system 
0 (low risk) Lymphocytosis only 11.5 years 
I (intermediate risk) Lymphocytosis and lymphadenopathy 11.0 years 
II (intermediate risk) Lymphocytosis in blood and marrow with 
splenomegaly and/or hepatomegaly ( with or 
without lymphadenopathies) 
7.8 years 
III (high risk) Lymphocytosis and anemia (hemoglobin 
<110g/L or a hematocrit <33%) 
5.3 years 
IV (high risk) Lymphocytosis and thrombocytopenia 
(platelet count <100x10
9
/L) 
7.0 years 
      
Binet et al. 
staging 
  
A Enlargement of <3 lymphoid areas (cervical, 
axillary, inguinal, spleen, liver); no anemia or 
thrombocytopenia 
11.5 years 
B Enlargement of ≥3 lymphoid areas  8.6 years 
C Anemia (hemoglobin <100 g/L) or 
thrombocytopenia (platelet count 
<100x10
9
/L), or both 
7.0 years 
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the clinical impact of biallelic vs. monoallelic del(13q) still remaning controversial. In this 
regard, it should be noted that while biallelic loss of chromosome 13q is frequently seen as a 
secondary cytogenetic event with a limited impact on prognosis, the progressive accumulation 
of high percentages of cells (>90%) carrying del(13q) has been described as an independent 
prognostic factor for risk stratification of patients with del(13q).277  
TP53 and SF3B1 mutations emerge among the strongest biological markers with an 
independent prognostic value in CLL patients receiving current standard first-line therapy.278 
CLL patients with TP53 mutation have a poor prognosis when treated with fludarabine (F)-
based chemotherapeutic regimens regardless of the presence of del(17p) and should be 
considered for alternative treatment approaches.279 In turn, SF3B1 mutations have a lower 
incidence in early CLL stages, and they are more commonly observed in advanced disease, 
tending to be associated with a poorer prognosis.16,280 NOTCH1, XPO1 and MYD88 are other 
three genes that are recurrently mutated in CLL, being associated with a better (e.g. MYD88) 
or a poorer outcome (NOTCH1, XPO1).  
In addition to tumor cytogenetics, several immunophenotypic markers of CLL cells, 
have also been associated with the prognosis of the disease. Thus, both CD38 and ZAP70 
expression have been shown to be associated with a poorer outcome in CLL.281,282 Similarly, 
increased expression of the CD49d integrin has consistently been identified as an independent 
negative prognosticator for CLL, particularly among IGHV unmutated cases, defining a subset 
of CLL patients characterized by an aggressive and accelerated clinical course;271,283,284 in 
contrast, preliminary data also suggests that CD305 (LAIR1), an inhibitory B-cell signaling 
molecule, appears to confer a better prognosis in CLL.285 Other markers that have been also 
associated with adverse prognostic features of CLL include: higher expression of CD74286 and 
absence of CTLA4 expression.287 Of note, specific polymorphic variants of CTLA4 have been 
associated with advanced Rai stages and an increased risk of progression of CLL.288 
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Table 4. Outcome of CLL patients distributed according to selected prognostic factors [Adapted 
from Shanafelt et al.268]. 
  
Clinical Risk 
  
Low High  
M
aj
o
r 
Sex Female Male 
Clinical stage Binet A Binet B or C 
  Rai 0, I Rai II, III, IV 
    
BM infiltration pattern Non-diffuse  Diffuse  
Morphology of lymphocytes Typical  Atypical 
Lymphocyte doubling time > 12 months < 12 months 
% of CD38
+
CLL cells <20-30% >20-30% 
Interphase FISH cytogenetics/ 
Whole-genome sequencing mutated 
genes 
Normal; del13q (sole)/ 
MYD88 
del(11q); del(17p)  
TP53  
SF3B1 
NOTCH1 
XPO1 
    
IGHV mutational status Mutated (≥2%) Unmutated (<2%) 
Cellular expression of ZAP-70 
Cellular expression of CD49d 
Cellular expression of CD74 
Low 
Low 
Low 
High 
High 
High 
Cellular expression of CD305 High Low 
Cellular expression of CTLA4 High Low 
   
Serum thymidine kinase activity  Low or Normal Elevated 
 
    
O
th
e
r Beta2-microglobulin (serum levels) Low (<2.5 mg/L) High (>2.5 mg/L) 
Soluble CD23 (serum levels) Low (<574 U/mL) High (>574 U/mL) 
 
 
3.2.5.2. Immunogenetic parameters and profiles with prognostic impact in CLL 
 
The load of somatic mutations across the sequence of the rearranged IGHV genes was 
the first highly accurate molecular marker for prognostication of CLL and it still remains one of 
the strongest prognostic markers of the disease, which is independent from the Binet/Rai 
staging (Table 4). Thus, mutated (<98% homology with germline sequences) CLL is usually 
associated with early stage and more stable forms of the disease, whereas unmutated (≥98% 
homology) CLL typically shows more aggressive features and a poorer outcome.278,289 Most 
interestingly, the mutational status of the IGHV genes also appears to be associated with 
acquisition of specific genetic alterations. Thus, mutations of the MYD88 gene are 
predominant in CLL with mutated IGHV and define a good-prognosis subgroup of young 
adults;290 in contrast, NOTCH1, SF3B1 and XPO1 mutations are mainly detected in patients with 
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unmutated Igs.263 These patterns of association between the IGHV somatic mutation profile 
and specific genetic changes, support the notion that recurrent mutations of the NOTCH1, 
MYD88, SF3B1 and XPO1 genes are oncogenic changes that contribute to the clinical evolution 
of specific subsets of CLL patients defined by their IGHV gene status.6  
In addition to the IGHV mutational status, specific IGHV genes have been also 
associated with the prognosis of CLL. The first hints suggesting that not only the mutational 
status of the IGHV genes, but also other BCR features could be prognostically relevant in CLL, 
came more than 10 years ago, in 2002. At that time, it was already found that usage of the 
IGHV3-21 gene was associated with an adverse prognosis, regardless of the SHM load.291 
Afterward, other reports confirmed the association between specific IGHV genes and 
prognosis of CLL; while some IGHV genes confer an adverse prognosis (e.g. IGHV3-23)292 others 
are associated with a more favorable outcome (e.g. IGHV3-30 and IGHV3-72) of CLL.293 
However, except for the data on the prognostic impact of the IGHV3-21 gene, for which there 
is strong evidence,294,295 the prognostic association of other IGHV gene usage profiles is based 
on retrospective analyses of rather small patient series, hence requiring definitive 
confirmation in prospective studies including larger numbers of patients.  
In parallel, specific associations have also been reported in CLL between subsets of 
cases with (quasi-identical) 'stereotyped' BCR and several clinical features of the disease.238,296 
As an example, CLL cases expressing stereotyped IGHV4-39/IGHD6-13/IGHJ5 BCR more 
frequently experience aggressive disease complicated by severe recurrent infections, Richter’s 
transformation and/or the occurrence of secondary neoplasias (e.g. solid tumors).238 Another 
clinically relevant example of such association, relies on cases showing expression of 
stereotyped IGHV4-34/IGKV2-30 BCR of the IgG isotype together with unique patterns of SHM, 
occurring in younger CLL patients237,297,298 presenting a more indolent disease.237,297 Also, the 
cooperative association between IGHV4-39 gene usage and specific BCR stereotypes,  NOTCH1 
mutation and trisomy 12, more frequently leads to CLL transformation into Richter 
syndrome;236 similarly, coexistence of SF3B1 mutations and specific BCR stereotypes 
associated to the IGHV3-21 gene, invariably leads to disease progression among such CLL 
cases.236  
 
3.2.6. The cell of origin of CLL-like MBL and CLL 
 
In human hematopoietic cells, genetic alterations which are responsible for oncogenic 
transformation should in principle accumulate in cells that already have (or will acquire) self-
renewing proprieties, such as HSCs. Such cells can continuously produce a number of 
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progenitors which carry the same genetic alteration and that are potential targets for 
additional mutations,299 which might become leukemia stem cells with self-renewal capacity 
and a limited ability to differentiate normally.300,301 
While myeloproliferative neoplasms and myelodysplastic syndromes are known to 
arise at the HSC stage in hematopoiesis, many other hematologic malignancies have been 
linked to later stages in the hematopoietic hierarchy.302-304 For example, aggressive acute 
leukemias are generally believed to arise from early progenitors, with some initial 
leukemogenic events occurring in the HSC themselves.303,304 In turn, most mature B cell 
lymphomas and leukemias are classified according to their presumed cell of origin along the 
continuum of B cell development and differentiation, early oncogenic events potentially 
targeting long living pre-GC B-cells, memory B-cells and/or plasma cells.7 
In recent years, the focus of research in CLL has moved towards the molecular genetic 
level. This is due to the fact that there is a general believe that the identification and the 
understanding of those genetic and molecular mechanisms directly responsible for the course 
of the disease, such as clinical progression, response to treatment and overall survival, will 
contribute to accelerate the cure of the disease, at the same time they will provide insight into 
those events leading to the development and malignant transformation, in CLL. Consequently, 
an increasing number of studies have been reported which provide useful information to 
delineate part of the history of the malignant CLL clone, particularly during the period that 
precedes malignant transformation, e.g. at the stage of MBL.  
 
3.2.6.1. Multistep models for human CLL development 
 
The precise B-cell subset targeted at the initial stages of CLL, still remains a matter of 
debate, and current knowledge about the history of the cell of origin of CLL, prior to leukemic 
transformation, is incomplete. Consistent expression of CD5 on CLL cells led to initial 
speculations that CLL might be a malignancy of CD5+ B-cells,305,306 a subset of B-lymphocytes 
that represent a distinct B cell lineage (B1 B-cells) in mice where they are capable of self-
renewing, producing natural/polyspecific antibodies and responding to T-independent Ags; 
based on this hypothesis, CLL cells were claimed to be potentially stimulated in vivo in a 
continued way by self-antigens.307,308 Recently, human PB CD5+ B cells have been shown to 
correspond to the so called immature/transitional B cells,121 as confirmed by unsupervised 
analysis of gene expression profile (GEP) for >10,000 transcripts of CLL cells vs. distinct subsets 
of normal mature B-lymphocytes.309,310 However, despite most CD5+ B-lymphocytes are 
regarded as pre-GC B-lymphocytes with unmutated IGHV genes, around half of all CLL cases 
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harbor mutated IGHV genes.270,311,312 In line with these findings, a small fraction of CD5+ B-cells 
(4–17%) that coexpress the memory B-cell associated CD27 marker has also been described in 
healthy subsets.152 Moreover, a small subpopulation of all CD5+ B-cells (between 0.5 and 2% of 
all CD5+ PB B cells), appears to be class-switched to IgG or IgA.309  
In fact, not only unmutated CLL but also mutated CLL appears to be highly similar to 
normal CD5+ B-lymphocytes.311-313 Thus, transcriptome analyses revealed that IGHV gene 
unmutated CLL might derive from unmutated mature CD5+ B lymphocytes, while mutated CLL 
would most likely derive from a distinct CD5+CD27+ post-GC B cell subset.309 Notably, these 
CD5+ B cell populations appear to be enriched in stereotyped IGHV gene rearrangements, at 
the same time they also include oligoclonal expansions already among young healthy adults. 
Therefore, these CD5+ PB B-cells may potentially already represent an early phase in CLL 
development, prior even to the CLL-like MBL precursor cell. Alternatively, it has also been 
proposed that CLL cells could derive from splenic marginal zone B-cells, based on the 
functional similarities between CLL and this subset of normal B-lymphocytes (Figure 3A).22 In 
this regard, it should be noted that several studies which have focused on IGHV/IGLV gene 
usage by CLL cells, including analysis of the IGHV mutational status and the IGHV repertoire, 
gene expression profiling and cellular phenotypes (e.g. CD27, ZAP-70 or CD38 expression) have 
found that CLL cells are more similar to memory than to naïve B-lymphocytes; consequently, 
CLL cells appear to potentially have a past history that would include Ag 
stimulation.227,228,237,292,314-316  
Interestingly, the Ag reactivity profile of the BCR of CLL cells appears to overlap with 
that of natural antibodies produced in the absence of exogenous Ag stimulation, and that play 
a crucial role in immediate host defense against a wide range of pathogens.247,317 Further 
studies have demonstrated that both self-reactive and polyreactive BCR profiles are inversely 
related to the mutational load of the BCR.318 These apparently discrepant findings could be 
related to the fact that BCR-dependent transductional signaling pathways are still efficient in 
unmutated CLL, while deficient in mutated CLL cells.319 Since unmutated IGVH/IGVL genes 
generally encode for antibodies with a natural/polyspecific profile, it has been proposed that 
the neoplastic B-cells using these genes would be continuously stimulated in vivo by self-
antigens that have the capacity to react with their SmIg.320 Thus, neoplastic transformation 
might potentially occur when these B cells are expanding in response to T-independent Ags, 
and they may continue to do so, also after neoplastic transformation. This would explain, at 
least in part, the expression of activation markers like ZAP-70 and/or CD38 on such stimulated 
and transformed cells, which occurs less frequently among those cases where the neoplastic 
cells used mutated IGHV genes.321 These latter cases typically express surface Ig which do not 
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show a natural/polyspecific reactivity profile.322 Although such IGHV mutated CLL cells may 
have expanded in response to antigenic stimuli acting before (or during) transformation they 
do not appear to be affected by antigenic stimulation thereafter, once the transformation 
process had been completed.323  
Based on all the above, it could be hypothesized that unmutated CLL would derive 
from marginal zone B-cells, while mutated CLL cases would have their origin on memory B-cells 
that have exited the GCs at the end of their selection process.8 However, several features of 
these two groups of CLL (unmutated and mutated CLL) do not seem to confirm such 
hypothesis. Firstly, most memory B-cells that transit through the GC and undergo isotype 
switch, express surface IgG or IgA, rather than IgM;324 secondly, CLL cells from both unmutated 
and mutated cases present rather similar gene expression profiles as assessed by high-density 
microarrays.315,325,326 An alternative possibility would be that both subsets of CLL originate from 
the same type of cell (e.g. from marginal zone B-cells), IGHV mutations potentially occurring in 
mutated CLL cases, while the cells respond to a particular TI Ag, either prior to or during 
neoplastic transformation in the marginal zone (Figure 3A).327 As a result of these mutations, 
the polyspecificity of the antibody itself is lost and the cells are no longer susceptible to in vivo 
stimulation by self-antigens. Hence, without this important promoting factor in 
leukemogenesis, B-cells which had undergone SHM would expand less rapidly and would 
exhibit a more benign clinical course than the unmutated CLL cases. In line with this latter 
hypothesis, site-directed mutagenesis tests on the IGHV/IGLV genes have demonstrated that 
elimination of the mutated spots and reversion to the unmutated IGVH/IGVL gene 
configuration, results in the synthesis of antibodies with natural/polyspecific activity;318 these 
observations reinforce the concept that the same cells that initially had natural/polyspecific 
activity had given origin to both the mutated and the unmutated CLL cases.318 If this hypothesis 
holds true, then, it would also contribute to explain their similar surface phenotype and GEP, 
as well as the shared biological features of CLL cells from these two groups of CLL cases. 
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 Figure 3. Schematic representation of "multistep" models for human CLL development. Panel A: Encounter of naive 
B-cells with antigen may proceed either through a T cell–dependent reaction occurring in the germinal center (GC), 
leading to the generation of memory B-cells that have undergone somatic hypermutation of the IGHV genes, or in T 
cell–independent immune responses, it may lead to the formation of antigen-experienced B cells harboring 
unmutated IGHV genes. CLL, and the preceding MBL phase, may originate from either of these subsets of antigen-
experienced B cells. Two distinct CD5
+
 B cell subsets (unmutated mature CD5
+
 B cells and CD5
+
CD27
+
 post–GC B 
cells) and marginal zone (MZ) B cells have been identified as the potential cell compartment in which CLL originates. 
Panel B: alternatively, based on a xenogeneic transplantation model, it has been shown that genetic abnormalities 
can accumulate on CLL hematopoietic stem cells (HSC) that might amplify B cell differentiation and produce a high 
number of polyclonal B cells carrying the same genetic aberrations. B cell clones would be then selected and they 
would expand in response to BCR signaling, presumably driven by autoantigens, simulating progression of MBL. 
Additional abnormalities such as aberrant karyotypes might play a role in progression from MBL into CLL in humans 
[Adapted from: Gaidano, G et al. 
328
 and Kikushige, Y et al.
329
]. 
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3.2.6.2. Stepwise model of development of MBL into CLL from early HSC 
 
In order to trace the origin of CLL B cells, it should be noted that CLL cells from 
individual patients are not always monoclonal, and that two or more coexisting CLL clones are 
found in up to ≈5% of CLL patients.21 Furthermore, a recent cohort study has shown that 44/45 
patients with CLL had a precursor MBL state which had been identified between 6 months and 
7 years in advance.212 Of note, MBL is more frequently composed of two or more coexisting B 
cell clones (20%–70% of total cases) than CLL, this being a particularly frequent finding among 
MBLlow and in familial CLL cases.15,20,203 These findings strongly support a model for stepwise 
development of CLL from an MBL oligoclonal precursor state, similarly to what has been 
described for other human cancers. Thus, stepwise development of MBL into CLL could have 
its onset in a mixture of polyclonal cells with one single dominant clone progressively taking 
over, such expanded B-cell clone either obscuring or eliminating other MBL clones. Recent 
evidences suggest that in such model, the first oncogenic event could be traced back at least 
up to the progenitor or HSC that has not rearranged the IGHV genes (Figure 3B).329 In parallel, 
signaling through receptors on the expanded cells, particularly BCR signaling, would play a 
critical role in the pathogenesis of CLL, through its contribution to further oligoclonal and/or 
monoclonal expansion of B cells from the initial pool of (precursor) polyclonal B-cells.  
In line with this hypothesis, recent studies by Kikushige et al.329 in a xenogeneic mouse 
model, reported that HSC from CLL patients have an increased susceptibility to generate 
expansions of (oligo-mono)clonal B cells carrying V(D)J gene rearrangements which are always 
unrelated to those of the original CLL cells. These findings, suggest that aberrant CLL-HSC have 
already intrinsic abnormalities that cause their skewing towards the B-cell lineage, supporting 
early involvement of HSC in the pathogenesis of the disease, as aberrant preleukemic cells that 
produce an increased number of polyclonal (altered) pro-B cells (Figure 3B). The resulting 
mature B cells could be then selected most likely via the recognition of autoantigen(s), 
resulting in expanded mono- and/or oligoclonal B cell populations. Later on, along the B-cell 
differentiation pathway, additional genomic abnormalities would develop, eventually resulting 
in a typical clonal MBL and/or CLL disorder. Despite all the above, it should be noted that the 
role of such genetic abnormalities of HSC may be very limited (or even nonexisting) in the early 
phases of development of MBL, whenever the microenvironmental stimuli would play a more 
prominent role. Subsequently, genetic abnormalities disrupting the control of cell growth and 
survival may cooperate with microenvironment triggered events, mainly represented by 
antigen-mediated BCR and coreceptor stimulation, to trigger and fuel clonal B-cell expansion. 
In line with this, whole-genome sequencing (WGS) approaches have contributed to the 
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identification of multiple recurrent somatic mutations (e.g. NOTCH1, MYD88 and XPO1), which 
appear to contribute to determine or modulate the clinical evolution of CLL.6 In this regard, 
integrated mutational and cytogenetic analyses, have shown that clonal evolution from lower 
to higher risk CLL is associated with the emergence of molecular alterations (e.g. mutations) of 
the NOTCH1, SF3B1, and BIRC3 genes in addition to those of the TP53 and ATM genes;264 
moreover, SF3B1 mutations primarily occur in CLL cases with del(11q)330 and NOTCH1 
mutations are frequently associated with trisomy 12.331 In addition, other altered genes such 
as BAFF, specific Lyn substrate 1 (HS1) and Toll IL-1R 8 (TIR8) appear to influence the natural 
history of the disease.332 Most interestingly, previous studies indicate that virtually all 
recurrent mutations described so far in CLL appear to emerge and act only at relatively late 
stages of MBL and/or CLL; some of them may even underlie CLL transformation to Richter 
syndrome.333 Therefore, such molecular/genetic alterations appear to contribute more to 
elucidate the genetic basis of CLL progression, rather than of MBL evolution, the potential 
initiating genetic alterations still remaining to be identified. The only exception relies on a 
recent report which is based on a model where deletion of the entire minimal deleted region 
at 13q14 chromosome, encoding for the DLEU2/miR-15a/16-1 gene cluster, which suggests 
that del(13q) could lead to the development of low penetrance indolent B-cell clonal 
lymphoproliferative disorders that appear to recapitulate the whole spectrum of human CLL-
associated phenotypes from MBL to Richter syndrome.334 This approach underlines the critical 
importance of the deleted region, which appears to harbor gene(s) involved also in the first 
steps of leukemogenesis in CLL, but it would not explain the origin of cases which have 
unaltered chromosome 13q14 sequences.  
 
3.3. B-cell lymphoproliferative disorders (B-CLPD) other than chronic lymphocytic 
leukemia (CLL)  
 
Classification of B-CLPD other than CLL relies to a significant extent on the relationship 
between the expanded B-cells and the GC reaction within secondary lymphoid organs. Thus, B-
CLPD other than CLL are currently classified as pre-GC, GC and post-GC neoplasms since these 
WHO 2008 categories of ‘‘mature’’ B-cell tumors are considered to arise from B cells, that have 
already undergone V(D)J recombination at the IGH and IGL loci and that are independent of 
early hematopoiesis and HSC.181 However, it should be noted that most evidences supporting a 
model of cell-of-origin that links these mature B cell tumors to post-VDJ recombination stages 
of the B-lymphoid ontogeny and the GC reaction, are indirect evidences, based on shared 
phenotypes by normal and tumor B-cells such as the pattern of expression of cell surface 
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markers and the capacity for ongoing SHM of the tumor cells and their “normal” counterparts 
(Figure 4).7 
Figure 4. Cellular origin and immunophenotypic profile of human B-cell lymphoproliferative disorders (B-CLPD). 
Human B-CLPD are assigned to their potential normal B-cell counterpart, despite they also display aberrant patterns 
of protein expression which are presumably related to the cytogenetic abnormalities carried by the tumor cells 
and/or the altered microenvironment. ABC DLBCL, activated B-cell diffuse large B-cell lymphoma; GC DLBCL, 
germinal center derived DLBCL [adapted from Sagaert, et al.
324
 and Zenz, et al.
335
].  
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3.3.1. Peripheral/mature B-cell chronic lymphoid leukemias other than CLL  
 
Peripheral/mature B-cell chronic lymphoid leukemias other than CLL, traditionally 
include two major WHO 2008 disease categories: B-cell prolymphocytic leukemia (B-PLL) and 
hairy cell leukemia (HCL). 
 
3.3.1.1. B-cell prolymphocytic leukemia  
 
B-PLL is a rare and aggressive mature/peripheral lymphoid malignancy. For its 
diagnosis, the presence of prolymphocytes which account for more than 55% of all PB 
lymphoid cells on morphological grounds (usually > 90%), is required.181 Of note, mature B-cell 
leukemias, such as CLL (particularly CLL/PLL), MCL or SMZL, and HCL variant (HCLv) share 
similar features at presentation to those of PLL, and recent studies indicate that most PLL cases 
could in fact represent a unique subgroup of MCL.336 Despite its similarity to both SMZL and 
HCLv in terms of its clinical presentation, no cytoplasmic hairy projections or “villi ” are seen in 
PLL, and the presence of B symptoms, a very high white blood cell (WBC) count (> 100 × 109/L), 
and an aggressive clinical course, are much more characteristic of PLL than of SMZL or 
HCLv.337,338 In comparison to CLL/SLL, PLL has been described as having strong Ig, CD20/FMC7 
and CD79b expression, in association with CD23low/– and decreased staining for CD5 in a 
fraction of the patients (Figure 4).  
The most common cytogenetic abnormality seen in PLL is del(17p) involving loss of the 
TP53 gene339 and t(11;14) associated with expression of cyclin D1 and/or SOX11, the latter 
supporting the close relationship between PLL and MCL with a leukemic presentation.340,341 
Regarding their molecular features, PLL leukemic cells express a skewed repertoire 
characterized by predominant usage of distinct members of the IGHV3 gene family (73%), 
preferentially of the IGHV3–23 gene (50% of the IGHV3 genes).342 The type and distribution of 
IGHV mutations clearly indicates that in some cases the tumor cells have undergone through 
an Ag selection process.  
 
3.3.1.2. Hairy cell leukemia 
 
HCL is a rare type of leukemia characterized by the presence of large mature-appearing 
B cells, with an abundant cytoplasm and characteristic micro-filamentous (“hairy”) projections 
– hairy cells (HC) –.343 HC typically infiltrate the BM, the spleen, and to a lesser extent also the 
liver, LN and the skin.  
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Studies about the GEP of B cells from discrete subsets of normal B-cells vs. HCL cells 
have shown that HC are related to memory B-cells, although with an altered pattern of 
expression of genes controlling cell adhesion and expression of chemokine receptors.344 
Moreover, several phenotypic features of HC can be explained in the context of a highly 
activated B-cell that appears to have undergone the sequence of reactions that during normal 
immune responses occur upon stimulation by Ag, accessory cells and cytokines. Therefore, HCL 
is typically associated with an increased expression of activation-associated markers at 
intermediate to bright intensity, such as CD25, CD11c, FMC7, and CD103.345 Other unique 
immunophenotypic features of HC that contribute to the diagnosis of the disease include: 
overexpression of CD20, CD22, CD19, CD72 and CD305 (LAIR1); intermediate intensity of 
expression of CD79b, CD123, T-bet, anexin A1 and HC2; intermediate to bright positivity for 
SmIg (generally SmIgM or SmIgD but also SmIgG or SmIgA), and; lack of expression of CD23 
and CD24.346-350 In addition, CD5 and CD10 are expressed on HC from a minority of cases 
(Figure 4).177,345 Although, AID is expressed in HCL, HC fail to express GC-associated markers 
such as CD38, CD10 and Bcl6, at the same time they lack the CD27 memory B-cell marker in 
the great majority of cases.351 
For many years, no recurrent chromosomal translocations and molecular alterations 
had been identified in HCL. More recently, the BRAF V600E mutation has been reported in the 
classic forms of HCL only, as the first genetic alteration recurrently associated with this 
disease.352 Some cytogenetic alterations involving monoallelic deletions of TP53 and BCL6 have 
also been reported in a subset of cases.353 
Due to the rarity of the disease, analysis of the IGHV gene has been only performed in 
small series of cases.354 Despite this, results show that most HCL carry mutated IGHV genes 
with low levels of intraclonal heterogeneity, unmutated IGHV genes occurring only in a minor 
subset of patients who are refractory to (single-agent) cladribine and have a more aggressive 
behavior.351,355 In turn, HCL is characterized by biased usage of the IGHV3-21, IGHV3-30 and 
IGHV3-33 genes which are highly homologous gene segments; thus, the BCR of HCL patients 
may share the ability to bind identical or highly similar Ags, and potentially react with common 
bacterial superantigens, such as modified staphylococcus aureus protein A or the natural 
staphylococcus aureus enterotoxin A.356 In line with this hypothesis, IGHV3-30 has been 
reportedly involved in the immune response against Toxoplasma.356 Clearly, the pressure on 
IGHV selection in HCL appears to be different from that potentially occurring in other B-cell 
neoplasms, particularly in CLL. For example, IGHV4-34 is used predominantly in a mutated 
conformation by CLL cells, while it is preferentially unmutated in HCL cases.357,358 Interestingly, 
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the apparent lack of HCDR3 stereotypy in HCL is another distinctive feature of HCL vs. CLL and 
suggests that Ag driving in HCL may not rely on HCDR3-mediated interactions.  
 
3.3.2. Peripheral/mature B-cell lymphomas other than SLL 
 
3.3.2.1. Marginal zone lymphoma 
 
MZL represents about 8-10% of all lymphomas and the third most frequent type of 
lymphoma, just after diffuse large B-cell lymphoma (DLBCL) and FL. At present it is widely 
accepted that MZL comprises distinct lymphoma types, which are considered to originate from 
marginal zone B cells. Depending (mainly) on the organ in which the lymphoma arises, the 
current WHO 2008 classification recognizes three distinct types of MZL: nodal (NMZL), 
extranodal MZL of MALT type (or MALT lymphoma) and splenic marginal zone lymphoma 
(SMZL), depending on whether the disease arises in the LN, mucosal sites and the spleen, 
respectively.180 MZL shares some common immunophenotypic features, but the clinical course 
and molecular characteristics are different for each of the distinct subtypes of the disease. 
More recently, a fourth subtype of MZL named “primary BM MZL” (PBM-MZL) has also been 
described as a provisional entity that still deserves full recognition prior to inclusion into the 
new WHO classification.359 
 
3.3.2.1.1. Extranodal marginal zone lymphoma of mucosa-associated lymphoid 
tissue or MALT lymphoma 
 
MALT lymphoma is the most common type of MZL. It is a clinically indolent disease 
which preferentially arises in the stomach and small intestine, but that can occur in almost all 
mucosal tissues and in the skin. MALT lymphoma is therefore thought to arise from peripheral 
lymphoid tissues by long-standing (auto)antigenic stimulation, such as that observed during 
chronic infection and inflammatory disorders.360,361 Several infectious agents and inflammatory 
disorders have been associated with MALT lymphomas, among which the association between 
gastric MALT lymphoma and Helicobacter pylori infection (up to 90% of cases) is the best 
characterized.361 
MALT lymphoma cells express CD19, CD20, CD22, CD25, CD79b and CXCR3, typically in 
the absence of CD5, CD10 and CD45RO, and they show variable patterns of expression of CD23 
and CD27 (Figure 4).362 From the genetic/molecular point of view, it presents with several 
recurrent genomic lesions, including chromosomal translocations and unbalanced 
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alterations.10 Thus, MALT lymphomas frequently have translocations involving the API2, 
MALT1, BCL10, and FOXP1 genes.363 T(11;18)(q21;q21) involving the API2 gene at chromosome 
11q21 and the MALT1 gene at 18q21 chromosome, is the most common structural 
chromosomal abnormality in MALT lymphoma and its presence is usually correlated with the 
lack of any further genetic instability or chromosomal imbalances; in turn, t(3;14) and t(14;18) 
fuse the BCL10 and MALT1 genes to the heavy chain of the Ig locus, respectively.364 Of note, 
the above mentioned chromosomal translocations are mutually exclusive and they typically 
show a different anatomic distribution.365  
 
3.3.2.1.2. Splenic marginal zone lymphoma 
 
SMZL is a relatively rare disease comprising 1-2% of all NHL and roughly 20% of MZL. It 
is mostly, but not always, a clinically indolent lymphoma.180 The lymphoma originates in the 
spleen, and spreads in most cases to the BM; in addition, it is also detectable in the PB in a 
variable number of cases. SMZL is assumed to arise from the splenic marginal zone B-cells and 
it has a concordant CD20high, CD19+, CD79bhigh, CD20/FMC7+, CD22+, CD43+/–, CD11c+, 
SmIgMhigh, SmIgDlow, CD27+, CD5–/+, CD103–, HC2–, CD25–, CD10– and CD23– immunophenotype 
(Figure 4).366 
Skewed VH gene usage is pronounced in SMZL, with about 30% of cases using the 
IGHV1-2 genes.244 Also highly homologous CDR3 regions are observed among the latter cases, 
which may indicate Ag stimulation as part of SMZL lymphomagenesis.367,368 In geographic areas 
where HCV and malaria infections are endemic, SMZL cases associated with these infections 
are frequently observed.369  
In the largest series of SMZL (n=330 cases) in which cytogenetic analyses have been 
performed, it has been shown that 72% of cases exhibit chromosomal aberrations, of which 
53% include complex genetic changes.370 However, none of these cytogenetic abnormalities is 
considered to be characteristic of SMZL, with the exception of del(7q32) that occurs in 39% of 
the cases.370 Other cytogenetic alterations involving chromosomes 8, 9p34, 12q23-24, 18q, and 
17p have been reported.370 In contrast to what occurs in MALT lymphoma, chromosomal 
translocations involving the Ig loci are rarely found in SMZL. 
 
3.3.2.1.3. Nodal marginal zone lymphoma 
 
NMZL, also called monocytoid B-cell lymphoma, is a primary nodal B-cell MZL in the 
absence of evidence for splenic or extra-nodal involvement; it represents 1.5–1.8% of all 
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lymphoid neoplasms.181,371,372 Most NMZL cells express pan-B-cell markers including CD20, 
CD79a and PAX5, together with CD43 in around half of the cases.373 NMZL cells typically lack 
expression of CD5, CD23, CD10, Bcl6, anexin A1, and cyclin D1, whereas Bcl2 is positive in most 
cases.181,367,373  
As for other types of MZL, NMZL cases have been reported in association with 
infections (e.g. HCV)374,375 and autoimmune  disorders (e.g. rheumatoid arthritis, systemic 
lupus erythematosus, Sjögren’s syndrome).376 However, this evidence remains far from 
sufficient to establish a definitive role for these stimuli in lymphomagenesis. In turn, multiple 
studies have shown that in the majority of NMZL patients, SHM of rearranged Ig genes and 
preferential usage of IGHV3 and IGHV4 (particularly of IGHV4-34) occurs, further suggesting 
that antigenic stimulation is involved in the ontogenesis of this type of MZL.377 Despite 
preferential usage of IGHV4-34, no association with EBV and CMV has been established, as for 
CLL.249 However, in NMZL patients with HCV, IGHV1-69 seems to be preferentially used.378,379  
Finally, no unique and/or characteristic cytogenetic abnormality of NMZL has been 
reported so far. The cytogenetic alterations reported in this subtype of MZL include trisomy 3 
(present in about 20-25% of cases),380 7, 12, and trisomy 18, plus structural rearrangements of 
chromosome 1 with breakpoints at the 1q21 or 1p34 chromosomal regions;381,382 in contrast, 
SMZL-related 7q losses have not been reported among NMZL cases.383 
 
3.3.2.1.4. Primary bone marrow marginal zone lymphoma  
 
Among MBL cases with <5,000 B-cells/µl of PB and a CD5– non-CLL-like 
immunophenotype in the absence of LN, spleen and extranodal involvement, a new B-CLPD 
entity showing clonal B-cell lymphocytosis with marginal zone features, has been identified.359 
These cases usually correspond to adults between the 4th and 8th decades of life with a similar 
distribution per sex, and variable levels of PB infiltration by small B-lymphocytes with a 
monocytoid-like morphology, mixed with villous lymphocytes and lymphocytes with 
plasmacytoid features and a MZL phenotype; presence of serum paraproteinemia is observed 
in one third of the cases359 and BM infiltration with a mixed nodular-interstitial pattern that 
varies from 10% to 70% of the whole BM cellularity, is also usually present. From the 
cytogenetic point of view, most cases show a normal karyotype (≈70% of cases) while others 
have complex cytogenetic profiles, where chromosomes 3, 12, 17 and 7 are those 
chromosomes more frequently involved, with e.g. del(7q) and iso17q in 13% and 17% of the 
cases, respectively. Most PBM-MZL patients show mutated IGHV genes with a clear 
predominance of the IGHV4-34 gene. 
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From the clinical point of view, most PBM-MZL display an indolent and stable (clinical) 
course of the disease, although in some cases (particularly those with complex karyotypes) 
progression to symptomatic MZL, usually to a splenic MZL, is observed.384  
 
3.3.2.2. Follicular lymphoma  
 
FL accounts for 20%–30% of all lymphoid tumors, with the highest incidence in the 
Western countries.385 From a biological point of view, FL represents the neoplastic equivalent 
of the reactive GC B-cell, presenting with varying and abnormal ratios of centroblasts and 
centrocytes. Tumor cells may leave and (re)enter the GC; consequently, they may periodically 
acquire novel SHM in their IGH and IGL genes. Indeed, either analysis of individual tumor cells 
or molecular cloning of IGH gene rearrangements from a pool of tumor cells, have both 
demonstrated that not all tumor cells share the same SHM within each individual lymphoma, 
as a result of subclonal evolution associated with distinct patterns of ongoing SHM of the IG 
loci.386,387 
The t(14;18)(q32;q21) chromosomal translocation represents the cytogenetic hallmark 
of FL and it is detected in 80%–90% of cases. Its molecular consequence is the juxtaposition of 
the BCL2 protooncogene close to the enhancer sequences of the IGH promoter region;388,389 
this leads to deregulated expression of Bcl2, resulting in overexpression of the Bcl2 protein in 
the neoplastic follicles.390 Less frequently, variant translocations of t(14;18) also occur, such as 
t(2;18) or t(18;22), in which the BCL2 gene is juxtaposed to the loci of the Ig light chains genes 
(κ or λ, respectively). All these events lead to accumulation of inappropriately rescued GC B-
cells with a prolonged life span, allowing for the occurrence of additional genetic hits that are 
required for the establishment of an overt FL. Consequently, a relatively high number of 
secondary chromosomal alterations have been described in FL including structural and 
numerical changes. Of note, it has long been recognized that these alterations occur in a non-
random fashion, and a temporal order in the emergence of these aberrations has been 
described, some occurring early in the course of the disease, whereas others usually represent 
late genetic events.391-394 In addition, some of the reported alterations are mutually exclusive, 
while others frequently cluster together, potentially leading to coordinated deregulation of 
specific genetic pathways.395 From the clinical point of view, such secondary genetic hits are 
crucial to distinguish different subgroups of FL with distinct biological behavior, risk of 
transformation to aggressive lymphoma, prognosis and overall survival (e.g. BCL2 plus CMYC 
double hit transformed FL).396 
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Phenotypically, tumor cells from FL are most frequently characterized by 
overexpression of Bcl2, strong reactivity for SmIgM, CD20/FMC7, CD22 and CD79b. As normal 
GC B-cells, FL cells also express intermediate intensity CD10, Bcl6 and CD38 (Figure 4).397,398 
Conversely, these cells usually lack CD5, CD11c, CD23, CD43, CD103, CD200, CD305 and HC2 
expression. CD19 is frequently underexpressed, or even negative in some FL cases (Figure 
4).397,398 Ki-67 is typically recommended for the assessment of the proliferation index of FL 
which is highly variable.  
 
3.3.2.3. Mantle cell lymphoma 
 
MCL is a relatively rare subtype of B-cell lymphoma, comprising 5%–7% of all 
lymphomas.399 Typically, MCL is a very aggressive disease with a poor outcome,400 that has 
specific genetic lesions and a characteristic CD5+ immunophenotype. This phenotype differs 
from that of typical CLL/SLL in that MCL cells express CD20, CD22, CD79b and SmIg at 
moderate to bright intensity, and they are usually CD23 and CD200 negative while FMC7+ 
(Figure 4).397,401 Both CD38 and the proliferation marker Ki-67 show variable levels of 
expression.402 Recently, an indolent variant of MCL termed asymptomatic B cell lymphocytosis 
with cyclin D1 expression has been described with a unique CD38– CD200low vs. CD38low/+ 
CD200– immunophenotype.403 
The genetic lesion typical of MCL is the t(11;14)(q13;q32) translocation which 
juxtaposes the CCND-1 gene (also known as BCL-1 or PRAD-1 gene) encoded at chromosome 
11q13 with an enhancer of the IGH gene at chromosome 14q32.404 As a consequence, this 
translocation leads to an enhanced/continuous cell proliferation due to constitutive activation 
of the CCND1 proto-oncogene and overexpression of cyclin D1 mRNA and protein.404 In rare 
cases, MCL is cyclin D1–; when this happens, cyclin D2 or cyclin D3 can be overexpressed.405  
The t(11;14)(q13;q32) translocation most likely occurs as an initial oncogenic event at 
the pre–B-cell stage of differentiation in the BM, during recombination of the V(D)J segments 
of the IGHV. However, the tumor is composed of a unique population of mature-appearing B 
lymphocytes, indicating that the full neoplastic phenotype is acquired at later stages of the B-
cell differentiation process.406 Based on the pattern of expression of SmIgM/SmIgD and CD5 by 
the tumor cells, their topographic distribution in the mantle zones, and the predominant usage 
of unmutated IGHV genes, naive B-cells have been generally considered the normal 
counterpart of MCL tumor cells.407 However, analysis of BCR diversity in MCL has shifted this 
view to a more complex ontogenetic model, in which Ag selection would play also an 
important role in the pathogenesis of the disease, at least in a subset of the cases. For 
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example, some studies have shown that 15%–40% of MCL carry IGHV hypermutation, with 
around 10% of MCL showing stereotyped Ig heavy chain CDR3 sequences and a restricted VH 
gene repertoire, associated with predominant usage of the IGHV3-21, IGHV4-34, and IGHV5-51 
genes.408 Of note, the two former VH genes have a strong association with autoimmunity and 
the VH3-21 gene seems to be also overrepresented in CLL with mutated IGHV genes, and 
associated with a significantly poorer overall survival than that found for CLL cases with other 
mutated IGHV genes.357,409 Moreover, IGHV3-21+ MCL patients appear to almost exclusively 
show usage of the IGVλ3-19 gene.357 In contrast to CLL, the IGHV gene mutation status is not 
prognostically informative among MCL patients. 
 
3.3.2.4. Diffuse large B-cell lymphoma 
 
DLBCL is the most common subtype of NHL, accounting for approximately one-third of 
all adult lymphomas.410 It is characterized by a diffuse proliferation of large mature B-cells that 
mainly occurs in LN, although involvement of extranodal sites is observed in up to 40% of the 
cases.362 BM involvement is found in 11% to 27% of all cases, whereas PB is rarely (5%-10%) 
infiltrated.180 DLBCL is a heterogeneous lymphoma which may arise either as primary (de 
novo), or may result from a transformation of an indolent lymphoma.  
The great morphological, clinical and biological heterogeneity of DLBCL confirms the 
existence of several subtypes of the disease with different clinical outcomes.  According to the 
WHO 2008 classification, DLBCL may be subdivided into several morphological variants (Table 
1).180,411,412 Similarly, GEP studies grouped DLBCL into three subtypes which are 
morphologically indistinguishable; these three GEP subgroups of DLBCL are associated with 
different pathogenetic mechanisms and they include activated B-cell DLBCL, germinal center 
DLBCL and primary mediastinal DLBCL (Table 1).413 Consistent with this heterogeneity, the 
genetic lesions associated with DLBCL are also diverse and include balanced reciprocal 
translocations deregulating the expression of BCL6, BCL2 and MYC, gene amplifications, 
nonrandom chromosomal deletions (e.g. 6q) and aberrant somatic hypermutation.414-418 
Nonetheless, in a significant fraction of DLBCL, no specific genetic changes have been 
identified which could potentially contribute to the pathogenesis of the disease.  
The BCL6 gene is one of the most frequently affected genes in DLBCL. BCL6 promotes a 
higher cell survival and genetic instability, which both contribute to malignant 
transformation.419 In turn, t(14;18) results in overexpression of the Bcl2 protein in an identical 
way as in FL, this cytogenetic alteration being found in 15% to 30% of all DLBCL cases and 
virtually all GC-associated DLBCL patients.419,420 Genetic recombination of the MYC gene can be 
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found in 2% to 16% of DLBCL cases being specially frequent among extranodal DLBCL cases; 
MYC gene rearrangements are associated with a great rate of central nervous system 
involvement, lower complete remission rates and a poorer overall survival.421 
There is no specific DLBCL immunophenotype. Large neoplastic B-cells have strikingly 
higher forward light scatter (FSC) and sideward light scatter (SSC), once compared to normal B 
lymphocytes, and they express variable patterns of pan-B-cell markers (CD19, CD20, CD22 and 
CD79b) (Figure 4); despite a mature B-cell phenotype, a subset of these lymphomas does not 
demonstrate SmIg or CyIg expression.422 A proportion of cases express CD5 and/or CD10, the 
former marker being associated with an unfavorable clinical course.423 Indeed, CD5+ DLBCL 
may consist of a large cell lymphoma transformed from a lower-grade CD5+ B-cell neoplasm 
such as CLL/SLL (Richter syndrome) or de novo CD5+ DLBCL, including extremely rare cases of 
CD5+ intravascular large B-cell lymphoma (Table 1).424  
 
3.3.2.5. Burkitt lymphoma 
 
Three different clinical variants of BL have been described so far: EBV-associated 
endemic and sporadic BL, and immunodeficiency (HIV)-associated BL.180,181 Although all three 
variants share many morphologic and immunophenotypic features, they have distinct clinical 
and geographical presentations.181 Regarding cytogenetics, there is considerable overlap 
among the three subtypes of BL, but unique genetic features have also been described among 
these variants, potentially reflecting distinct pathogenetic mechanisms.425   
BL cells express SmIgM, Bcl6, CD19, CD20, CD22, and CD79a, and they are negative for 
CD5, CD23, and TdT, in association with a characteristic CD38high, CD81high, CD10+ GC-
phenotypic profile (Figure 4). Since CD10 is positive in nearly all cases, the typical absence of 
Bcl2 expression in association with very high levels of CD81 is helpful in ruling out “double-hit” 
lymphomas with dual translocations affecting MYC and BCL2.426,427 Translocations involving the 
CMYC oncogene are the molecular hallmark of BL, and they are seen in virtually all cases in 
association with a high proliferation rate. In most cases, CMYC gene rearrangements involve 
the IGHV gene on chromosome 14; less commonly, the light chain genes on chromosomes 2 
and 22 are involved in the CMYC translocation.426,427 Sometimes, CMYC translocations may also 
involve a non-IG partner gene.428,429 
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3.3.2.6. Lymphoplasmacytic lymphoma / Waldenström macroglobulinemia  
 
LPL/WM is a B-cell lymphoproliferative disorder characterized by IgM paraproteinemia 
and the accumulation of clonally related lymphocytes, lymphoplasmacytic cells and plasma 
cells in the BM.362,430 Some patients suffer from hyperviscosity caused by exceeding levels of 
the IgM paraprotein, which may be useful in differentiating LPL/WM from other neoplasms 
with plasmacytoid differentiation.362,431 
Morphologically, LPL/WM is characterized by proliferation of small B-cells, 
plasmacytoid cells and also plasma cells. The plasma cell component expresses the same Ig 
light chain as the lymphocytic component, it is positive for CD138 and shows low expression of 
B cell–associated Ags such as CD20, Pax5 and SmIg.432 The lymphoma cells typically express 
CD19, CD20, CD22 and CD79b, CD27 and Bcl2, while they usually lack CD5, CD10 and CD23, 
which helps to discriminate LPL/WM from FL, CLL and MCL (Figure 4).432,433 However, 
expression of these latter markers may be found in 10–20% of cases, often at weak and 
variable levels.434 The distinction between LPL/WM and other CD5- small B-cell lymphomas is 
more difficult, and it often requires detailed evaluation of a combination of 
immunophenotypic, genetic, morphologic and clinical features. 
At the molecular level, the neoplastic clone from most LPL/WM cases has undergone 
IGHV somatic hypermutation, but not isotype class switching, retaining the capability for 
plasma cell differentiation.431 The lack of a unique molecular/genetic hallmark of the disease 
has complicated the distinction between LPL/WM and other B-cell lymphomas presenting a 
monoclonal serum component.435 Recently, the MYD88 L265P mutation has been found in 
>90% of cases of LPL/WM, pointing out the utility of this molecular marker to distinguish 
LPL/WM from other entities,431 and the potential involvement of e.g. TLR-signaling in the 
pathogenesis of this disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
In the WHO 2008 classification it is stated that t(9;14) would be present in at least 50% 
of cases. However, translocations involving the IGH genes are actually rare in LPL/WM.436 The 
t(9;14)(p13;q32) translocation results in up-regulation of PAX5, implicating this gene as a 
putative oncogene in the pathogenesis of a subset of LPL.437,438 Overexpression of PAX5 seems 
to prevent expression of high levels of Ig that result in paraproteinemia, supporting the 
absence of t(9;14)(p13;q32) in typical LPL/WM cases associated with a serum monoclonal 
component.439 In turn, there are sporadic reports of WM tumors with IGH gene 
rearrangement, t(11;18)(q21;q21) and chromosome 6q abnormalities, which may also occur in 
other B-cell lymphomas types.439  
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On immunophenotypic grounds, both the lymphoid and the plasma cell compartments 
of LPL/WM neoplastic cells, show an immunophenotype that largely overlaps with their 
normal counterparts with expression of CD25 on the B lymphocyte compartment and positivity 
for immature markers (e.g. CD20+ and SmIg+) on plasma cells, usually associated with 
expression of SmIgK light chains (≈80% of cases).  
 
3.3.3. Multiclonal lymphoproliferative disorders 
 
Generally, neoplastic B-cells from B-CLPD are believed to result from the expansion of 
a single B-cell clone within which all cells share an original transforming mutation, identical 
V(D)J gene segments of the IGH gene, and a restricted expression of the rearranged Ig light 
chain (e.g. kappa or lambda). Additional genetic alterations in association also with different 
phenotypic features, may be gained during the evolution of the disease. However, presence of 
two or more morphologically and/or phenotypically different populations of neoplastic 
lymphocytes in the same patient, detected either simultaneously or at different time points 
during follow-up, has been reported in the literature440-443 at an overall frequency of around 
5% of all B-CLPD.21 Actually, once the prevalence of B-cell neoplasias in elderly patients is 
considered, simultaneous emergence of two distinct clones turns out to be not that 
uncommon. Usually the presence of such coexisting ≥ 2 B-cell populations is interpreted as a 
result of either two completely different (apparently) unrelated B-cell populations –
multiclonality – or subclone formation within the original malignant tumor stem cell line –
intraclonal evolution/heterogeneity –.  
 
3.3.3.1. Composite lymphomas 
 
Composite lymphomas are defined by the coexistence of two or rarely, more than two 
morphologically and/or immunophenotypically different types of lymphoid neoplasms in the 
same patient,  which arise synchronously or metachronously within the same anatomic site.444 
Although these lymphomas can be clonally related or unrelated, and they may comprise many 
different combinations of mature B-cell subtypes,445 they are broadly categorized as follows: 1) 
cases where distinct types of NHL of the same lineage, mostly B-cell lymphomas, coexist; 2) 
coexistence of a B-NHL and a Hodgkin lymphoma (HL);446 3) distinct types of NHL of different 
lineages, e.g. B- and T-NHL,447 and; 4) colocalization of a T-NHL and a HL.448 Most cases in the 
first category represent tumor progression and transformation from an indolent B-cell 
lymphoma, with two or more abnormal B-cell populations usually showing distinct 
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morphological features, light scatter characteristics and/or DNA cell contents, but an identical 
phenotype; for example, Richter transformation of CLL/SLL or transformation of a FL to 
DLBCL.449 In contrast, in a few cases, simultaneous occurrence of two distinct small B-cell 
lymphomas is demonstrated which may involve any specific B-NHL subtype, e.g. MCL and/or 
SMZL. A recent report, about composite lymphoma cases included patients diagnosed with 
MCL and FL, MCL with Hodgkin lymphoma (HL), and MCL with plasmacytoma or SLL, together 
with a case of composite FL with SLL; of note, in none of these patients, the two neoplastic B-
cell compartments were found to be clonally related, based on molecular analysis of the Ig 
gene rearrangement profile.450 Rare cases of composite lymphomas involving SMZL include 
cases associated with HL,451 DLBCL,452 BL,453 or CLL,454 and also, cases of T-cell large granular 
lymphocyte leukemia associated with SMZL.455,456 
 
3.3.3.2. Intraclonal evolution versus multiclonality in B-cell chronic 
lymphoproliferative disorders 
 
Coexistence of two apparently distinct hematological malignancies always raises the 
question about whether or not they share a common cell of origin. As mentioned above, the 
detection of two different, apparently unrelated B-cell clones – already at diagnosis or during 
follow up –, is usually interpreted as the emergence of two clonal populations arising from a 
single primary tumor (intraclonal evolution),457,458 rather than coexistence of two distinct 
lymphoid tumors (true multiclonality).459 Intraclonal evolution and conversion between two 
histological subtypes of B-cell lymphoma is commonly interpreted as being associated with 
differentiation of neoplastic B-cells towards more aggressive disease leading to a shortened 
survival. Conversely, multiclonality appears to be rare. However, multiclonality might have 
been underestimated, since the precise diagnosis of these cases usually requires a 
multidisciplinary approach encompassing histopathology, cytomorphology, 
immunophenotypic, cytogenetic and molecular analyses in each of the cell populations, and 
such studies have frequently not been performed in a substantial fraction of the composite 
lymphomas reported in literature, the potential clonal relationship between the two tumoral 
components, being therefore disregarded.  
 
3.3.3.3. Criteria for multiclonality  
 
Documentation of multiclonality greatly depends on the type of diagnostic methods 
used for the characterization of the co-existing tumor cell populations. Histopathological and 
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immunophenotypic studies, usually reveal this situation – e.g. coexistence of two or more 
distinct and expanded abnormal lymphoid populations –, but neither of the two approaches 
guarantees the nature of the clonal relationship that exists among the coexisting tumor cell 
populations from most cases. Only the genetic rearrangements of the IGHV and/or the 
cytogenetic abnormalities of the coexisting B-cell populations may provide definitive evidence 
to distinguish between a potentially common vs. distinct origin of the involved tumor cell 
populations.460 Hence, multiclonality can only be clearly demonstrated through the 
combination of these techniques (i.e., histopathology and/or flow cytometry plus molecular 
and cytogenetic characterization of each individual population) (Figure 5).  
Regarding MFC immunophenotyping, usage of multicolor gating strategies, involving 
the combined evaluation of the patterns of expression of both Ig heavy and light chains, 
together with maturation-associated markers, is mandatory for precise identification and 
definition of such coexisting cell populations and the identification of distinctive features that 
might be used for their purification, for subsequent molecular/cytogenetic analyses. Physical 
isolation of each individual pathological cell populations through high-throughput cell sorting 
procedures or laser microdissection techniques, allows for a better characterization of the 
coexisting B-CLPD (sub)clones by other methods, such as PCR analysis of IGH gene 
rearrangements and/or the assessment of different genetic abnormalities by iFISH procedures.  
Figure 5. Illustrating example of a gating strategy based on the definition of CD19
+
 cells (Panel A) for the 
immunophenotypic identification and characterization of multiclonal B-CLPD using multiparameter flow cytometry. 
Panels B to E show the gating strategy used for the identification of the two coexisting pathologic B-cell populations 
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(pink dots) and their phenotypic discrimination from the remaining normal B-cells (blue dots) coexisting in the same 
peripheral blood sample. After cell sorting the purified B-cell populations can be evaluated by e.g. PCR analysis of 
IGH gene rearrangements and iFISH (upper right panels) which demonstrated the presence of different IGHV gene 
rearrangements in the two B-cell clones and trisomy 12 retricted to only one of them. SSC, sideward light scatter; 
APC, allophycocyanin; Cy, cytoplasmic; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCPCy5.5, peridinin 
chlorophyll protein-cyanin 5.5.  
 
3.3.3.4. Multiclonality in chronic lymphocytic leukemia  
 
So far, multiclonal CLL has not been fully characterized since only rare cases of CLL with 
>2 CLL-like or non-CLL-like clones have been reported in the literature.21,441,459,461,462 Reported 
cases include multiclonal CLL associated with MCL,443 HCL,463 FL,464 and another CLL.462 
Therefore, the occurrence of multiclonal CLL is currently viewed as unusual and raises 
questions about whether these patients are particularly susceptible to develop B-CLPD in 
general, particularly CLL, and their actual clinical significance. Despite all the above, 
preliminary studies indicate that the frequency of multiclonality among CLL ranges between 
5% and 10% of cases, and it may appear already at diagnosis (≈ 5% of cases) or during follow-
up, sometimes even more than ten years after the initial diagnosis.465 From the clinical point of 
view, CLL patients who present ≥2 B-cell clones, particularly when the CLL clone coexists with a 
non-CLL B-cell clone, seem to have a poorer outcome, as regards the requirement for early 
treatment (treatment-free survival).21 In turn, no data about the impact of multiclonality on 
the final outcome (overall survival) of CLL patients followed for long periods of time (≥ 5-10 
years), is currently available.  
 
 
4. HYPOTHESIS AND OBJECTIVES 
 
B-CLPD are a heterogeneous group of diseases that usually show (mono)clonal 
expansion of a single mature-appearing and aberrant population of B-lymphocytes, arrested at 
a given stage of differentiation. Despite this, patients diagnosed with composite lymphomas 
and other B-cell chronic lymphocytic leukemias – e.g. CLL – have been occasionally reported in 
the literature for decades, particularly among immunocompromised subjects.21,441,461 Although 
early reports considered this phenomenon to be a rare event, current data suggests that it 
might have been underestimated due to the need for sophisticated multidisciplinary 
approaches encompassing combined histopathology, cytomorphology, immunophenotypic 
and cytogenetic techniques, and/or molecular analyses of purified cell populations. Actually, B-
CLPD consisting of two or more phenotypically distinct populations which are clonally 
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unrelated, but that coexist in the same patient (detected either simultaneously or at different 
time points during follow-up), have been reported in the literature (e.g. multiclonal B-CLPD) at 
an overall incidence of around 5% of all B-CLPD.21 Interestingly, presence of different unrelated 
B-cell clones in individual subjects has been shown to be particularly higher (>20%) in 
premalignant B-cell states such as MBL.20,22 In this regard, preliminary data based on a 
relatively small series of subjects also demonstrated that the frequency of multiclonality could 
be particularly high among CLL-like MBL cases from CLL relatives.20 Altogether, these findings 
suggest that, similarly to what occurs in other types of cancer, the development of CLL and 
potentially also of other B-CLPD, at the earliest steps, may involve a mixture of polyclonal cells, 
with one to a few clones progressively taking over. However, the immunobiology of such 
abnormally expanded B cell clones in multiclonal MBL and CLL, remains largely unknown.  
In parallel to the above findings, it has been demonstrated that the SHM status of the 
IGHV genes can divide CLL into two subgroups and that these subgroups experience markedly 
distinct clinical outcomes; at the same time, the identification of these IGHV subgroups of CLL 
also represented an important advance in the understanding of the disease and its 
pathogenesis. Thus, at present it is well-established that CLL B cells, as well as tumor B-cells 
from other B-CLPD, express a distinct restricted BCR repertoire, which suggests a selection 
process driven by specific Ags. Moreover, recent identification of quasi-identical (stereotyped) 
BCR expressed by different CLL patients, reinforces the notion that BCR reactivity may play an 
important role in the B-cell transformation process leading to CLL, although the specific Ags 
recognized by CLL antibodies still remain largely elusive.  
Altogether, these observations indicate that CLL and potentially also other B-CLPD, 
could represent antigen-driven expansions of specific subsets of normal B cells which have 
undergone neoplastic transformation from a multiclonal phase to a monoclonal state, in 
association with stepwise acquisition of genetic alterations and potentially also BCR-
independent growth stimulation, MBL representing an intermediate stage in this oncogenic 
process. Despite this and the already recognized risk factors, it should be noted that at 
present, very limited knowledge exists about the transformation events that select individual 
normal B-cells to become first CLL-like MBL and then, CLL B cells.  
 
Based on the above background, the general objective of this study aimed at gaining 
insight into the early stages of development of B-CLPD through detailed analysis of the 
immunophenotypic, genetic and molecular characteristics of clonal B-cells, paying special 
attention to the role and features of the BCR in both CLL-like MBL and CLL, and their subsets of 
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monoclonal vs. multiclonal cases, as different stages of a putative model of disease 
progression and malignant transformation.  
 
In order to accomplish this goal, we addressed the following three specific objectives: 
 
- To investigate whether specific IGHV repertoires are associated with unique cytogenetic 
profiles, as the basis for stepwise transformation pathways from MBL to CLL; 
 
- To analyze the molecular and cytogenetic features of the expanded B-cell clones from 
multiclonal vs. monoclonal B-cell lymphoproliferative disorders (particularly CLL-like MBL 
and CLL cells) in order to determine whether multiclonality is associated with molecular 
features indicating a greater probability of interaction with shared/common immunological 
determinants, and; 
 
- To investigate the potential relationship between an altered/clonal hematopoiesis and 
antigenic driving forces acting during the expansion of stereotyped vs non-stereotyped CLL 
and CLL-like MBL clones. 
 
In the following sections of this doctoral thesis, a detailed description of the patients 
from whom samples were obtained and studied, the materials and methods used for such 
studies, as well as the results obtained are presented and discussed separately for each of the 
proposed three specific objectives.  
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2.1. Abstract 
  
CLL-like MBL with (MBLhigh) or without (MBLlow) absolute B-lymphocytosis precedes 
most CLL cases, the specific determinants for malignant progression remaining unknown. For 
this purpose, simultaneous iFISH and molecular analysis of well-established cytogenetic 
alterations of chromosomes 11, 12, 13, 14 and 17 together with the pattern of rearrangement 
of the IGHV genes were performed in CLL-like cells from MBL and CLL cases. Our results based 
on 78 CLL-like MBL and 117 CLL clones from 166 subjects living in the same geographical area, 
show the existence of three major groups of clones with distinct but partially overlapping 
patterns of IGHV gene usage, IGHV mutational status and cytogenetic alterations. These 
included a group enriched in MBLlow clones expressing specific IGHV genes (e.g. VH3-23) with 
no or isolated good-prognosis cytogenetic alterations, a second group which mainly consisted 
of clinical MBLhigh and advanced stage CLL with a skewed but different CLL-associated IGHV 
gene repertoire (e.g. VH1-69), frequently associated with complex karyotypes and poor-
prognosis cytogenetic alterations, and a third group of clones with intermediate features, with 
prevalence of mutated IGHV genes, and higher numbers of del(13q)+ clonal B-cells. These 
findings suggest that the specific IGHV repertoire and IGHV mutational status of CLL-like B-cell 
clones may modulate the type of cytogenetic alterations acquired, their rate of acquisition 
and/or potentially also their clinical consequences. Further long-term follow-up studies 
investigating the IGHV gene repertoire of MBLlow clones in distinct geographic areas and 
microenvironments are required to confirm our findings and shed light on the potential role of 
some antigen-binding BCR specificities contributing to clonal evolution. 
 
2.2. Materials and Methods  
 
2.2.1. Patients and samples  
 
A total of 166 subjects presenting one or more CLL-like MBL and/or CLL clonal B-cell 
populations were included in this study: 15 cases (9%) corresponded to healthy individuals 
with MBLlow – <200 clonal B-cells/µL in peripheral blood (PB); 5 males and 10 females; mean 
age of 68±13 years; range: 49-84 years, –33 (20%) were MBLhigh – ≥200 and <5,000 clonal CLL-
like B-cells/µL of PB – (20 males and 13 females; mean age of 72±12 years; range: 37-89 years), 
–114 (69%) had newly-diagnosed untreated CLL (66 males and 48 females; mean age of 70±13 
years; range: 35-89 years) and 4 (2%) had other B-cell lymphoproliferative disorders (B-CLPD) 
with coexistence of one or two CLL-like MBL B-cell population(s) (Table 5). From the 33 MBLhigh 
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cases, 20 (61%) showed clinical MBL (>2,000 clonal B-cells/µl of PB). Individuals corresponded 
to consecutive MBL and CLL subjects from Salamanca (Spain) and Coimbra (Portugal) in the 
western area of the Iberian Peninsula. 
PB samples were obtained from each subject after written informed consent was 
given, and the study was approved by the local ethics committees of the two participating 
centres (University Hospital of Salamanca and Histocompatibility Centre of Coimbra). Diagnosis 
of MBL and CLL was based on the WHO 2008 criteria.466 Clinical staging of CLL subjects 
according to Binet classification466 was collected retrospectively; 46/77 (60%) CLL cases were 
diagnosed as stage A and the remaining cases (31/77, 40%) as stage B/C. Overall, 37/166 
subjects (22%) showed co-existence of two or three phenotypically different aberrant B-cell 
populations (multiclonal cases; 25 males and 12 females with a mean age of 76±8 years; range: 
57-89 years), while the remaining 129 individuals showed one single phenotypically aberrant 
monoclonal B-cell population (monoclonal cases; 69 males and 60 females with a mean age of 
68±12 years; range: 35-89 years). In 26/37 multiclonal cases, all different B-cell populations 
showed a typical CLL-like phenotype, while in the remaining 11 cases only one B-cell 
population displayed a typical CLL-like phenotype co-existing with population(s) phenotypically 
compatible with other B-CLPD.192 For this study, analysis was focused only on those aberrant B-
cell populations displaying a typical CLL-like and CLL phenotype (n=195 B-cell clones). The 
distribution of all CLL-like and CLL clonal populations analyzed in the distinct diagnostic 
categories was as follows: 27 corresponded to CLL-like MBLlow, 51 to CLL-like MBLhigh and 117 
to CLL (Table 5). 
 
Table 5. Distribution of subjects included in the study and the corresponding CLL and CLL-like 
MBL clones, according to diagnosis. 
   Diagnostic subgroups 
  No. of cases  MBL
low
 MBL
high
 CLL Other B-CLPD 
Subjects Monoclonal 129 13 (87%) 25 (76%) 91 (80%) - 
Multiclonal 37
†
 2 (13%)* 8 (23%)* 23 (20%)*   4 (100%)* 
Total 166 15  33  114  4 
B-cell 
clones 
From monoclonal cases 129 13 (48%) 25 (49%) 91 (78%) - 
From multiclonal cases 66 14 (52%) 26 (51%) 26 (22%) - 
Total 195 27 51 117  - 
*For multiclonal CLL and CLL-like MBL cases as well as for other B-CLPD cases other than CLL, only CLL-like clones 
were considered; the later B-CLPD cases included the following diagnoses: HCL, hairy cell leukemia; SMZL/MALT, 
splenic marginal zone B-cell lymphoma/ extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid 
tissue lymphoma. CLL, chronic lymphocytic leukemia; MBL, monoclonal B-cell lymphocytosis; B-CLPD, B-cell chronic 
lymphoproliferative disorders. 
†
The number of clones per multiclonal case was of two in all diagnostic subgroups, 
except in three tri-clonal subjects corresponding to one CLL patient, one MBL
high
 case and one patient with a B-CLPD 
other than CLL. 
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2.2.2. Immunophenotypic analyses 
 
Immunophenotypic studies to screen for the presence and full characterization of 
clonal B-cell populations were performed on erythrocyte-lysed PB samples according to 
procedures which have been previously described in detail.192,467,468 PB white blood cells (WBC) 
were systematically stained with the following monoclonal antibody (mAb) combinations 
following the EuroFlow recommendations:469,470 1) CD20-pacific blue (PacB)/ CD45-pacific 
orange (PacO)/ CD8-fluorescein isothiocyanate (FITC)+ anti-SmIgλ-FITC / CD56-phycoerythrin 
(PE) +anti-SmIgκ-PE/ CD4-peridinin chlorophyll protein-cyanin 5.5 (PerCPCy5.5)/ CD19-PE–
cyanin 7 (PE-Cy7)/ CD3-allophycocyanin (APC)/ CD38-AlexaFluor 700 (AF700); 2) CD20-PacB/ 
CD45-PacO/ Cybcl2-FITC/ CD23-PE/ CD19-PerCPCy5.5/ CD10/-PE-Cy7 CD5-APC/ CD38-AF700 
and 3) CD20-PB/ anti-sIgλ-FITC/ anti-SmIgκ-PE/ CD19-PerCPCy5.5/ CD10-PE-Cy7/ CD5-APC. All 
cases showed a clonal (imbalanced SmIgκ:SmIgλ ratio of >3:1 or <1:3) and/or an aberrant CD5+ 
B-cell population for the above mAb combinations, as reported elsewhere;15 in every case, the 
phenotypic study was extended with the following additional 5- and 6-color stainings 
(PacB/FITC/PE/PerCPCy5.5/PECy7/APC): 1) CD20/ CD22/ CCR6/ -/ CD19/ CD5; 2) CD20/ CD103/ 
CD25/ CD5/ CD19/ CD11c; 3) CD20/ CD43/ CD79b/ CD5/ CD19/ CD49d; 4) CD20/ SmIgM/ 
CD27/ -/ CD19/ CD5; 5) CD20/ FMC7/ CD24/ - / CD19/ CD5; and 6) CD20/ CD3/ Cyzap70/ -/ 
CD19/ CD5. For the staining of Cybcl2 and Cyzap70, the Fix & Perm reagent kit (Invitrogen, 
Carlsbad, CA, USA) was used, following the recommendations of the manufacturer. All 
reagents were purchased from Becton/Dickinson Biosciences (BDB; San Jose, CA, USA), except 
for CD19-PECy7 (Beckman/Coulter, Miami, FL), CD20-PacB (e-Biosciences, San Diego, CA, USA), 
CD38-AF700 (Exbio, Prague, Czech Republic), CD45-PacO (Invitrogen, Carlsbad, CA, USA), 
CD79bPE, CD24PE and CD43FITC (Immunotech, Marseille, France), and bcl2-FITC, anti-IgM-
FITC, anti-SmIgλ-FITC and anti-SmIgκ-PE (DAKO, Glostrup, Denmark). 
Data acquisition was performed on a FACSCanto II flow cytometer (BDB) using the 
FACSDiva software (v6.1; BDB); in MBLlow cases, acquisition was done using a double-step 
procedure: firstly, information on 1x105 events corresponding to the whole sample cellularity 
was stored; in the second step, information was stored on CD19+ and/or CD20+ gated events, 
containing a minimum of 5x106 leucocytes/tube.  
Instrument setup and calibration were performed according to well-established 
protocols, and a daily quality control program was followed, using the Cytometer Setup and 
Tracking (CST)TM  Beads and CST Module (BDB).  
Data analysis was performed using the INFINICITYTM software program (Cytognos SL, 
Salamanca, Spain). B lymphocytes were identified according to their SSC/CD19+ distribution 
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and their numbers were calculated after excluding cell debris and platelets. The definition of a 
CLL-like/CLL phenotype was based on the presence of a CD19+, CD5+, CD20low, CD23+, CD79blow, 
FMC7-/low, Cybcl2high and SmIgκlow or SmIgλlow, in the absence of CD10 expression. The minimum 
number of cellular events required to define the presence of a CLL-like/CLL B-cell cluster was 
of 50 cells.  
The frequency of distribution of sIgκ+ vs. sIgλ+ populations within the CLL-like/CLL B 
cells were visually analyzed by superimposing the two fluorescence profiles in a double 
exposed picture (κ/λ distribution). An imbalanced sIgκ/sIgλ ratio of >3:1 or <1:3 was 
considered abnormal. 
 
2.2.3. Fluorescence-activated cell sorting (FACS) purification of B-cell populations 
(FACSorting)  
 
For all individuals studied, each CLL-like CD5+ B-cell population identified was purified 
in a FACSAria III flow cytometer (BDB). In those samples with more than one aberrant B-cell 
population (n=37), discrimination among them was based on their distinct patterns of 
expression for ≥1 of the B-cell markers analyzed, as described elsewhere.467 The clonal nature 
of each FACS-purified B-cell population (purity: 98%±0.8%) was assessed by both cytogenetic 
and molecular techniques, as described below. 
 
2.2.4. Cytogenetic and molecular studies  
 
The presence of the most common cytogenetic abnormalities associated with CLL was 
investigated by multicolour iFISH on slides containing FACS-purified and fixed CLL-like and CLL 
cells, as previously described.253 Analysis of trisomy 12, del(11q23), del(17p13.1), and 
del(13q14), as well as structural abnormalities involving the IgH gene were systematically 
investigated using the following DNA probes purchased from Vysis (Downers Grove, IL): CEP12 
DNA probe conjugated with spectrum orange (SO), LSI ATM (11q22.3), LSI MLL (11q23.3) dual-
color probe, LSI p53 (17p13.1) conjugated with SO, LSI13/RB1 gene (13q14) conjugated with 
SO, LSI D13S25 (13q14.3) conjugated with SO, and LSI IgH/bcl2 t(14;18)(q32;q21) dual color 
probe, respectively. FISH studies were then performed on purified CLL-like/CLL B-cells fixed in 
3/1 (vol/vol) methanol/acetic and hybridized. Briefly, pepsin-digested slides containing both 
the cells´ DNA and the probes´ DNA were denatured at 75°C for 1 min and immediately 
hybridized (overnight at 37°C), in a Hybrite thermocycler (Vysis). Then, slides were sequentially 
washed (5 min at 46°C) in 50% formamide/2X saline sodium chloride citrate buffer (SSCb) and 
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PBS with 1% Tween-20 (vol/vol), and counterstained with 35 µl of a mounting medium 
containing 75 ng/ml of DAPI (Sigma, St Louis, MO); Vectashield (Vector Laboratories, 
Burlingame, CA) was used as antifading agent. 
Analysis of the patterns of rearrangement of the IGHV genes was performed for each 
FACS-purified CLL and CLL-like B-cell population. Genomic DNA preparation, PCR amplification, 
sequencing and analysis of V, (D), J genes were performed following well-established 
protocols.471,472 
High molecular weight DNA from sorted CLL-like/CLL B-cells was isolated by standard 
proteinase K digestion, and isopropanol precipitation in the presence of glycogen to increase 
the DNA yield; final washing of the DNA pellet was performed in ice cold 70% ethanol. For 
amplification of complete IGH VDJ rearrangements, six different family-specific VH primers and 
one JH consensus primer were used in one multiplex PCR reaction covering framework region 
(FR) 1. The primers were produced in scale (0.02 µM) and they were purified by standard HPLC 
(InvivoScribe Technologies, La Ciotat, France). The BIOMED-2 consortium has developed and 
clinically validated these primers for immune receptor amplification and their sequences were 
as follows: Primer name VH1/7-FR1 (5´ GGCCTCAGTGAAGGTCTCCTGCAAG-3´), Primer name 
VH2-FR1 (5´ GTCTGGTCCTACGCTGGTGAAACCC-3´), Primer name VH3-FR1 (5´ 
CTGGGGGGTCCCTGAGACTCTCCTG-3´), Primer name VH4-FR1 (5´ 
CTTCGGAGACCCTGTCCCTCACCTG-3´), Primer name VH5-FR1 (5´ 
CGGGGAGTCTCTGAAGATCTCCTGT-3´), Primer name VH6-FR1 (5´ 
TCGCAGACCCTCTCACTCACCTGTG-3´) and Primer name JH consensus-FR1 (5´ 
CTTACCTGAGGAGACGGTGACC-3´). PCR amplifications were performed using 50 or 100 ng of 
template genomic DNA, 10 pmol of each primer, and 0.2 µl of AmpliTaq Gold enzyme (Applied 
Biosystems, Foster City, CA) per 35 µl reaction. The PCR amplification used was as follows: 
denaturation at 95°C for 7 min; 40 cycles at (94°C for 30s, 59.8 °C for 45s, 72°C for 90s); and a 
final extension at 72°C for 10 min. To obtain high-quality sequencing results, efficient post-PCR 
amplicon purification using ExoSAP-IT reagent (USB products, Affymetrix, Santa Clara, CA) was 
carried out. After ExoSAP-IT PCR clean up, the DNA was sequenced in an Applied Biosystems 
3130xl Genetic Analyzer.  
The IgBLAST algorithm (National Center for Biotechnology Information) was used to 
localize those sequences which show a perfect match between forward (F) and reverse (R) 
reads. For each B-cell clone, we generated a consensus IGHV-D-J sequence with the matched 
F-R region and the correct base reads found before and after such region in the original 
chromatograms. Alignment of rearranged IGHV-D-J sequences to germ line V, D and J 
segments and determination of V-D and D-J junctions were performed using the IMGT 
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database and tools (http://imgt.org). For MBLlow clones, whole genomic amplification (WGA) 
was performed prior to analysis, using the RepligRUltraFast Mini kit (Qiagen, Valencia, CA) as 
per the recommendations of the manufacturer. Those MBLlow cases showing more than one 
productive rearrangement corresponding to different IGHV genes within each purified CLL-like 
B-cell population were excluded from this study, because in such cases we could not establish 
the precise association between each IGHV gene and the underlying cytogenetic alterations 
detected. For each FACS-sorted B-cell population, only in-frame rearrangements were 
evaluated. Sequences containing >2% deviation from the germline sequence were considered 
as being somatically mutated. 
Analysis of CLL-associated NOTCH1 mutations331 was performed via PCR of previously 
amplified genomic DNA from each FACS-purified CLL-like B-cell population for a total of 70 
clones (5 MBLlow, 14 MBLhigh and 51 CLL clones). 
 
2.2.5. Statistical methods  
 
Conventional descriptive and comparative statistics – the nonparametric Kruskal-Wallis 
and Mann-Whitney U tests (for continuous variables), or the Pearson’s 2 and Fisher exact 
tests (for categorical variables) – were performed using the SPSS software program (SPSS 15.0 
Inc. Chicago, IL). P values <0.05 were considered to be associated with statistical significance. 
For multivariate comparisons among MBLlow, MBLhigh and CLL clones, based on the 
count of clonal B cells/µL and the percentage of aberrant/clonal cells carrying the different 
cytogenetic profiles, principal component analysis (PCA) was applied, and graphically visualized 
with the 3D Automated Population Separator (APS) view – Principal Component 1 (PC1) vs PC2 
vs PC3 – of the InfinicytTM software (Cytognos SL, Salamanca, Spain). As previously described in 
detail, in this APS view, each axis of a plot is represented by a different PC as a linear 
combination of parameters with distinct statistical weights.473 
For the assignment of MBLlow, MBLhigh and CLL clones to different groups, the size of 
the clone and the percentage of altered cells for each cytogenetic abnormality were the 
continuous variables included in the PCA-based assay performed with the Infinicyt softwareTM, 
while IGHV gene usage, IGHV mutational status and clinical staging of CLL subjects according to 
the Binet classification were treated as categorical variables, used only for labelling the 
different clones within each group, after applying the PCA. 
 
 
 
 79 
 
Chapter 2 Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in MBL vs. CLL 
2.3. Results 
 
2.3.1. Overall size and BCR features of CLL-like MBL and CLL B-cell clones 
  
The median relative percentage and absolute count of CLL-like and CLL B-cells 
progressively increased from MBLlow (0.6% and 20 cells/μl), to MBLhigh (14% and 2,000 cells/μl) 
and CLL clones (57% and 17,400 cells/μl) (P <0.0001) (Table 6). 
Of note, around half of all MBLlow and MBLhigh cell populations (52% and 51%, 
respectively) derived from multiclonal cases, whereas only 22% of CLL clones were identified in 
multiclonal cases (P ≤0.03; Table 6). In addition, CLL clones less frequently showed mutated 
IGHV genes (53%) compared to both MBLhigh (73%) and MBLlow (67%) clones (P ≤0.02) (Table 6).  
 
Table 6. Peripheral blood B-cell counts and BCR features of clonal MBLlow, MBLhigh and CLL B 
cells. 
 
MBL
low
 
n= 27 
MBL
high
 
n=51 
CLL 
n=117 
P value 
No. of  PB clonal B cells 
(x10
6
/L)* 
20 (0. 09-200) 2,000 (350-4,900) 17,400 (1,300
†
-369,000) P < 0.0001
a,b,c,d,e 
% of PB clonal B cells 
from WBC* 
0.6% (0.001%-7.5%) 14% (0.7%-45%) 57% (17%-97%) P < 0.0001
a,b,c,d,e
 
No. of B-cell clones 
from multiclonal cases 
14/27 (52%) 26/51 (51%) 26/117(22%) P ≤ 0.002
a,b,d
; 
P = 0.03
e
 
No. of IGHV mutated 
clones 
18/27 (67%) 37/51 (73%) 60/113 (53%) P ≤ 0.02
a,d
 
Results expressed as number of B-cell clones and percentage between brackets or as *median value (range). 
Statistically significant differences (P< 0.05) found between 
a
MBL
high 
vs CLL, 
b
MBL
low 
vs CLL, 
c
MBL
low 
vs MBL
high
, 
d
MBL
low
 plus MBL
high 
vs CLL and 
e
MBL
low 
vs MBL
high
 plus CLL. BCR, B-cell receptor; CLL, chronic lymphocytic leukemia; 
MBL, monoclonal B-cell lymphocytosis; SmIg, surface membrane immunoglobulin; IGHV, immunoglobulin heavy 
chain variable region genes.
†
Includes 6/117 cases with <5,000 clonal CLL B-cells/µL of PB, diagnosed with small 
lymphocytic lymphoma (SLL). 
 
2.3.2. Cytogenetic features and NOTCH1 mutation in CLL-like MBL and CLL B-cell 
clones 
 
Overall, MBLlow B-cell clones showed a significantly lower frequency of genetic 
alterations associated with CLL (33%) than MBLhigh (51%) and CLL (62%) B-cells (P ≤0.02) (Table 
7). Furthermore, only a small proportion of MBLlow (7%) and MBLhigh clones (14%) showed 
coexistence of ≥ 2 cytogenetic alterations, while this was found in 33% of all CLL clones (P 
≤0.04). 
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Table 7. Cytogenetic and molecular features of MBLlow, MBLhigh and CLL B-cell clones. 
Cytogenetic/molecular alterations MBL
low
 
N= 27 
MBL
high
 
N=51 
CLL 
N=117 
P value 
No. of genetically altered CLL-like/ CLL 
clones 
9/27 (33%) 26/51 (51%) 72/117 (62%) P ≤ 0.02
b,e
 
No. of clones with ≥2 genetic 
alterations 
2/27 (7%) 7/51 (14%) 38/117 (33%)
†
 P≤ 0.04
a,b,d
 
     
Type of cytogenetic/molecular changes     
No. of del(13q)
+
 clones (%) 
% del(13q)
+
cells * 
7/27 (26%) 
73% (19%-96%) 
16/51 (31%) 
56% (15%-99%) 
46/117 (39%) 
87% (10%-99%) 
NS 
NS 
No. of del(13q14.3)
+
 clones (%) 
% del(13q14.3)
+
cells * 
5/27 (19%) 
70% (19%-96%) 
16/51 (31%) 
46% (15%-99%) 
45/117 (39%) 
75% (5%-99%) 
NS 
NS 
No. of del(13q14)
+
 clones (%) 
% del(13q14)
+
cells * 
1/26 (4%) 
86% (86%-86%) 
3/51 (6%) 
96% (15%-98%) 
18/117 (15%)
 
79% (10%-99%) 
P= 0.04
d
 
NS 
     
No. of trisomy 12
+
 clones (%) 
% trisomy 12
+
 cells * 
2/27 (7%) 
50% (41%-59%) 
10/51 (20%) 
87% (66%-95%) 
20/117 (17%) 
77% (33%-97%) 
NS 
P≤ 0.04
b,e
 
     
No. of t(14q32)
+
 clones (%) 
% t(14q32)
+
 cells * 
0/17 (0%) 
- 
2/51 (4%) 
42% (31%-52%) 
12/116 (10%) 
82% (18%-98%) 
NS 
NS 
     
No. of del(11q)
+
 clones (%) 
% del(11q)
+
cells * 
0/23 (0%) 
- 
2/51 (4%) 
57% (20%-93%) 
9/116 (8%) 
58% (21%-98%) 
NS 
NS 
No. of del(11q22.3)
+
 clones (%) 
% del(11q22.3)
+
cells * 
0/23 (0%) 
- 
2/51 (4%) 
57% (20%-93%) 
7/116 (6%) 
71% (24%-98%) 
NS 
NS 
No. of del(11q23)
+
 clones (%) 
% del(11q23)
+
cells * 
0/15 (0%) 
- 
0/51 (0%) 
- 
4/116 (3%) 
32% (21%-64%) 
NS 
- 
No. of del(17p13.1)
+
 clones (%) 
% del(17p13.1)
+
cells * 
0/24 (0%) 
- 
0/51 (0%) 
- 
5/117 (4%) 
44% (33%-88%) 
NS 
- 
No. of NOTCH1 mutated clones (%) 0/5 (0%) 0/14 (0%) 5/52 (10%) NS 
Results expressed as number of B-cell clones with cytogenetic abnormalities from all clones in the corresponding 
group (percentage) or as *median values of altered cells/clone (range). In 9 clones (1 MBL
low
,1 MBL
high
 and 7 CLL) 
biallelic del(13q14.3) was detected and hyperdiploidy was found in one MBL
low
 clone. 
a
MBL
high 
vs CLL, 
b
MBL
low 
vs CLL, 
d
MBL
low
 plus MBL
high 
vs CLL and 
e
MBL
low 
vs MBL
high
 plus CLL. NS, no statistically significant differences observed (P ≥ 
0.05); CLL, chronic lymphocytic leukemia; MBL, monoclonal B-cell lymphocytosis.
†
Includes the 5/66 cases with 
NOTCH1 mutation associated to trisomy 12 in 3 cases, to biallelic del(13q14.3) in one and to both mono allelic 
del(13q14.3) and del(17p) in the remaining cases. 
 
Regarding each specific cytogenetic/molecular alteration, a tendency towards a 
greater frequency of del(13q) and trisomy 12 was observed from MBLlow to MBLhigh and CLL 
clones, although differences only reached statistical significance for the frequency of 
del(13q14) involving the RB1 gene (P =0.04). In addition, presence of t(14q32) and 
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del(11q22.3) were exclusively found among MBLhigh and CLL, while del(17p), del(11q23) and 
NOTCH1 mutations were only present in CLL clones (Table 7). Of note, among the 
cytogenetically altered clones, no significant differences were observed in the percentage of 
altered cells, except for a greater proportion of B-cells with trisomy 12 among both MBLhigh and 
CLL vs MBLlow B-cell clones (P ≤0.04) (Table 7).  
NOTCH1 mutations occurred in 5/52 CLL cases (10%), in which a preferential 
association with IGHV unmutated clones (80%, P =0.02) and a high frequency of cases (3/5, 
60%) harbouring trisomy 12 as an additional isolated chromosomal abnormality (P =0.007) was 
observed; in the remaining two CLL cases, the presence of NOTCH1 mutation was associated 
with del(13q14) involving the RB1 gene and to both del(13q14.3) and del(17p), respectively. 
None of the 19 MBL cases investigated showed NOTCH1 mutations (Table 7). 
 
2.3.3. Molecular characteristics of CLL-like MBL and CLL B-cell clones 
 
Analysis of the IGHV gene revealed single in frame gene rearrangements for each 
clonal B-cell population analyzed. Interestingly, shorter CDR3 sequences of the IGHV gene 
were found among MBLlow versus CLL clones. So, the frequency of CLL clones with CDR3 
sequences coding for >20 aa became significantly higher than that observed among MBLlow and 
MBLhigh clones (P =0.02) (Table 8).  
Regarding IGHV, DH and JH gene usage, no significant differences were found between 
the three groups of CLL-like B-cell clones, except for the VH3 and DH3 IGHV genes (Table 8): 
CLL showed lower frequency of VH3 usage and a greater proportion of DH3+clones vs MBLlow 
and MBLhigh (P ≤0.04) (Table 8).   
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Table 8. Molecular characteristics of the BCR of CLL-like MBLlow, MBLhigh and CLL B-cell clones. 
Results expressed as number of B-cell clones from all clones in the corresponding group (percentage) or or as 
*median (range). Statistically significant differences were found between 
a
MBL
high 
vs. CLL, 
b
MBL
low 
vs. CLL, 
c
MBL
low 
vs. MBL
high
, 
d 
MBL
low
 plus MBL
high 
vs. CLL and 
e
MBL
low 
vs. MBL
high
 plus CLL; NS, no statistically significant differences 
observed (P ≥0.05); BCR, B-cell receptor; CLL, chronic lymphocytic leukemia; MBL, monoclonal B-cell lymphocytosis; 
aa, amino acids; HCDR3,heavy chain complementarity-determining region 3. 
 
Of note, a significant percentage of all CLL (72%), MBLhigh (74%) and MBLlow (85%) 
clones corresponded to only 12 IGHV genes, namely V3-23, V3-11, V5-51, V3-21, V1-2, V1-3, 
V4-39, V3-7, V3-30, V4-34, V3-48 and V1-69 (Figure 6). Among these, preferential usage (P 
<0.04) of the VH3-23 gene was observed in both MBLlow (7/27, 26%) and MBLhigh (10/51, 20%) 
vs. CLL (5/113, 4%) clones (Figure 6). 
 
 
MBL
low
 
N= 27 
MBL
high
 
N=51 
CLL 
N=113 
P value 
HCDR3 length* 13 (6-22) 17 (8-26) 18 (8-32) P≤0.02
b,d,e
 
HCDR3> 20 aa 3/27 (11%) 8/51 (16%) 38/113 (34%) P = 0.02
a,b,d
 
     
VH subgroups 
VH1 4/27 (15%) 7/51 (15%) 28/113 (25%) NS 
VH2 0/27 (0%) 1/51 (2%) 2/113 (2%) NS 
VH3 18/27 (66%) 31/51 (60%) 47/113 (42%)    P≤ 0.04
a,b,d
 
VH4 4/27 (15%) 9/51 (17%) 32/113 (28%) NS 
VH5 1/27 (4%) 3/51 (6%) 2/113 (2%) NS 
VH6 0/27 (0%) 0/51 (0%) 1/113 (1%) NS 
     
DH subgroups 
DH1,4,7 5/27 (18.5%) 7/50 (14%) 15/109 (14%) NS 
DH2 5/27 (18.5%) 12/50 (24%) 19/109 (17%) NS 
DH3 5/27 (18.5%) 16/50 (32%) 48/109 (44%) P≤ 0.03
b,d,e
 
DH5 5/27 (18.5%) 8/50 (16%) 12/109 (11%) NS 
DH6 7/27 (26%) 7/50 (14%) 15/109 (14%) NS 
     
JH genes 
JH1,2,3,5 4/27 (15%) 14/50 (28%) 23/113 (20%) NS 
JH4 13/27 (48%) 21/50 (42%) 45/113 (40%) NS 
JH6 10/27 (37%) 15/50 (30%) 45/113 (40%) NS 
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Figure 6. Frequency of CLL-associated cytogenetic alterations (A) and the cytogenetic profile (B) for those IGHV 
genes most commonly detected in MBL
low
, MBL
high
 and CLL B-cell clones, as assessed by iFISH. The three diagnostic 
categories studied are depicted by different colors (green, MBL
low
; red, MBL
high
; blue, CLL B-cell clones) and the 
absence vs. presence of one vs≥2 chromosomal alterations per clone, is indicated by empty circles, light colored and 
dark colored circles, respectively. For each IGHV subgroup, the clones are represented in the Y-axis according to the 
absolute number of clonal B cells per µL of PB (A) and the percentage of cells genetically altered, by iFISH (B). 
Different FISH patterns are defined by the following symbols in panel B:    , del(13q14.3);   , biallelic del(13q14.3);    , 
del(13q14);    , trisomy 12; Δ, del(11q);,del(17p) and; , t(14q32); dotted contour lines in panel A highlight those 
clones phenotypically classified as SLL(small lymphocytic lymphoma); dotted blue lines in panel B indicate cells from 
the same B-cell clone showing different cytogenetic abnormalities; U = unmutated clones; a = clones with NOTCH1 
mutation. 
 
2.3.4. Relationship between the most frequently used IGHV genes and the 
cytogenetic profile of CLL-like MBL and CLL B-cell clones 
 
As mentioned above, preferential usage of the VH3-23 gene was observed in both 
MBLlow and MBLhigh vs. CLL clones (Figure 6A). VH3-23+ MBL clones typically showed no 
cytogenetic alterations (8/17) or they carried an isolated cytogenetic alteration which 
corresponded either to trisomy 12 (3/17) or deletion of 13q (3/17) (Figure 6B). Nevertheless, 
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two MBLhigh clones showed co-existence of trisomy 12 and del(11q22.3) and one MBLlow clone 
showed del(13q) including both the 13q14.3 and 13q14 (RB1) chromosomal regions (Figure 
6B). From the five VH3-23+ CLL clones only one carried genetic alterations – trisomy 12 and 
del(13q) –. Most interestingly, VH3-23+ MBLlow clones frequently showed unmutated IGHV 
genes, including most  unmutated MBLlow clones, with <10 CLL-like cells/µl (5/8; 63%), which 
contrasts to the much lower frequency of unmutated VH3-23 CLL clones. 
A similar frequency of usage of the VH3-11, VH5-51, VH3-21 and VH1-2 genes was 
observed in both MBLlow and MBLhigh vs. CLL (Figure 6). In none of the clones expressing these 
IGHV genes, cytogenetic alterations associated with a poor disease outcome – e.g. del(17p) 
and/or del(11q) – were found; in addition, most MBL and CLL clones expressing these IGHV 
genes showed no cytogenetic alteration, or they just had a single abnormality. Despite this, 
NOTCH1 mutations were more frequently observed among cytogenetically altered, IGHV 
unmutated CLL clones expressing these IGHV genes (one VH3-11+, one VH3-21+ and one VH1-
2+ clones). Noteworthy, 4/6 CLL cases classified as small lymphocytic lymphoma (SLL) variants 
were also included among cases with a VH3-11 (n=2), VH3-21 (n=1) and VH1-2 (n=1) repertoire 
in this group. 
Finally, among those clonal B-cell populations which expressed the VH1-3, VH4-39, 
VH3-7, VH3-30, VH4-34, VH3-48 and VH1-69 genes, CLL clones were overrepresented (61/113, 
54%) vs. both MBLlow (10/27, 37%) and MBLhigh (18/51, 35%) clones. Notably, a high number of 
CLL clones carrying these IGHV genes in association with one or more cytogenetic alterations, 
including poor prognosis cytogenetic alterations, was found among these cases (44/61, 72%). 
In this regard, del(13q) including both the 13q14.3 and 13q14 (RB1) chromosomal regions was 
frequently detected (single or combined lesion) in these CLL and also MBLhigh clones, 
particularly among those cases expressing the VH3-30 and VH4-34 gene genes; presence of 
trisomy 12, del(11q) and t(14q32) were also common among these CLL cases (16%, 13% and 
18%, respectively) while being infrequent in MBL cases (only 2 MBLhigh clones showed isolated 
trisomy 12). Moreover, del(17p) alone and complex karyotypes with ≥3 cytogenetic/molecular 
alterations were also found in 4 of the CLL clones which expressed the VH1-3, VH4-39, VH3-30, 
VH3-48, VH4-34 and VH1-69 IGH genes, respectively (Figure 6B). Remarkably, ≥1 genetic 
alteration was systematically detected in a major fraction of the VH1-69+ clonal cells (Figure 
6A) while being absent in the few MBL clones which expressed this specific IGHV gene. Of 
note, unmutated IGHV genes were a hallmark of both VH1-69+ (12/14 clones; 86%) and VH4-
39+ (9/10 clones; 90%), independently of their MBL vs CLL nature (Figure 6A). 
Based on the observation of the above described associations, we performed a 
multivariate analysis based on PCA, in searching for unique patterns of association between 
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cytogenetic alterations and IGHV repertoires among MBL vs. CLL clones. Three major groups of 
CLL-like MBL and CLL clones were identified, according to the absolute number of clonal B 
cells/µL and the percentage of cells carrying cytogenetic alterations (Figure 7) and then 
labelled according to their pattern of IGHV gene usage and the VH mutational status. Of note, 
the most homogeneous group (Group 1) included virtually all MBLlow clones (77%) and half of 
the MBLhigh clones (54%), but only around one fourth of Binet stage B/C CLL (28%); by contrast, 
no MBLlow clones were included in Group 3 (Figure 7D). Group 2 showed a more 
heterogeneous distribution with an intermediate pattern. In detail, Group 1 was mainly 
characterized by cases with a normal karyotype (83%) and lower numbers of cytogenetically 
altered cells mostly displaying the VH1-2, VH3-23 and VH4-34 IGHV genes (Supplemental Table 
1); in turn, Group 2 typically showed a higher number of cases with mutated IGHV genes, and 
higher numbers of del(13q)+ clonal B cells, while Group 3 included high numbers of cases with 
unmutated IGHV genes, trisomy 12 and an IGHV repertoire enriched in unmutated VH1-69+ CLL 
clones (Supplemental Table 1). 
Figure 7. Principal component analysis (3-dimensionalX-Y-Z axis view of PC1 vs. PC2 vs. PC3, respectively) for 
comparison of MBL
low
, MBL
high
 and CLL B-cell clones according to the absolute number of clonal B cells/µL and the 
pattern of cytogenetic alterations (including the percentage of altered cells), using the Infinicyt
TM
software. Overall, 
MBL
low
, MBL
high
 and CLL cases are clustered into groups distinguished by different colors in A: magenta, gray, and 
black circles (A). The distribution of MBL
low
, MBL
high
, CLL-stage A and CLL-stage B/C clones are coloured differently in 
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B: MBL
low
, green; MBL
high
, red, CLL stage A and B/C light blue and dark blue, respectively (B). The most informative 
parameters contributing to the best discrimination between 1 x 1 comparisons of the three groups are displayed in 
a decreasing order of percentage contribution to each of the principal component (C); Distribution of MBL
low
, 
MBL
high
 and CLL clones among the three major groups defined in panel A by principal component analysis (D); CLL, 
chronic lymphocytic leukemia; MBL, monoclonal B lymphocytosis; PC: principal component. 
 
2.4. Discussion 
It is now well established that emergence of CLL is typically preceded by MBL.212 
However, only a fraction of all MBLhigh will evolve to CLL, at a rate of 1.1% persons/year,474 
while the outcome of MBLlow remains unknown. Despite this, general consensus exists in that 
stepwise acquisition of specific genetic alterations may determine the rate of progression, not 
only from MBLhigh to CLL, but potentially also from MBLlow to MBLhigh and eventually to CLL. 
Concurrence of chronic Ag stimulation through specific BCRs may further support and 
accelerate the expansion of MBL clones, facilitate acquisition of new genetic alterations and 
therefore contribute to progression to CLL.20,218 Although data has accumulated in the last 
decade about the cytogenetic alterations and the IGHV gene repertoire of CLL-like clonal B-
cells in both MBL and CLL, to our knowledge, this is the first report about the combined 
patterns of cytogenetic alterations and IGHV gene repertoire in MBLlow vs. MBLhigh vs. CLL 
clones. 
In recent years, more than a thousand different molecular/genetic alterations 
reflected in multiple distinct and complex cytogenetic/molecular profiles in individual CLL 
patients, have been described through high-throughput WGS approaches.475,476 However, only 
a relatively small number of cytogenetic/molecular alterations recurrently occur at relatively 
high frequencies (e.g. >5% cases).333,477 Such alterations include del(13q14), reported in around 
half of all CLL cases, trisomy 12, present in about one third of the patients and del(11q), 
del(17p), t(14q32) and NOTCH1 mutations, which occur in between 5-15% of all CLL 
cases.253,333,477 In around half of CLL cases, unmutated IGH genes associated with preferential 
usage of specific IGHV genes (i.e. VH1-69 and VH4-34) and the above described cytogenetic 
alterations have also been reported in CLL. In turn, MBLhigh cases share molecular features with 
good-prognosis CLL in terms of both the IGHV gene repertoire and chromosomal 
alterations,206,478 with a greater frequency of IGHV mutated cases. By contrast, preliminary 
data indicates that the IGHV repertoire expressed by MBLlow could be strikingly different from 
that of both typical CLL and MBLhigh cases;479 in addition, such MBLlow clones appear to display a 
much lower frequency of chromosomal alterations, restricted to del(13q14.3) and trisomy 12, 
with a high prevalence of IGHV mutated cases (similar to that of MBLhigh cases),20 and no poor-
prognosis cytogenetic alterations.203,206 
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In line with such observations, we also found a lower frequency of both cytogenetically 
altered and IGHV unmutated CLL-like clones in MBLlow vs. both MBLhigh and CLL and vs. CLL 
clones, respectively. Interestingly, the proportion of B-cell clones carrying ≥2 alterations 
significantly increased from MBLhigh to CLL. On top of the progressively higher number of 
cytogenetic/molecular alterations found in MBLlow vs. MBLhigh and CLL, the cytogenetic profile 
of clonal B-cells also became significantly more heterogeneous among the latter two groups. 
Accordingly, while del(13q14.3) and to a much lesser extent, del(13q14) involving the RB1 
gene and trisomy 12, were already detected in a small fraction of MBLlow clones, del(11q) and 
t(14q32) emerged at an MBLhigh stage, whereas del(17p), del(11q23) and NOTCH1 mutations 
were only found in CLL. These latter three alterations typically involved CLL clones that already 
had other cytogenetic alterations and therefore, had more complex cytogenetic/molecular 
profiles. In line with these findings, the altered CLL-like MBL and CLL clones showed 
progressively increasing percentages of cells carrying del(13q14.3), del(13q14), trisomy 12, 
t(14q32),del(11q)and del(17p13.1),respectively. In accordance with previous observations,480 
NOTCH1 mutations were exclusively detected in CLL (preferentially among unmutated CLL 
clones) which also had other cytogenetic alterations – e.g., trisomy 12, del(13q14) and/or 
del(17p).  
The overall increased frequency of all cytogenetic alterations, together with the more 
complex cytogenetic/molecular profiles, observed from MBLlow to MBLhigh and CLL would 
support the notion that evolution from MBLlow to MBLhigh and CLL is paralleled by progressive 
acquisition of recurrent cytogenetic alterations, each of which appears to emerge at specific 
MBL and CLL stages, in line with previous data from our and other groups.15,481 Accordingly, 
del(13q), and to a lesser extent trisomy 12, are relatively early cytogenetic events which may 
frequently occur at an MBLlow stage, whereas del(17p), NOTCH1 mutations, and to a lesser 
extent also del(11q) and t(14q32), would typically arise later, as secondary cytogenetic events 
occurring at an MBLhigh or CLL stage. Acquisition of these and other genetic changes may 
potentially be associated with an increased proliferation and/or survival of the altered CLL-like 
cells. At the earliest stages of development of MBL, proliferation and/or survival signals could 
be provided to the MBL clone by chronically sustained BCR stimulation. If this holds true, the 
BCR features could also play a critical role in determining the probability of cytogenetic 
progression. Unfortunately, our series of MBL – particularly of MBLlow – is quite short at this 
time to further confirm this hypothesis, due to the difficulty in collecting cases with enough 
number of CLL-like B-cells, to perform in parallel reliable iFISH and molecular analyses. In this 
regard, the limited number of MBLlow cases included in our series may predominantly present 
with the genetic/molecular patterns of a low risk MBL cohort, which may not be related to CLL 
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progression. Despite this, in accordance with other recent reports,16,185,482 non-random usage 
of IGHV genes with clearly different IGHV gene repertoires was found in our series in MBL vs. 
CLL. As expected, the most frequently used IGHV genes in CLL were the VH4-34, VH3-30, VH1-
69, VH3-48, VH4-39, VH1-2 and VH3-7 genes, accounting for around half of the CLL clones. 
Interestingly, also half of the CLL clones showed unmutated IGHV genes, strikingly high 
frequencies of unmutated clones being detected among cells expressing VH1-69, VH4-39 and 
VH1-2. By contrast, VH3-23+ B-cells predominated among the MBLlow and MBLhigh clones, most 
VH3-23+ MBLlow cases showing very low counts of IGHV unmutated clonal B-cells. Of note, the 
IGHV genes used by the MBLhigh clones were commonly observed in either CLL (e.g. VH4–34, 
VH1-2, VH3–48 and VH4–39) or MBLlow (e.g. VH3-23 and VH4-34), but usually at lower 
frequencies. The fact that these particular IGHV genes have been associated with previously 
reported stereotypic B-cell receptors in CLL clones,13 together with our own results which show 
that the CDR3 of the IGHV genes are highly homologous in around one fifth of the B-cell clones 
from our short cohort (Supplemental Table 2), would reinforce the role of some antigen-
binding BCR specificities in clonal evolution. 
Based on the overall patterns of cytogenetic alterations and IGHV gene usage together 
with the BCR mutational status, it could be concluded that while some unmutated IGHV genes 
appear to be associated with the acquisition of complex cytogenetic profiles, rapid expansion 
of clonal CLL-like B-cells and progression to CLL (e.g. IGHV1-69), others would not (e.g. IGHV3-
23); the latter clones would show a more benign behaviour. This could potentially be due to a 
lower binding affinity of the unmutated BCR for the antigen, the recognition of specific 
subtypes of low concentrated antigens and/or unique immune response profiles. In line with 
this hypothesis, IGHV genes over-represented among CLL clones (e.g.VH4-39 and VH1-69) 
frequently corresponded to IGHV genes enriched in genes encoding for antibodies that 
recognise a broad variety of relatively common and abundant (auto)antigens, including low-
affinity BCR, e.g. myoglobulin, thyroglobulin, actin, and ssDNA296,483 associated with T-
independent, type II autoimmune responses.235 In contrast, the unmutated IGHV3-23 BCR was 
over-represented among our MBLlow cases, normal peripheral blood IGHV3-23+ IgM+ B-cells 
being associated with recognition of superantigens.24,484,485 Thus, the association between 
MBLlow and unmutated IGHV3-23 could be potentially due to a low affinity of this particular 
BCR for low concentrated/prevalent (super)antigens, which would limit the development of 
repetitive immune responses associated with the expansion of MBL clones and/or their 
cytogenetic progression. A recent study203 also reported MBLlow cases to display an IGHV gene 
repertoire different from that of CLL patients (e.g. absence of IGHV1-69+ MBLlow clones, 
together with a low frequency of the IGHV4-34 gene and overrepresentation of the IGHV4-
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59/61 genes); however, no preferential usage of the IGHV3-23 gene was found among MBLlow 
cells in this series. Further studies investigating the IGHV gene repertoire of MBLlow clones in 
distinct geographic areas and microenvironments, may shed light on those factors accounting 
for such apparent discrepancies, as an association between MBLlow and previous history of 
infections has been recently reported in this setting.204 
Taken together, these results would support the notion that antigen-driven BCR-
stimulation could be a triggering factor in driving CLL-like B-cells to expand, in line with recent 
data showing a significant association between MBL in the general population and the 
individual history of infectious diseases and vaccination,204 whilst depending on the nature of 
the antigenic stimuli, distinct patterns of cytogenetic changes might then occur. Thus, the 
specific combination of cytogenetic alterations acquired by the CLL-like B-cells may determine, 
for distinct antigenic stimuli, and specific BCR repertoires, the outcome of the genetically-
targeted cell. Long-term longitudinal studies, ideally of the same cases at different time-points 
and at different stages of the disease, would be crucial to definitively confirm these 
hypotheses, although based on our preliminary follow-up date19 this may require decades due 
to the stable nature of most MBLlow clones in the short-term.  
In summary, MBL and CLL clones appear to display a distinct but partially overlapping 
pattern of IGHV gene usage, IGHV mutational status and cytogenetic alterations, which may 
translate into distinct groups of clones with different genetic/molecular features associated 
with a distinct clinical behavior. Sequential studies in larger series of cases followed for long 
periods of time are ongoing to investigate the risk of progression and outcome of MBL clones 
with specific IGHV and iFISH cytogenetic profiles.  
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3.1. Abstract  
 
Chronic antigen-stimulation has been recurrently involved in the earlier stages of MBL, 
CLL and other B-CLPD. Among these individuals, expansion of ≥2 B-cell clones has been 
frequently reported; potentially, such coexisting clones have a greater probability of 
interaction with common immunological determinants. Here, we comparatively analyzed the 
BCR repertoire and the molecular profile, as well as the phenotypic, cytogenetic and 
hematological features of 228 CLL-like and non-CLL-like clones between multiclonal (n=85 
clones from 41 cases) vs. monoclonal (n=143 clones) MBL, CLL and other B-CLPD. The BCR of B-
cell clones from multiclonal cases showed a slightly higher degree of HCDR3 homology than B-
cell clones from monoclonal cases, in association with unique hematological (e.g. lower B-
lymphocyte counts) and cytogenetic (e.g. lower frequency of cytogenetically altered clones) 
features usually related to earlier stages of the disease. Moreover, a subgroup of coexisting B-
cell clones from individual multiclonal cases which were found to be phylogenetically related, 
showed unique molecular and cytogenetic features: they more frequently shared IGHV3 gene 
usage, shorter HCDR3 sequences with a greater proportion of IGHV mutations and 
del(13q14.3), than other unrelated B-cell clones. These results would support the antigen-
driven nature of such multiclonal B-cell expansions, with potential involvement of multiple 
antigens/epitopes. 
 
3.2. Materials and Methods  
 
3.2.1. Patients and samples 
 
 A total of 184 subjects with one (n=143 monoclonal cases) or ≥2 (n=41 multiclonal 
cases) CLL/non-CLL B-CLPD (n=140) and/or CLL-like/non-CLL-like MBL (n=88) B-cell clones – as 
defined by the WHO criteria 2008486 – were included. Binet staging466 of CLL subjects was 
retrospectively collected.  
  From the 41 multiclonal cases, 2 (5%) corresponded to healthy individuals with CLL-
like MBLlow, 8 (19.5%) were CLL-like MBLhigh cases, 23 (56%) had CLL and 8 (19.5%) had B-CLPD 
other than CLL; 4 of these latter cases showed coexistence of either one or two CLL-like MBL B-
cell population(s). In 3/41 multiclonal cases, three coexisting B-cell populations were detected. 
From the 143 monoclonal cases, 13 (9%) corresponded to healthy adults with CLL-like MBLlow, 
26 (18%) were CLL-like MBLhigh, 89 (62%) had CLL, 2 (1%) were non-CLL-like MBLlow, 2 (1%) non-
CLL-like MBLhigh cases and 11 (8%) had other B-CLPD. MBL was defined by the presence of 
 94 
 
Chapter 3 Molecular and cytogenetic characterization of B-cell clones from multiclonal vs. monoclonal B-CLPD 
small clones of aberrant B-cells in the PB, with a clonal B-cell count below the threshold for 
diagnosis of CLL (< 5.0 × 109 cells/L).14 A MBL case was subclassified as MBLlow when the 
absolute number of clonal B-lymphocytes was less than 200 cells/µL in PB and as MBLhigh when 
this number ranged between ≥200 and <5,000 clonal CLL-like B-cells/µL of PB.468 The 
age/gender distribution for each diagnostic group, is detailed in Table 9. 
Peripheral blood samples were obtained from each subject after written informed 
consent was given, and the study was approved by the local ethics committees of the 
University Hospital of Salamanca and the Blood and Transplantation Center of 
Coimbra/Portuguese Institute of Blood and Transplantation, in accordance with the Helsinki 
Declaration of 1975, as revised in 2008.  
 
Table 9. Age and gender features of subjects included in the study. 
  Diagnostic subgroups 
  CLL and CLL-like MBL Non-CLL B-CLPD and non-CLL MBL 
 Age/Gender 
Features 
MBL
low
 MBL
high
 CLL MBL
low
 MBL
high
 Non-CLL 
Cases Monoclonal (n=143) 13 (9%) 26 (18%) 89 (62%) 2 (1%) 2 (1%) 11 (8%) 
 Age (years)* 66±13 (49-84) 69±13 (37-89) 69±13 (35-89) 65 & 95 79 & 80 71±9 (53-84) 
 Male/Female 4/9 15/11 50/39 1/1 0/2 7/4 
 Multiclonal (n=41) 2 (5%) 8 (19.5%) 23 (56%) - (0%) - (0%) 8 (19.5%) 
 Age (years)* 77 & 83 76±6 (65-82) 75±9 (57-89) - - 74±9 (56-81) 
 Male/Female 1/1 5/3 16/7 - - 6/2 
Age values expressed as *media ± one standard deviation (range) when n>2. MBL, monoclonal B-cell lymphocytosis; 
CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; B-CLPD, B-cell chronic lymphoproliferative 
disorders other than CLL or MBL. 
 
3.2.2. Immunophenotypic analyses 
 
  Immunophenotypic studies to screen for the presence and full characterization of 
clonal B-cell populations were performed by high-sensitive MFC on erythrocyte-lysed 
peripheral blood samples, according to previously described procedures (see the Materials and 
Methods section of Chapter 2 for detailed descriptions). In all cases studied, each SmIg light 
chain restricted and phenotypically aberrant B-cell population identified was purified in a 
FACSAria II flow cytometer (BDB). In those samples (n=41) containing ≥2 aberrant B-cell 
populations, discrimination among them was based on their distinct patterns of expression for 
≥1 of the B-cell markers analyzed, as described elsewhere.467 The clonal nature of each FACS-
purified B-cell population (purity: 98%±0.8%) was assessed by both cytogenetic and molecular 
techniques. 
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3.2.3. Cytogenetic and molecular studies 
 
Cytogenetic analyses were performed by multicolor iFISH on slides containing FACS-
purified and fixed aberrant B-cells, as previously described in detail (see the Materials and 
Methods section of Chapter 2 for detailed descriptions).253,468 In parallel, analysis of the 
patterns of rearrangement of the IGHV and IGKV and IGʎV genes was performed for each 
FACS-purified B-cell clone (see the Materials and Methods section of Chapter 2 for detailed 
descriptions).468,471,472 Each deduced "IMGT/V-QUEST aa sequence" corresponding to individual 
IGHV gene sequences from purified B-cell clones from both monoclonal and multiclonal cases 
was aligned using the bioinformatic tools available at the web services of the European 
Bioinformatics Institute (EMBL-EBI Cambridge, UK). More than 12,400 alignments of IGHV aa 
sequences, with a coverage ranging from framework region (FR) 1 to the HCDR3 region (both 
regions included) were obtained for all B-cell clones (a total of 8,891 alignments within the 
monoclonal and 3,560 alignments within the multiclonal groups of cases). Then, the 
percentage of alignment of IGHV aa sequences obtained after two-by-two comparisons 
between the distinct B-cell clones, was calculated for every pair of B-cell clones. Finally, each 
single paired-alignment obtained – 8,891 and 3,560 in monoclonal vs. multiclonal cases, 
respectively – was included in a final database, to calculate the median and range of the total 
IGHV aa alignment percentages and to calculate the statistical significance of their differences 
observed between the two groups (P-values). 
To investigate the level of phylogenetic relationship among IGHV aa sequences 
corresponding to distinct clones from multiclonal cases, as well as monoclonal cases, a 
sequence distance tree was built using the neighbor-joining method implemented in the freely 
available Molecular Evolutionary Genetic Analysis (MEGA) software (version 5.2, 
http://www.megasoftware.net). Examination of the different branches of the sequence 
distance tree allowed the distinction of multiclonal cases whose clones had IGHV aa sequences 
phylogenetically closer than others. Thus, sequences in the same major branch were 
guaranteed to exhibit ≥50% aa identity (from FR1 to HCDR3, both regions included).239 As 
might be expected, sequences in sub-branches emerging from the same major branch exhibit 
even more aa identity, ranging from 60% to 99%. In our analysis, those co-existing B-cell clones 
with IGHV aa sequences that belonged to the same major branch with >60% aa identity or 
belonged to close located sub-branches were assumed to be “phylogenetically” related 
sequences. This “identity” threshold was based on previously published concepts about the 
phylogeny of human IGHV genes based on their aa sequences,239 and on the minimum identity 
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percentage observed in colocalized sub-branches (presumably with the highest evolutionary 
relationship239) of the sequence distance tree built in this study. 
HCDR3-alignments were carried out for each multiclonal case whose co-existing B-cell 
clones showed HCDR3 regions with identical or one aa differing lengths using the bioinformatic 
tools available at the web services of the European Bioinformatics Institute (EMBL-EBI 
Cambridge, UK). Through the EMBL-EBI tools, the identical aa or those with analogous side-
chain polarity per case-paired HCDR3 alignments were highlighted taking into account their 
conserved composition in terms of "hydropathy", "volume" and "chemical characteristics" as 
outlined in the IMGT classification of aa". 
 
3.2.4. Statistical methods 
 
Comparisons between groups were performed with either the nonparametric Kruskal-
Wallis and Mann-Whitney U tests (for continuous variables) or the Pearson’s2 and Fisher 
exact tests (for categorical variables) using the SPSS software/version 20.0 (IBM SPSS Statistics, 
IBM, Armonk, NY, USA). P values <0.05 were considered to be associated with statistical 
significance. 
 
3.3. Results 
 
3.3.1. Distribution and immunophenotypic features of B-cell clones  
 
A total of 228 B-cell clones were identified. These corresponded to 143 B-cell clones 
(89 CLL, 11 non-CLL, 39 CLL-like MBL and 4 non-CLL-like MBL clones) from monoclonal cases 
and 85 B-cell clones (26 CLL, 14 non-CLL, 40 CLL-like MBL and 5 non-CLL-like MBL clones) from 
multiclonal cases (Table 10). The complete immunophenotypic and cytogenetic features of the 
individual clones of multiclonal cases are summarized in Supplemental Table 3. 
In 26/41 multiclonal cases, all coexisting B-cell clones showed a CLL-like phenotype, 
while in 11 of the remaining 15 cases, at least one CLL-like B-cell population coexisting with 
another non-CLL aberrant B-cell population was identified. In the remaining 4 cases, two 
distinct non-CLL-like B-cell clones were found (Supplemental Table 3). The distribution of all 
CLL/non-CLL and CLL-like MBL/non-CLL-like MBL clones analyzed (from all monoclonal and 
multiclonal cases considered together) in the distinct diagnostic categories was as follows: 27 
B-cell clones corresponded to CLL-like MBLlow, 52 to CLL-like MBLhigh, 115 to CLL, 5 to non-CLL-
like MBLlow, 4 to non-CLL-like MBLhigh and 25 to non-CLL B-CLPD (Table 10). The precise 
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diagnoses of the B-cell clones from B-CLPD patients other than CLL are specified in the 
footnote of Table 10.  
 
Table 10. Distribution of subjects included in the study and their corresponding CLL and non-
CLL like B cell clones, according to diagnosis. 
  Diagnostic subgroups 
  CLL and CLL-like MBL Non-CLL B-CLPD and non-CLL MBL* 
  MBLlow MBLhigh CLL MBLlow MBLhigh Non-CLL 
Cases Monoclonal 
(n=143) 
13 (87%) 26 (76.5%) 89 (80%) 2 (100%) 2 (100%) 11 (58%) 
 Multiclonal (n=41) 2 (13%) 8 (23.5%) 23 (20%) - (0%) - (0%) 8 (42%) 
 Total (n=184) 15 34 112  2 2 19 
B cell clones Monoclonal 
(n=143) 
13 (48%) 26 (50%) 89 (77%) 2 (40%) 2 (50%) 11 (44%) 
 Multiclonal (n=85) 14 (52%) 26 (50%) 26 (23%) 3 (60%) 2 (50%) 14 (56%) 
 Total (n=228) 27 52 115 5 4 25 
CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma (n=115 clones); MBL, monoclonal B-cell 
lymphocytosis (n=88 clones: 79 CLL-like MBL clones and 9 non-CLL-like MBL clones); B-CLPD, B-cell chronic 
lymphoproliferative disorders other than CLL (n=25 clones). *Patients other than CLL included the following 
diagnoses: HCL, hairy cell leukemia (n=1 clone); MZL, marginal zone lymphoma (n=17 clones); MALT, lymphoma of 
mucosa-associated lymphoid tissue (n=7); MCL, mantle cell lymphoma (n=3 clones); FL, follicular lymphoma (n=4 
clones); DLBCL, diffuse large B-cell lymphoma (n=1 clones); LPL, lymphoplasmacytic lymphoma (n=1 clone). 
The precise diagnosis of multiclonal cases (CLL vs. non-CLL) were based on consistent clinic-biological features, 
according to the WHO 2008 criteria 
486
. 
 
3.3.2. Overall size and BCR features of B-cell clones from multiclonal versus 
monoclonal MBL, CLL and other B-CLPD cases 
 
 The relative and absolute median number of PB clonal B-cells was significantly lower 
in multiclonal than in monoclonal cases (13% vs. 45% and 2,692 cells/µL vs. 9,115 cells/µL, 
respectively; P =0.001). Of note, the absolute median number of CLL-like MBLhigh and CLL B-cell 
clones were also significantly lower in multiclonal than in monoclonal cases (1,254 vs. 2,464 
cells/µL and 9,113 vs. 18,600 cells/µL, respectively; P =0.004 and P =0.02) (Figure 8). In 
contrast, the absolute median number of PB CLL-like MBLlow B-cell clones was significantly 
higher in multiclonal than in monoclonal cases (79 vs. 1 cells/ µL, P =0.002). No significant 
differences were found in the clone size between non-CLL like and non-CLL B-cell clones in 
multiclonal vs. monoclonal cases (Figure 8). In addition, the frequency of CLL-like MBL B-cell 
clones was significantly higher in multiclonal than in monoclonal cases (47% vs. 27%, 
respectively; P =0.002), whereas the frequency of CLL B-cell clones was higher in monoclonal 
vs. multiclonal subjects (62% vs. 31%, respectively; P =0.001). CLL B-cell clones from 
multiclonal and monoclonal CLL patients showed a similar distribution in Binet stage A vs. 
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Binet stages B/C (P >0.05). Of note, non-CLL B-cell clones were present at higher frequencies in 
multiclonal vs. monoclonal cases (17% vs. 8%, respectively; P =0.04) (Table 11). 
 
Figure 8. Absolute number of CLL-like MBL
low
, CLL-like MBL
high
, CLL, non-CLL MBL and non-CLL B-cell clones per µL of 
peripheral blood in multiclonal vs monoclonal cases distributed according to diagnosis. Boxes extend from the 25
th
 
to the 75
th
 percentiles, the lines in the middle represent median values (50
th
 percentile). Vertical lines represent the 
highest and lowest values that are not outliers or extreme values (being outliers and extreme values those values 
that lie more than 1.5- and 3- fold the length of the box). The adjacent table compiles the median number and 
range of each subgroup of CLL-like and non-CLL like clonal B-cells/µL of peripheral blood and the exact P-values 
obtained after comparing multiclonal vs. monoclonal cases (Mann-Whitney U test) for the MBL
low
, MBL
high
 and CLL 
subgroups. NS: no statistical significant differences were detected (P ≥0.05). 
 
Regarding BCR features, a similar distribution of IGHV mutated and IGHV unmutated B-
cell clones was found in multiclonal vs monoclonal cases − 51/85 (60%) vs. 84/139 (60%) and 
34/85 (40%) vs. 55/139 (40%), respectively; Table 11 −. Despite this, the percentage of 
alignment of IGHV aa sequences among B-cell clones from multiclonal cases (n =3,560 two by 
two comparisons of clonal IGHV aa sequence) was slightly higher than that obtained among B-
cell clones from monoclonal cases (n =8,891 comparisons): median of 52% vs. 50%, 
respectively; (P =0.001; Table 11).  
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Table 11. Peripheral blood B-cell counts and BCR features of multiclonal vs. monoclonal B-cell 
clones from B-CLPD and MBL cases. 
 
Multiclonal B-cells 
n=85 clones 
Monoclonal B-cells 
n=143 clones 
TOTAL 
n=228 clones 
N. of  PB clonal B cells(x10
6
/L)* 2,692 (0.6-156,168)
a
 9,115 (0.1-369,288) 5,530 (0.1-369,288) 
% of PB clonal B cells from WBC* 13% (0.1%-89%)
a
 45% (0.002%-97%) 35% (0.001%-97%) 
CLL like MBL
low
 B-cell clones 14/85 (16%) 13/143 (9%) 27/228 (12%) 
CLL like MBL
high
 B-cell clones 26/85 (31%)
a
 26/143 (18%) 52/228 (38%) 
CLL B-cell clones 26/85 (31%)
a
 89/143 (62%) 113/228 (50%) 
 CLL-stage A clones 12/20 (60%) 53/89 (60%) 65/109 (60%) 
 CLL-stage B/C clones 8/20 (40%) 36/89 (40%) 44/109 (40%) 
Non-CLL like MBL B-cell clones 5/85 (6%) 4/143 (3%) 9/228 (4%) 
Non-CLL B-cell clones 14/85 (17%)
a
 11/143 (8%) 25/228 (11%) 
IGHV mutated CLL-like  B-cell clones 40/66 (61%) 76/128 (59%) 116/194 (60%) 
IGHV mutated non-CLL-like  B-cell 
clones 
11/19 (58%) 8/15 (53%) 19/34 (56%) 
%  alignment of  IGHV aa sequences  
between coexisting B-cell clones* 
51% (38%-79%) NA 51% (38%-79%) 
% alignment of  IGHV aa sequences 
between each B-cell clone and the 
other clones* 
52% (31%-100%)
a
 50% (29%-100%) 51% (29%-100%) 
Results expressed as number of B-cell clones and percentage between brackets or as *median value (range). PB, 
peripheral blood; WBC, white blood cells; CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; 
MBL
low
, low count monoclonal B-cell lymphocytosis; IGHV, immunoglobulin heavy chain variable region genes; 
CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MBL
high
, clinical monoclonal B-cell 
lymphocytosis; aa, amino acids. NA, not appropriate. 
a
Statistically significant differences (P <0.05) found 
between clones from multiclonal vs. monoclonal
 
cases. Information about the parameters included in this table is 
separately displayed for CLL-like vs. non-CLL-like clones in Supplemental Table 4. 
 
3.3.3. Cytogenetic features of B-cell clones from multiclonal versus monoclonal MBL 
and B-CLPD cases  
 
The frequency of CLL-like MBL and CLL clones from multiclonal cases that showed 
cytogenetic alterations was significantly lower than that found among CLL-like MBL and CLL 
clones from monoclonal cases: 27/66 (41%) vs. 77/128 (60%), respectively (P =0.02). Likewise, 
the proportion of CLL-like B-cell clones showing coexistence of ≥2 cytogenetic alterations was 
also significantly lower in multiclonal than in monoclonal cases − 8/66 (12%) vs. 32/128 (25%); 
P =0.047 −; this was specially true among B-cell clones from CLL patients − 2/26 (8%) vs. 29/89 
(33%), respectively; P =0.03 – (Table 12). 
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Regarding each specific cytogenetic alteration, only a decreased frequency of CLL-like 
B-cell clones with del(13q14) involving the RB1 gene and a lower percentage of del(13q14)+ 
cells was found in multiclonal vs monoclonal cases − frequency of del(13q14)+ clones − of 5% 
vs. 15% with a median of del(13q14)+ cells of 55% vs. 86%, respectively; P =0.01) (Table 12). Of 
note, these differences were mostly due to the lower frequency of B-cell clones with 
del(13q14) (4% vs 19%, P =0.01) found among CLL clones from multiclonal vs. monoclonal 
cases (Table 12).  
 
 
 
 
 
 
 
 
 
  
 
Table 12. Cytogenetic features of CLL-like MBLlow, MBLhigh and CLL B-cell clones from monoclonal versus multiclonal cases. 
Cytogenetic alterations 
MBL
low
 clones MBL
high
 clones CLL clones TOTAL 
Multiclonal 
n=14 
Monoclonal 
n=13 
Multiclonal 
n=26 
Monoclonal 
n=26 
Multiclonal 
n=26 
Monoclonal 
n=89 
Multiclonal 
n=66 
Monoclonal 
n=128 
No. of cytogenetically altered clones 2/14 (14%) 6/13 (46%) 13/26 (50%) 13/26 (50%) 12/26 (46%) 58/89 (65%) 27/66 (41%)
b
 77/128 (60%) 
No. of clones with ≥2 alterations 1/14 (7%) 1/13 (8%) 5/26 (19%) 2/26 (8%) 2/26 (8%)
a
 29/89 (33%) 8/66 (12%)
b
 32/128 (25%) 
Type of cytogenetic changes         
No. of del(13q)
+
 clones (%)  
% del(13q)
+
 cells * 
2/14  (14%) 
46% (19%-73%) 
5/13 (38%) 
86% (22%-96%) 
7/26 (27%) 
74% (15%-98%) 
8/26  (31%) 
38% (21%-99%) 
8/26 (31%) 
93% (30%-96%) 
36/89 (40%) 
80% (47%-99%) 
17/66 (26%) 
84% (10%-98%) 
49/128 (38%) 
79% (18%-99%) 
No. of del(13q14.3)
+
 clones (%) 
% del(13q14.3)
+
 cells * 
2/14  (7%) 
(19%-73%) 
4/13 (31%) 
78% (22%-96%) 
7/26 (27%) 
65% (15%-98%) 
8/26 (31%) 
38% (21%-99%) 
8/26 (31%) 
81% (30%-96%) 
35/89 (39%) 
73% (5%-99%) 
17/66 (26%) 
80% (15%-98%) 
47/128 (37%) 
71% (5%-99%) 
No. of del(13q14)
+
 clones (%) 
% del(13q14)
+
 cells * 
0/14 (0%) 
- 
1/12 (8%) 
86% (-) 
2/26 (8%) 
57% (15%-98%) 
1/26 (4%) 
96% (-) 
1/26 (4%)
a
 
95% (-) 
17/89 (19%) 
79% (47%-99%) 
3/66 (5%)
b
 
55% (10%-98%)
b
 
19/127 (15%)
 
86% (47%-99%) 
No. of trisomy 12
+
 clones (%) 
% trisomy 12
+
 cells * 
0/14 (0%) 
- 
1/13 (8%) 
59% (-) 
6/26 (23%) 
87% (19%-95%) 
5/26 (19%) 
84% (80%-93%) 
2/26 (8%) 
84% (75%-93%) 
17/89 (19%) 
76% (33%-97%) 
8/66 (12%) 
87% (41%-95%) 
23/128 (18%) 
80% (33%-97%) 
No. of t(14q32)
+
 clones (%) 
% t(14q32)
+
 cells * 
0/12 (0%) 
- 
0/10 (0%) 
- 
2/26 (8%) 
42% (31%-52%) 
0/26 (0%) 
- 
1/26 (4%) 
98% (-) 
10/89 (11%) 
82% (18%-94%) 
3/64 (5%) 
72% (28%-98%) 
10/125 (8%) 
59% (18%-94%) 
No. of del(11q)
+
 clones (%) 
% del(11q)
+
 cells * 
0/12 (0%) 
- 
0/11 (0%) 
- 
1/26 (4%) 
93% (-) 
1/26 (4%) 
20% (-) 
1/26 (4%) 
91% (-) 
7/89 (8%) 
57% (21%-98%) 
2/64 (3%) 
92% (91%-93%) 
8/126 (6%) 
57% (20%-98%) 
No. of del(11q22.3)
+
 clones (%) 
% del(11q22.3)
+
 cells * 
0/12 (0%) 
- 
0/11 (0%) 
- 
1/26 (4%) 
93% (-) 
1/26 (4%) 
20% (-) 
1/26 (4%) 
91% (-) 
6/89 (7%) 
70% (24%-98%) 
2/64 (3%) 
92% (91%-93%) 
7/126 (6%) 
68% (20%-98%) 
No. of del(11q23)
+
 clones (%) 
% del(11q23)
+
 cells * 
0/12 (0%) 
- 
0/11 (0%) 
- 
0/26 (0%) 
- 
0/26 (0%) 
- 
0/26 (0%) 
- 
3/89 (3%) 
32% (21%-64%) 
0/64 (0%) 
- 
3/126 (2%) 
40% (24%-64%) 
No. of del(17p13.1)
+
 clones (%) 
% del(17p13.1)
+
 cells * 
0/13 (0%) 
- 
0/12 (0%) 
- 
0/26 (0%) 
- 
0/26 (0%) 
- 
0/26 (0%) 
- 
5/89 (6%) 
44% (33%-88%) 
0/65 (0%) 
- 
5/127 (4%) 
44% (33%-88%) 
Results expressed as number of clones with cytogenetic changes from all clones in the corresponding group (percentage) or as *median values of altered cells/clone (range). In seven clones (1 multiclonal 
MBL
low
, 3 monoclonal and 3 multiclonal CLL clones) biallelic del(13q14.3) was detected, and polysomy was found  in 1 multiclonal CLL clone. Statistically significant differences found between multiclonal vs. 
monoclonal B-cell clone groups for 
a
CLL clones (P =0.01) and 
b
all
 
(total) clones (P =0.01). CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MBL, monoclonal B-cell lymphocytosis.
1
0
1
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No statistically significant differences were observed in the cytogenetic patterns of 
non- CLL B-cell clones from multiclonal vs monoclonal cases, which is probably due to the 
relatively low number of non-CLL clones included in the study; the precise cytogenetic 
alterations found in non-CLL/non-CLL-like MBL cases are shown in Supplemental Table 3 and 
Table 4. In turn, the overall cytogenetic features of non-CLL like B-cell clones from multiclonal 
(n=19; 3 non-CLL MBLlow, 2 non-CLL MBLhigh, 14 non-CLL B-cell clones) vs. monoclonal (n=15; 2 
non-CLL MBLlow, 2 non-CLL MBLhigh, 11 non-CLL B-cell clones) subjects were similar, as regards 
both the frequency of cytogenetically altered clones (6/19, 32% and 6/15, 40%) and the 
percentage of cases with ≥2 genetic alterations − 2/19 (11%) vs. 2/15 (13%) – (Supplemental 
Table 3 and Table 5). 
 
3.3.4. Molecular characteristics of the BCR of B-cell clones from multiclonal versus 
monoclonal MBL and B-CLPD cases 
  
The molecular profile of the BCR of CLL-like MBLlow, MBLhigh and CLL B-cell clones and of 
B-cell clones other than CLL from multiclonal vs. monoclonal cases was very similar (Table 13 
and Table 14).  
No statistically significant differences in multiclonal vs monoclonal VH gene usage were 
found for most groups. Despite this general behavior, CLL-like MBLhigh B-cell clones from 
multiclonal cases less frequently showed usage of the DH1, DH4 and DH7 gene families than B-
cell clones from monoclonal cases; in addition, JH6 genes were also less frequently used by CLL 
B-cell clones from multiclonal vs. monoclonal cases (Table 13). Overall, 33 functional IGHV 
gene rearrangements were identified from which 12 (V4-34, V3-23, V3-48, V3-30, V1-69, V3-
21, V4-39, V3-33, V3-11, V3-53, V1-2, V3-7) were highly represented among the B-cell clones 
(≥5% of all B-cell clones corresponding to ≥4 and ≥5 B-cell clones sharing the same IGHV gene 
in multiclonal and monoclonal cases, respectively) (Figure 9A). Interestingly, 11 of these IGHV 
genes were found at similar frequencies within the clones of multiclonal vs. monoclonal cases, 
while the V3-33 gene was typically associated with multiclonal cases (6% vs. 1%, P =0.03). 
Regarding IGHD genes, no significant differences were observed between B-cell clones from 
multiclonal and monoclonal cases, the D3-3, D5-12, D3-10, D6-19, D2-15, and D2-2 genes being 
the most frequently used and shared by both groups of B-cell clones (Figure 9B). Among IGHJ 
genes, significant differences were only observed for the JH6 gene, which was more frequently 
used in monoclonal cases (40% vs. 26%, P = 0.03) (Figure 9C). 
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Table 13. Molecular characteristics of the BCR of CLL-like MBLlow, MBLhigh and CLL B-cell clones 
from monoclonal versus multiclonal cases.  
 MBLlow clones MBLhigh clones CLL clones TOTAL 
 
Multiclonal  
n= 14 
Monoclonal 
n= 13 
Multiclonal  
n= 26 
Monoclonal 
n= 25 
Multiclonal  
n= 26 
Monoclonal 
n= 87 
Multiclonal  
n= 66 
Monoclonal  
n= 126 
HCDR3 length*  
(N. of aa) 
15 (6-22) 13 (11-20) 16 (8-23) 17 (9-26) 17 (11-26) 18 (8-32) 17 (6-26) 17 (8-32) 
         
VH families 
VH1 2/14 (14%) 2/13 (15%) 3/26 (12%) 4/25 (16%) 4/26 (15%) 25/87 (29%) 9/66 (14%) 31/125 (25%)  
VH3 9/14 (65%) 9/13 (69%) 15/26 (58%) 16/25 (64%) 11/26 (42%) 36/87 (41%) 35/66 (53%) 61/125 (49%) 
VH4 2/14 (14%) 2/13 (15%) 6/26 (23%) 3/25 (12%) 9/26 (35%) 23/87 (27%) 17/66 (26%)  28/125 (22%) 
VH2, VH5, VH6 1/14 (7%) 0/13 (0%) 2/26 (8%) 2/25(8%)  2/26 (8%) 3/87 (3%) 5/66 (7%) 5/125 (4%) 
         
         
DH families 
DH1, DH4, DH7 3/14 (21%) 2/13 (15%) 1/26 (4%)a 6/24 (25%) 6/26 (23%) 11/86 (13%) 10/66 (15%) 19/123 (16%) 
DH2 2/14 (14%) 3/13 (23%) 5/26 (19%) 7/24 (29%) 4/26 (15%) 15/86 (17%)  11/66 (17%) 25/123 (20%) 
DH3 3/14 (21%) 2/13 (15%) 9/26 (35%) 7/24 (29%) 13/26 (50%) 36/86 (42%) 25/66 (38%) 45/123 (37%) 
DH5 2/14 (14%) 3/13 (23%) 6/26 (23%) 2/24 (8%) 3/26 (12%)  9/86 (11%) 11/66 (17%) 14/123 (11%) 
DH6 4/14 (29%) 3/13 (23%) 5/26 (19%) 2/24 (8%) 0/26 (0%)  15/86 (17%) 9/66 (13%) 20/123 (16%) 
         
         
JH genes 
JH1, JH2, JH3, JH5 3/14 (21%) 2/13 (15%) 7/26 (27%) 7/24 (29%) 9/26 (35%) 14/86 (16%) 19/66 (29%) 23/123 (19%) 
JH4 6/14 (43%) 7/13 (54%) 13/26 (50%)  8/24 (33%) 10/26 (38%) 34/86 (40%) 29/66 (44%)  49/123 (40%)  
JH6 5/14 (36%) 4/13 (31%) 6/26 (23%) 9/24 (38%) 7/26 (27%)a 38/86 (44%)  18/66 (27%)a 51/123 (41%)  
         
         
LCDR3 length*  
(N. of aa) 
9 (8-13) 10 (8-10) 10 (8-12)a 9 (7-12) 10 (8-15) 9 (5-12) 10 (8-15)a 9 (5-12)  
         
VK families 
VK1 0/6 (0%) 1/4 (25%) 6/14 (43%)  3/12 (25%) 6/12 (50%) 23/48 (48%) 12/32 (38%) 27/64 (42%) 
VK2, VK5, VK6 1/6 (17%) 0/4 (0%) 1/14 (7%) 3/12 (25%) 2/12 (17%) 8/48 (17%) 4/32 (13%) 11/64 (17%) 
VK3, VK4 5/6 (83%)  3/4 (75%) 7/14 (50%) 6/12 (50%) 4/12 (33%) 17/48 (35%) 16/32 (50%)  26/64 (41%) 
         
JK genes 
JK1, JK3, JK5 3/6 1/4 5/14  7/12  5/12  21/47  13/32  29/63  
 (50%) (25%) (36%) (58%) (42%) (45%) (40%) (46%) 
JK2 2/6  2/4  8/14  3/12  4/12  10/47  14/32  15/63  
 (33%) (50%) (57%) (25%) (33%) (21%) (44%) (24%) 
JK4 1/6  1/4  1/14  2/12  3/12  16/47  5/32  19/63  
 (17%) (25%) (7%) (17%) (25%) (34%) (16%) (30%) 
         
Vλ families 
Vλ3 2/3 (67%) NA 1/7 (14%) 0/7 (0%) 2/7 (29%) 8/25 (32%) 5/17 (29%) 8/32 (25%) 
Other 1/3 (33%) NA 6/7 (86%) 7/7 (100%) 5/7 (71%) 17/25 (68%) 12/17 (71%) 24/32 (75%) 
         
Jλ genes 
Jλ1 1/3 (33%) NA 0/7 (0%) 0/7 (0%) 4/7 (57%) 6/21 (71%) 5/17 (29%) 6/28 (21%) 
Other 2/3 (67%) NA 7/7 (100%) 7/7 (100%) 3/7 (43%) 15/21 (29%) 12/17 (71%) 22/28 (79%) 
         
IGHV mutational 
status 
        
Mutated IGHV 9/14 (64%) 8/11 (73%) 17/26 (65%) 20/25 (80%) 14/26 (54%) 46/86 (54%) 40/66 (61%) 74/122 (61%) 
Unmutated IGHV 5/14 (36%) 3/11 (27%) 9/26 (35%) 5/25 (20%) 12/26 (46%) 40/86 (47%) 26/66 (39%) 48/122 (39%) 
Results expressed as number of B-cell clones from all clones in the corresponding group (percentage) or as *median 
(range). CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MBL, monoclonal B-cell lymphocytosis; 
BCR, B-cell receptor; HCDR3, heavy chain complementarity-determining region 3; LCDR3, light chain 
complementarity-determining region 3; aa, amino  acid. NA, not analyzed; 
a
 statistically significant differences found 
between groups of clones from multiclonal vs monoclonal cases (P ≤0.03). 
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Table 14. Molecular characteristics of the BCR of non-CLL B-cell clones from both MBL and B-
CLPD other than CLL. 
 
Non-CLL B-cell clones 
n=34 clones 
 Multiclonal Monoclonal 
HCDR3 length* (N. of aa) 14 (8-26) 16 (7-22) 
VH families 
VH1 4/19 (21%) 3/15 (20%) 
VH3 12/19 (63%) 8/15 (53%) 
VH4 3/19 (16%) 2/15 (13%) 
VH5 0/19 (0%) 1/15 (7%) 
VH6 0/19 (0%) 1/15 (7%) 
   
DH families 
DH1, DH4, DH7 5/19 (26%) 2/14 (14%) 
DH2 3/19 (16%) 4/14 (29%) 
DH3 4/19 (21%) 2/14 (14%) 
DH5 2/19 (11%) 5/14 (36%) 
DH6 5/19 (26%) 1/14 (7%) 
   
JH genes 
JH1, JH2, JH3, JH5 7/19 (37%) 3/15 (20%) 
JH4 8/19 (42%) 7/15 (47%) 
JH6 4/19 (21%) 5/15 (33%) 
   
   
LCDR3 length* (N. of aa) 9 (9-11) 9 (8-12) 
VK families 
VK1 4/11 (36%) 3/12 (25%) 
VK2 2/11 (18%) 1/12 (8%) 
VK3-4 5/11 (46%) 8/12 (67%) 
   
JK genes 
JK1, JK3, JK5 5/11 (42%) 5/11 (45%) 
JK2 2/11 (33%) 2/11 (21%) 
JK4 4/11 (25%) 4/11 (34%) 
   
Vλ families 
Vλ3 1/3 (33%) 1/1 (100%) 
Other 2/3 (67%) 0/1 (0%) 
   
Jλ genes 
Jλ2 2/3 (67%) 1/1 (100%) 
Jλ3 1/3 (33%) 0/1 (0%) 
Results expressed as number of B-cell clones from all clones in the corresponding group (percentage) or as *median 
(range). Non-CLL, clones mimicking or compatible with B-cell chronic lymphoproliferative disorders other than 
chronic lymphocytic leukemia; BCR, B-cell receptor; HCDR3, heavy chain complementarity-determining region 3; 
LCDR3, light chain complementarity-determining region 3; aa, amino acid. 
 
Except for slightly longer LCDR3 sequences of the IGKV and IGLV genes found among B-
cell clones from multiclonal versus monoclonal cases, specially among CLL-like MBLhigh clones 
(Table 13), no other significant differences were found in the molecular characteristics of the 
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immunoglobulin light chain genes, neither among CLL-like nor non-CLL like B-cell clones from 
multiclonal vs. monoclonal cases (Table 13 and Table 14). Regarding IGKV and IGLV genes, only 
the VK1-33 gene was associated with multiclonal cases (6% vs. 0%, P =0.02) (Figure 9D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Frequency of IGHV (panel A), IGHD (panel B), IGHJ (panel C) and both IGKV and IGLV (panel D) genes in 
multiclonal and monoclonal CLL versus non-CLL like B cell clones. Diagrams show the relative frequency of each IG 
gene in multiclonal compared to monoclonal B-cell clones (black and white bars, respectively). *Statistically 
significant differences were found between the multiclonal vs. monoclonal subgroups (P <0.05). 
 
 
 
Multiclonal 
Monoclonal 
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3.3.5. Molecular features of phylogenetically related BCRs of B-cell clones from 
multiclonal cases 
 
Thirty-two of the 85 B-cell clones from individual multiclonal cases were 
phylogenetically closely related and had exactly the same IGHV family (IGHV3 in 28 B-cell 
clones and IGHV4 in 4 B-cell clones) (Figure 10). Of note, this subgroup of B-cell clones 
frequently showed IGHV3 gene usage (28/85, 33%) and they displayed shorter HCDR3 
sequences than other (multiclonal and monoclonal) B-cell clones − 13 (6-25) vs. 17(9-26) and 
16 (8-32) aa; P =0.001 and P =0.004, respectively −; in addition, they also showed a higher 
frequency of del(13q14.3) compared to B-cell clones from multiclonal cases expressing 
phylogenetically unrelated IGHV families (41% vs. 17%, respectively; P =0.05). Moreover, a 
slightly higher frequency of multiclonal cases whose coexisting clones were cytogenetically 
altered was found among phylogenetically closely related clones vs phylogenetically unrelated 
clones from multiclonal cases (53% vs. 34%, respectively; P =0.06). Interestingly, a trend 
towards an increased percentage of IGHV mutated B-cell clones among phylogenetically 
related B-cell clones from multiclonal cases compared to other B-cell clones from multiclonal 
cases, was also found (70% vs. 54%, respectively; P =0.1). Interestingly, most of the co-existing 
phylogenetically related clones had a CLL-like phenotype (10/16 cases, identified in 
Supplemental Table 3 with the ¶ symbol), while in 4/16 multiclonal cases, one CLL-like B-cell 
clone coexisted with one non-CLL B-cell clone, (2 MZL, 1 MALT lymphoma and 1 HCL clones 
from cases 29, 32, 37 and 38, also identified in Supplemental Table 3 with the ¶ symbol). In a 
minority of cases (2/16), the two co-existing phylogenetically related clones were both non-CLL 
like, their phenotype being consistent with FL (case 16¶, in Supplemental Table 3) and MALT 
lymphoma (case 34¶, in Supplemental Table 3), respectively.  
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Figure 10. Sequence distance cladogram of IGHV gene usage in CLL-like and non-CLL like B-cell clones from 
multiclonal (dark colored bars in the outside circle) and monoclonal (light colored bars in the outside circle) cases.  
Five major branches were found in the sequence distance cladogram (i.e VH1, VH5, VH3, VH2-VH6, VH4). B-cell 
clones from individual multiclonal cases are represented by numbers; from them, those phylogenetically closely 
related B-cell clones, which share the same IGHV family, are specifically identified by bold numbers in the inner part 
of the circle and the symbol ¶. Of note, B-cell clones from multiclonal cases 14¶, 16¶ and 35¶ belong to closely 
located sub-branches of the cladogram, having their IGHV sequences an aa identity of 79%, 76% and 69%, 
respectively. In turn, B-cell clones from the multiclonal case 32¶ belong to the VH4 major branch with IGHV 
sequences whose aa identity is of 69%. Finally, the other B-cell clones from multiclonal cases – cases 2¶, 11¶, 15¶, 
18¶, 19¶, 27¶, 29¶, 31¶, 34¶, 37¶, 38¶ and 40¶– belong to the VH3 major branch, having IGHV sequences with an 
aa identity which is > 60% (–68%, 73%, 73.4%, 61%, 79%, 70%, 63%, 77%, 69.9%, 70%, 72% and 68.4%–, 
respectively).  
 
3.3.6. Homology of the HCDR3 region between B-cell clones coexisting in 
multiclonal cases versus non-coexisting (monoclonal) B-cell clones 
 
The HCDR3 aa sequence from coexisting B-cell clones had the same length or it just 
differed in one aa in 8/41 multiclonal cases analyzed (19%) (Table 15A). The homology of all 
these case-paired HCDR3 regions was calculated as the number of identical aa or aa with an 
analogous side-chain polarity (excluding the anchor second-CYS104 (C_) and the J-TRP 118 
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(_W) aa positions that delineate the HCDR3 region) divided by the corresponding HCDR3 
length (Table 15A). It is worth noting that the aa composition of HCDR3 sequences of the same 
length (±1 aa) that belonged to the same or evolutionary, highly-related, VH families (e.g. VH3-
48, VH3-21, VH3-11)239 (n=57) from monoclonal cases (Supplemental Table 6) showed a 
tendency towards a lower homology than that of multiclonal cases: median of 37% (range: 
11% to 71%) vs. 50% (range: 26% to 64%), respectively; (P =0.1). Since stereotyped sequences 
are widely represented in CLL 487, we further analyzed the frequency of stereotyped HCDR3 
sequences in multiclonal cases (Table 15B) vs. monoclonal cases (Table 15C). Interestingly, the 
number of multiclonal cases showing the same or highly similar stereotyped HCDR3 sequences 
was significantly higher than that of monoclonal cases: 8/41 (19%) vs. 11/143 (8%), 
respectively, (P =0.001). Furthermore, the aa composition of HCDR3 sequences from 
monoclonal cases with stereotyped HCDR3 sequences showed clearly less identical and/or 
conserved positions than those found among multiclonal cases (underlined aa in Table 15B and 
Table 15C). 
 
Table 15. Multiclonal cases with coexisting B-cell clones sharing HCDR3 features (A). 
Multiclonal (B) and monoclonal (C) cases with B-cell clones showing stereotyped HCDR3 aa 
sequences. 
A. Multiclonal cases with coexisting B-cell clones showing identical or one aa differing 
length of HCDR3 regions, and analogous composition of aa in some parallel positions. 
Multiclonal Case ID VH families aa composition of HCDR3 (length) % homology
#
 
8A 
8B 
V1-3 
V3-53 
C_ARDRVVIIPDTTTINWFDP_W (19) 
C_ATHPTNIYTRWPYVSDMDV_W (19) 
26 
11A 
11B 
V3-23 
V3-48 
C_ANRGETRGMDV_W (11) 
C_VRDGFHYYGFDI_W (11) 
54 
14A 
14B 
V4-34 
V4-34 
C_ARGPDRLYSGSYTRFDY_W (17) 
C_ARREDDNFWSGFYMDV_W (16) 
47 
22A 
22B 
V3-74 
V4-59 
C_ARDLDGSGSGVFDW_W (14) 
C_ARGWRSTDSYYGMDV_W (15) 
64 
29A 
29B 
V3-48 
V3-15 
C_VRELWFGNGGDY_W (12) 
C_ATAGQGSADFLY_W (12) 
42 
31A 
31B 
V3-33 
V3-23 
C_ARGELLHNWFDP_W (12) 
C_AKDGFPYYGFDI_W (12) 
58 
32A 
32B 
V4-39 
V4-34 
C_ARQTGWLAPSDY_W (12) 
C_ARRDSSGWYYFDY_W (13) 
54 
33A 
33B 
V2-26 
V3-53 
C_AGTNIPRQFDFWSGSSPNWFDP_W (22) 
C_ARAGGYCNSGSCRGAPRWYFDL_W (22) 
32 
Amino acids (aa) with analogous side-chain polarity (highlighted in gray): case 8 (I, V and F, M), case 11 (A, V and M, 
F), case 14 (L, F), case 22 (L, W; S, T and F, M), case 29 (A, V), case 31(L, F and H, Y), case 32 (T, S), case 33 (W, C) 
(EMBL-EBI Cambridge, UK). All cases had coexisting B-cell clones with CLL-like phenotype, except case 29 (one B-cell 
clone corresponded to a MALT lymphoma-like phenotype), cases 32 and 33 (both had one B-cell clone with a MZL-
like phenotype). MALT, lymphoma of mucosa-associated lymphoid tissue; MZL, marginal zone lymphoma. 
#
Number 
of aa with analogous side-chain polarity (excluding the delineating C_ and _W positions)/HCDR3 length*100. 
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B. Multiclonal cases with B-cell clones showing stereotyped HCDR3 sequences. 
Multiclonal Cases ID V(D)J rearrangement AA composition of HCDR3 
1 
2 
V3-30(D3-9)J6 
V3-30(D3-9)J6 
C_AKYGGVKLRYFDWLLYGDYYYGMDV_W 
C_AKYGGVKLRYFDWLLYGDYYYGMDV_W 
9 
15 
V3-23(D5-12)J6 
V3-23(D3-22)J6 
C_ANRGETRGMDV_W 
C_ANRGESWGMDV_W 
21 
35 
V3-21(D2-2)J6 
V3-21(D2-2)J6 
C_ARDANGMDV_W 
C_ARDANGMDV_W 
22 
40 
V3-74(D3-10)J4 
V3-21(D4-23)J4 
C_ARDLDGSGSGVFDW_W 
C_ARDLDGGNSVFDC_W 
Cases 1 and 2; 9 and 15; 21 and 35; 22 and 40 showed a highly similar HCDR3 sequence; the 
underlined aa were different. All the listed B-cell clones had a CLL-like phenotype. 
 
C. Monoclonal cases with B-cell clones showing stereotyped HCDR3 sequences. 
Monoclonal Cases ID V(D)J rearrangement AA composition of HCDR3 
117 
134 
V3-7(D3-3)J4 
V3-7(D3-3)J4 
C_VRENELWSGGWGLDG_W 
C_VRENEFWSGGWGLDG_W 
207 
208 
210 
V4-39(D2-2)J6 
V4-39(D2-2)J6 
V4-39(D2-2)J6 
C_ARHRLGYCSSTSCYYYYYGMDV_W 
C_ARHRLGYCSSTSCYYYYYGMDV_W 
C_ARDRLGYCSSTSCYYYYYGMDV_W 
187 
215 
V4-b(-)J4 
V4-b(D5-5)J4 
C_ARSWIQLWSEFDY_W 
C_ARAWIQLWSDFDY_W 
180 
204 
V1-2/D6-19/J4 
V1-2/D6-19/J4  
C_ARLQWLGISHFDY_W 
C_ARAQWLVLENFDY_W 
196 
198 
V4-34/D3-16/J6 
V4-34/D4-23/J6 
C_VRGYPSDYTERRYYYYGLDV_W 
C_ARGYGSTGETRRYYYYGMDV_W 
Cases 117 and 134; 207, 208 and 210; 187 and 215; 180 and 204; 196 and 198 showed a highly 
similar HCDR3 region; the underlined aa were different. All the listed B-cell clones had a CLL-like 
phenotype. 
 
 
3.4. Discussion 
 
Multiclonal expansions of phenotypically aberrant B-cell clones (MBLlow) have been 
reported as frequently present in the general population;19 of note, multiclonal expansions of 
immunophenotypically normal B-cells can also be found in non-malignant diseases, such as 
autoimmune disorders and inflammatory responses against several infectious agents (e.g. 
Helicobacter pylori, HCV).488,489 Whether clonal expansions of aberrant B-cells found in 
otherwise healthy individuals (MBLlow) reflect a prominent reactive process against potent 
antigenic stimuli with unknown clinical relevance, or they represent an early (multi)clonal 
manifestation of a BCR-dependent neoplastic event, still remains to be established. In this 
regard, it should be noted that between 30% and 40% of such cases show cytogenetic changes 
shared by MBL and CLL, e.g. del(13q). Of note, among other large structural chromosomal 
alterations, clonal mosaicism involving del(13q14) has also been recently found in peripheral 
blood cell populations from otherwise healthy individuals, particularly among subjects with 
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more advanced age (around 2-3% in the elderly), but its potential relationship with MBL and 
CLL remains unknown.490,491 Compared to the typical (monoclonal) MBL and B-CLPD, coexisting 
B-cell clones from multiclonal MBL and B-CLPD may potentially have a greater probability of 
interacting with common immunological determinants. However, there is still little information 
about the potential existence of shared BCR features in cases showing ≥2 coexisting B-cell 
clones vs. monoclonal cases.  
In the present study, we analyzed for the first time the molecular and cytogenetic 
features of a large group (n=85) of coexisting, but unrelated, B-cell clones from a series of 41 
multiclonal MBL and B-CLPD cases, in comparison to 143 monoclonal cases. Overall, the 
former clones more frequently showed cytogenetic and hematological features which are 
typical of the earliest MBL stages and/or initial phases of CLL.468,488,489 Accordingly, B-cell clones 
from multiclonal cases more frequently corresponded to MBL cases, whereas B-cell clones 
from monoclonal cases were more frequently found to correspond to overt CLL. Of note, these 
findings do not contradict the apparent discrepancy between such association and our 
previous observation among CLL patients of a worse clinical outcome for multiclonal cases 
carrying non-CLL clones,21 as this latter study was restricted to overt CLL cases. In addition, 
multiclonal cases were also associated with lower clonal B-cell counts in peripheral blood, a 
lower number of cytogenetically altered clones, particularly of those carrying del(13q), and a 
decreased frequency of clones with ≥2 alterations. Of note, clonal expansions of non-CLL like 
B-cell clones were also more frequently observed in multiclonal than in monoclonal cases, such 
expansions corresponding mainly to indolent lymphomas (e.g. MZL) which have been 
associated with chronic immune responses.492,493  
Altogether, these results support the notion that the presence of multiple B-cell clones 
in the same individual more closely reflects the earlier stages of the disease. If this holds true 
and chronic antigen stimulation is involved in the onset of MBL and B-CLPD – as it has been 
recently suggested for MBL, based on epidemiological studies204 –, it could be hypothesized 
that B-cell clones coexisting in multiclonal cases would show more closely related BCR features 
than B-cell clones from monoclonal cases. In this regard, our results point out the existence of 
a slightly higher level of HCDR3 homology among B-cell clones from multiclonal vs monoclonal 
cases. In fact, in around one fifth of all multiclonal cases, the co-existing B-cell clones showed a 
high homology in their HCDR3 aa sequences; this also hold true when we compared the 
homology of the HCDR3 sequences of these multiclonal against those of monoclonal cases 
whose B-cell receptors were restricted to the same and/or ontogenetically related IGHV 
families. In addition, the frequency of stereotyped HCDR3 was also higher in multiclonal vs. 
monoclonal cases. Such more closely related BCR features would be found independently of 
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whether common antigens or superantigens are specifically involved, although the former 
would potentially lead to a higher HCDR3 homology, whereas superantigens could contribute 
to a greater frequency of usage of specific IGHV, IGHD and/or IGHJ genes.22,244  
In the present study, we found a similar frequency of IGHV gene usage between 
coexisting multiclonal and non-coexisting monoclonal B-cell clones in association with a lower 
frequency of DH1, DH4 and DH7 as well as JH6 families in multiclonal vs. monoclonal B-cell 
clones. Overall, these results suggest that no single Ag or superantigen is involved in common 
in MBL and B-CLPD. This is further supported by the relatively low percentage of alignment 
(≈50%) of the IGHV aa sequences observed among the different clonal B-cell populations 
analyzed, since such potential antigens – including superantigens – would require interaction 
with highly conserved sites at the IGHV/HCDR3 regions of the BCR.494 Interestingly however, 
the higher representation of DH1, DH4, DH7 and JH6 IGH gene segments in monoclonal vs 
multiclonal B-cell clones, together with the slightly higher levels of HCDR3 homology observed 
among coexisting (multiclonal) vs non-coexisting (monoclonal) B-cell clones from MBL, CLL and 
other B-CLPD cases, would indicate that still non-random selection of specific HCDR3, DH and 
JH segments could exist in the MBL and CLL repertoire of both multiclonal and monoclonal 
cases, which could reflect antigen-driven selection and expansion of specific B-cell clones, both 
at the MBL and/or CLL stages.64  
In this regard, based on the phylogenetic proximity of their BCR, we could further 
identify within the B-cell clones from multiclonal cases, a considerably represented subgroup 
of B-cell clones showing preferential usage of IGHV3 genes and shorter HCDR3 sequences 
carrying a significantly higher number of IGHV mutations vs the unrelated clones. These results 
further support the involvement of a common antigen, at least in this specific subset of 
cases.495 Interestingly, these “phylogenetically-related” B-cell clones coexisting in multiclonal 
cases showed a significantly higher frequency of del(13q) than B-cell clones expressing other 
IGHV genes. These observations further suggest that the BCR features of this subset of 
coexisting multiclonal B-cell clones could also contribute to determine the probability and/or 
type of cytogenetic progression occurring at the earliest stages of the disease, as previously 
suggested by our group468 and others.479,496 Further long-term, longitudinal studies are required 
to confirm this hypothesis, since multiple productive IGHV gene rearrangements may also 
underline clonal drift leading to selection for more aggressive clones whose proportions would 
change over time.497 
In summary, based on the molecular features of the BCR and the cytogenetic profile of 
B-cell clones from the multiclonal vs monoclonal MBL, CLL and other B-CLPD cases here 
analyzed, it may be concluded that multiclonality is typically associated with early stages of B-
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CLPD, at the same time it appears to more closely reflect an antigen-driven nature of MBL and 
B-CLPD, with potential involvement of multiple and diverse antigenic determinants. 
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4.1. Abstract 
 
An increasing body of evidences suggests the potential occurrence of antigen 
encounter by the cell of origin in CLL and CLL-like MBL. However, the scenario in which this 
event might occur, remains unknown. In order to gain insight into this scenario we investigated 
the molecular, cytogenetic and hematological features of 223 CLL-like (n=84) and CLL (n=139) 
clones with stereotyped (n=32) vs. non-stereotyped (n=191) IGHV aa sequences. Overall, 
stereotyped CLL-like MBL and CLL clones showed a unique IGHV profile, associated with higher 
VH1 and lower VH3 gene usage (P =0.03), longer HCDR3 sequences (P =0.007) and unmutated 
IGHV (P <0.001) vs. non-stereotyped clones. Whilst the overall size of the stereotyped B-cell 
clones in PB did not appear to be associated with the CLL-related cytogenetic profile of B-cells 
(P >0.05) it did show a significant association with the presence of myelodysplastic syndrome 
(MDS)-associated immunophenotypes on PB neutrophils and/or monocytes (P =0.01). 
Altogether these results, point to the potential involvement of different selection forces in the 
expansion of stereotyped vs. non-stereotyped CLL and CLL-like MBL clones, the former being 
potentially favored by an underlying altered hematopoiesis. 
 
4.2. Materials and methods 
 
4.2.1. CLL patients and MBL subjects 
 
A total of 200 subjects (119 males and 81 females; mean age of 69±12 years; range: 
35-89 years) presenting one or more CLL-like and/or CLL clonal B-cell populations, were 
included in this study. Fifteen cases (7%) corresponded to healthy individuals with MBLlow 
(<200 CLL-like B-cells/µL in PB), 41 (20%) were MBLhigh (≥200 and <5 000 CLL-like B-cells/µL in 
PB), 131 (66%) had newly-diagnosed untreated CLL, 9 (4%) were CLL patients who had 
previously received chemotherapy for CLL, and 4 (2%) had other B-CLPD in association with ≥1 
CLL-like MBL B-cell population(s). PB samples were obtained from each subject after written 
informed consent was given, and the study was approved by the local ethics committees of the 
participating centres. Diagnosis of MBL and CLL was based on the WHO 2008 criteria466 and 
clinical staging of CLL subjects was established according to the Binet classification.498 
Immunophenotypic evaluation of the B-cell clones in MBL cases and both CLL and other B-
CLPD patients was performed as previously described.192,468,499 
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Overall, 37/200 subjects (18%) showed co-existence of two or three phenotypically 
different aberrant B-cell populations with a CLL-like (n=33) or other B-CLPD phenotype (n=4). 
For this study, analysis was focused only on those aberrant B-cell populations displaying a 
typical CLL-like MBL and CLL phenotype, for a total of 228 B-cell clones. The distribution of all 
clonal B-cell populations analyzed in the distinct diagnostic categories was as follows: 27 
corresponded to CLL-like MBLlow, 59 to CLL-like MBLhigh and 142 to CLL (see Table 16). 
  
Table 16. Distribution according to diagnosis of subjects included in the study and the 
corresponding CLL and CLL-like MBL clones. 
   Diagnostic subgroups 
  No. of cases  MBL
low
 MBL
high
 CLL Other B-CLPD 
Subjects Monoclonal 163 13 (87%) 33 (80%) 117 (84%)
#
 - 
 Multiclonal 37
†
 2 (13%)* 8 (19%)* 23 (16%)*
, # 
  4 (100%)*
, # 
 Total 200 15  41 140
#
 4
#
 
B-cell 
clones 
From monoclonal cases 163 13 (48%) 33 (56%) 117 (82%) - 
 From multiclonal cases 65 14 (52%) 26 (44%) 25 (18%) - 
 Total 228 27 59 142 - 
*For multiclonal CLL and CLL-like MBL cases as well as for B-CLPD cases other than CLL, only CLL-like clones were 
considered; the later B-CLPD cases included the following diagnoses: HCL, hairy cell leukemia; SMZL/MALT, splenic 
marginal zone B-cell lymphoma/ extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue 
lymphoma. CLL, chronic lymphocytic leukemia; MBL, monoclonal B-cell lymphocytosis; B-CLPD, B-cell chronic 
lymphoproliferative disorders. 
†
The number of clones per multiclonal case was of two in all diagnostic subgroups, except in three tri-clonal subjects 
corresponding to one CLL patient, one MBL
high
 case and one patient with a B-CLPD other than CLL. 
#
Six monoclonal and four multiclonal subjects had received conventional chemotherapy (see Supplemental Table 7). 
 
4.2.2. Cytogenetic and molecular studies 
 
Cytogenetic analyses were performed by multicolor interphase fluorescence in situ 
hybridization on slides containing FACS-purified and fixed aberrant B-cells, as previously 
described in detail.253,468,499 In parallel, analysis of the patterns of rearrangement of the IGHV 
was performed for each FACS-purified B-cell clone.468,471,472,499 Forward and reverse sequences 
were aligned into a single resolved sequence and then aligned with germline sequences using 
the IMGT database and tools (http://imgt.org). Only B-cell clones showing in-frame 
rearrangements were finally evaluated (n=223). Sequences containing >2% deviation from the 
germline sequence were considered as being somatically mutated. Those IGHV-IGHD-IGHJ 
rearrangements with HCDR3 sequences that matched stereotyped CLL subsets, as previously 
defined by Agathangelidis13 and Stamatopoulos et al.,237 were classified as stereotyped IGHV 
sequences; all other IGHV sequences were identified as being non-stereotyped.  
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4.2.3. Immunophenotypic analyses of PB myeloid cells 
 
Neutrophils were recognized as displaying MDS-associated phenotypes when they 
lacked or expressed low levels of CD10 and/or showed low SSC properties (e.g. granularity) vs. 
their normal counterpart;500 in turn, presence of CD56 expression on PB monocytes was also 
defined as an MDS-associated phenotype.500 
 
4.2.4. Statistical methods 
 
Conventional descriptive and comparative statistics –nonparametric Kruskal-Wallis and 
Mann-Whitney U tests (for continuous variables), or the Pearson’s 2 and Fisher exact tests 
(for categorical variables) – were performed using the SPSS software program (SPSS, version 
20.0; SPSS software, IBM, Armonk, NY, USA). P values <0.05 were considered to be associated 
with statistical significance. 
 
4.3. Results 
 
4.3.1. Molecular and cytogenetic features of CLL and MBL B-cell clones with 
stereotyped versus non-stereotyped IGHV amino acid sequences 
 
Thirty-two of the 223 B-CLPD clones (14%) analyzed showed stereotyped HCDR3 aa 
sequences. These stereotyped HCDR3 sequences corresponded to 19 different stereotyped CLL 
subsets, as previously defined by Stamatopoulos and Agathangelidis et al..13,237 From the 32 
stereotyped clones, 26 (81%) corresponded to B-cell clones from monoclonal B-CLPD, whereas 
6 (19%) derived from multiclonal B-CLPD cases (Table 17 and Table 18), the latter representing 
a slightly lower frequency than that found among non-stereotyped clones (19% vs. 30%, P 
=0.2)(Table 18). Further analysis of the specific IGHV gene sequences revealed a higher VH1 
gene usage in stereotyped vs. non-stereotyped B-cell clones; in contrast, the VH3 gene was 
less frequently found among the stereotyped clones (P =0.03) (Table 19). Moreover, 
stereotyped B-cell clones displayed longer median HCDR3 sequences and lower percentages of 
IGHV mutated aa sequences than non-stereotyped B-cell clones (P =0.007 and P <0.001, 
respectively) (Table 19).  
  
 
Table 17. Phenotypic, haematological, molecular and cytogenetic features of B-CLPD cases whose CLL-like B-cell clones had stereotyped HCDR3 
sequences defined according to previously reported stereotypic CLL profiles.13,237 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clone 
No 
Subset 
No. 
Clone 
Phenotype 
% 
Clone 
Abs. No. 
Clone (x106/L)  
MAP 
Binet 
Stage* 
IGHV 
MS 
IGHV-D-J gene 
rearrangements 
HCDR3 sequence (length) iFISH (% of altered cells) 
1 1 CLL 88 120 102 No B U V1-2/D6-19/J4 CARAQWLVLENFDYW (13) ND 
2 1 CLL-like MBLlow 3.1 112 No - U V1-2/D6-19/J4 CARLQWLGISHFDYW (13) ND 
3 1 CLL 87.6 79 839 Yes B U V1-3/D6-19/J4 CARWQWLVPSRFDYW (13) -13q14.3 (94%) 
4 1 CLL 35 5 085 No A U V1-18/D6-19/J4 CARKQWLGMYYFDYW (13) -13q14.3 (13%); t(14q32) (13%) 
5B† 2 CLL-like MBLhigh 9.8 2 078 Yes - M V3-21/D2-15/J6 CARDANGMDVW (9) ND 
6B 2 CLL-like MBLhigh 2.3 250 Yes - M V3-21/D2-15/J6 CARDANGMDVW (9) ND 
7 2 CLL-like MBLhigh 33.2 4 424 No - M V3-21/D1-26/J6 CARDANGMDVW (9) ND 
8 3 CLL 45.8 9 545 Yes NA U V4-34/D2-2/J6 CARADLLVVPAAIYYYYYGMDVW (21) -13q14 (90%);-13q14.3 (90%);-17p13.1 (83%) 
9 6 CLL 87 20 880 No A U V1-69/D3-16/J3 CARGGNYDYIWGSYRPNDAFDIW (21) -11q23 (24%) 
10 7 CLL 88 75 170 No A U V1-69/D3-3/J6 CARADGGYDFWSGYSTVNYYGMDVW (23) t(14q32) (91%) 
11 7 CLL 72 71 516 No B U V1-69/D3-3/J6 CARGPSSYDFWSGYYTGRDYYYYMDVW (25) -13q14 (12%);-13q14.3 (12%); t(14q32) (60%) 
12 7 CLL 43 8 544 Yes A U V1-69/D3-3/J6 CAREGGADKDYDFWSGYYPNYYYYGMDVW (27) ND 
13 7 CLL 68.3 30 093 No A M V1-69/D3-3/J6 CARAEQYYDFWSGHKGVDYYYYMDVW (24) +12 (33%); -11q22.3 (24%) 
14B 8 CLL-like MBLhigh 3 700 Yes - U V4-39/D6-13/J5 CASVQGYSSSWYGGDNWFDPW (19) +12 (93%) 
15 8 CLL 62.7 24 647 No NA U V4-39/D6-13/J5 CATQTGYSSSWYAVNWFDPW (18) t(14q32) (94%) 
16 10 CLL-like MBLhigh 44.6 4 594 Yes - U V4-39/D2-2/J6 CARHRLGYCSSTSCYYYYYGMDVW (22) ND 
17 10 CLL 40.6 17 214 No A U V4-39/D2-2/J6 CARHRLGYCSSTSCYYYYYGMDVW (22) ND 
18 10 CLL 86 22 704 No B U V4-39/D2-2/J6 CARDRLGYCSSTSCYLYYYGMDVW (22) ND 
19A 11 CLL 33.7 6 807 No NA U V4-34/D3-10/J4 CARGLYYYGSGVYFDYW (15) t(14q32) (98%) 
20 11 CLL 64.2 19 568 No C U V4-34/D3-10/J4 CARGLIGAYGSGSYYPFPFDYW (20) +12 (73%); t(14q32) (82%) 
21 12 CLL-like MBLhigh 15.3 1 454 NA - M V1-2/D3-22/J4 CARDLARYDSGGSYKRKMFDYW (20) ND 
22 16 CLL 90 186 012 Yes B M V4-34/D2-15/J6 CAGRFYCSGDTCHLPLYHYYYGLDVW (24) ND 
23 21 CLL 42 11 147 NA A U V3-23/D3-3/J6 CAKHQLTYYDFWSGYYTEYYYYYGMDVW (26) -13q14.3 (99%) 
24 22 CLL-like MBLhigh 18 2 531 No - U V3-11/D3-3/J6 CARDRRDDFWSGYRIYYYYYGMDVW (23) +12 (84%) 
25 22 CLL 66.9 17 488 Yes A M V3-23/D3-3/J6 CARDLTHHNFWSAYYETSYCGMDVW (23) ND 
26A† 23 CLL 62.9 49 600 Yes B U V3-30/D3-9/J6 CAKYGGVKLRYFDWLLYGDYYYGMDVW (25) ND 
27 25 CLL 65.6 33 003 No A U V1-8/D3-3/J6 CARGPSYYDFWSGPFDNYGMDVW (21) -13q14.3 (97%) 
28 31 CLL-like MBLhigh 19.5 1 661 No - U V3-48/D3-3/J6 CARSPGYDFWSGYPDYYGMDVW (20) +12 (84%) 
29 34 CLL 24.9 5 578 Yes A U V1-18/D3-9/J6 CARGAYYDILTGYRYYYGMDVW (20) +12 (75%) 
30A 38 CLL-like MBLhigh 23 3 174 Yes - U V4-39/D3-3/J5 CARHTSLYDFWSGYYRGWFDPW (20) -13q14 (15%);-13q14.3 (15%) 
31 77 CLL 91 219 537 No A M V4-59/D6-19/J4 CARGPDISGWNGLDYW (14) -13q14.3 (82%) 
32 201 CLL 65.4 11 523 No A M V4-34/D5-12/J3 CARREEDWKRSGRDSFDIW (17) Biallelic -13q14.3 (79%) 
*Specified for CLL cases only. Gray shadowed lines correspond to stereotyped CLL-like B-cell clones derived from multiclonal B-CLPD cases. U, unmutated; M, mutated; CLL, chronic 
lymphocytic leukemia; MBL, monoclonal B-cell lymphocytosis; B-CLPD, B-cell chronic lymphoproliferative disorders; MAP, myelodysplasia-associated phenotype; MS, mutational status. ND, 
not detected. NA, not available. †Patients that received chemotherapy for CLL. 
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Table 18. Peripheral blood B-cell counts, distribution of CLL-like MBLlow, MBLhigh and CLL B-cell 
clones and of CLL clinical stages according to the expression of non-stereotyped vs. 
stereotyped IGHV amino acid sequences. 
Results expressed as number of B-cell clones and percentage between brackets or as *median value (range). PB, 
peripheral blood; WBC, white blood cells; IGHV, immunoglobulin heavy chain variable region genes; CLL, chronic 
lymphocytic leukemia; MBL, monoclonal B-cell lymphocytosis; MDS, myelodysplastic syndromes. **Statistically 
significant differences (P <0.05). 
 
The frequency of cytogenetically altered stereotyped B-cell clones (59%) was similar to 
that found among non-stereotyped B-cell clones (58%). Likewise, the proportion of B-cell 
clones showing coexistence of ≥2 cytogenetic alterations was also similar in both groups (22% 
and 26%, respectively). Regarding each specific cytogenetic alteration, similar frequencies and 
percentages of cytogenetically altered cells were observed in stereotyped vs. non-stereotyped 
B-cell clones (Table 19). 
 
 
Non-stereotyped B-cell clones 
n=191 
Stereotyped B-cell clones 
n=32 
N. of  PB clonal B cells(x10
6
/L)* 7,408 (0.09-369 289) 11,336 (112-219 537) 
% of PB clonal B cells from WBC* 37% (0.001%-97%) 45% (2.3%-91%) 
% of multiclonal B-cell clones 58/191 (30%) 6/32 (19%) 
   
clones and CLL clones: cell-Blike -CLL   
CLL-like MBL
low
 B-cell clones 25/191 (13%) 2/32 (6%) 
CLL-like MBL
high
 B-cell clones 49/191 (26%) 8/32 (25%) 
         CLL B-cell clones 117/191 (61%) 22/32 (69%) 
             CLL-stage A clones 62/106 (59%) 12/19 (63%) 
             CLL-stages B clones    27/106 (25%) 6/19 (32%) 
             CLL-stages C clones 17/106 (16%) 1/19 (5%) 
   
% of cases with MAP (MDS-associated 
phenotypes) 
27/154 (17%) 12/30 (40%)** 
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Table 19. Molecular and cytogenetic features of CLL-like MBL and CLL clones with non-
stereotyped versus stereotyped IGHV amino acid sequences. 
Molecular and cytogenetic features 
Non-stereotyped clones Stereotyped clones 
n=191 n=32 
VH subgroups 
VH1 
VH3 
VH4 
VH2,VH5, VH6 
 
37/191 (19%) 
101/191 (53%) 
43/191 (23%) 
10/191 (5%) 
 
12/32 (38%)** 
8/32 (25%)** 
12/32 (38%) 
0/32 (0%) 
HCDR3 length*, aa 16 (6-32) 20 (9-27)
**
 
IgH mutated clones 122/191 (64%) 9/32 (28%)
**
 
   
   No. of genetically altered CLL-like clones 110/191 (58%) 19/32 (59%) 
   No. of CLL-like clones with ≥2 alterations 50/191 (26%) 7/32 (22%) 
   Type of cytogenetic alterations   
No. of del(13q)
+
 clones (%) 
% del(13q)
+
 cells * 
74/191 (39%) 
82% (10%-99%) 
9/32 (28%) 
79% (15%-90%) 
No. of del(13q14.3)
+
 clones (%) 
% del(13q14.3)
+
 cells * 
71/191 (37%) 
76% (5%-99%) 
9/32  (28%) 
82% (12%-99%) 
No. of del(13q14)
+
 clones (%) 
% del(13q14)
+
 cells * 
28/190 (15%) 
80% (7%-99%) 
3/32  (9%) 
15% (12%-90%) 
No. of del(13q)
+
 clones with another alteration (%) 40/191 (21%) 5/32 (16%) 
   
No. of trisomy 12
+
 clones (%) 
% trisomy 12
+
 cells * 
30/191 (16%) 
76% (8%-97%) 
6/32 (19%) 
80% (33%-93%) 
No. of trisomy 12
+
 clones with another alteration (%) 14/191 (7%) 2/32 (6%) 
   
No. of t(14q32)
+
 clones (%) 
% t(14q32)
+
 cells * 
20/180 (11%) 
27% (6%-91%) 
6/32 (19%) 
87% (13%-98%) 
No. of del(11q)
+
 clones (%) 
% del(11q)
+
 cells * 
8/186 (4%) 
68% (20%-98%) 
2/32 (6%) 
24% (24%-24%) 
   No. of del(11q22.3)
+
 clones (%) 
% del(11q22.3)
+
 cells * 
8/186 (4%) 
82% (20%-98%) 
1/32 (3%) 
24% (-) 
No. of del(11q23)
+
 clones (%) 
% del(11q23)
+
 cells * 
3/176 (2%) 
64% (40%-93%) 
1/32 (3%) 
24% (-) 
   No. of del(17p13.1)
+
 clones (%) 
% del(17p13.1)
+
 cells * 
6/188 (3%) 
56% (33%-88%) 
1/32 (3%) 
83% (-) 
Results expressed as number of CLL and CLL-like MBL clones with cytogenetic alterations from all CLL and CLL-like MBL clones in the 
corresponding group (percentage) or as *median values (range). In eight clones, biallelic del(13q14.3) was detected and polysomy 
was found in 1 (multiclonal) clone. **Statistically significant differences (P < 0.05).  
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4.3.2. Haematological features of CLL and CLL-like MBL B-cell clones with 
stereotyped versus non-stereotyped IGHV amino acid sequences 
 
Within the two groups of B-cell clones classified according to the presence of 
stereotyped vs non-stereotyped IGHV aa sequences, a similar distribution of CLL-like MBLlow, 
MBLhigh and CLL B-cell clones was found, albeit the stereotyped group included a slightly 
higher, but statistically not significant, ratio of CLL/CLL-like MBL B-cell clones (CLL/ CLL-like 
MBL ratio of 2.2 vs. 1.6, respectively; P =0.3) (Table 18). Similarly, the overall distribution of CLL 
B-cell clones per clinical stage showed a predominance of Binet stage A (63% and 59% of the 
clones, respectively) vs. Binet stage B (32% and 25%, respectively) and Binet stage C (5% and 
16%, respectively) among both the stereotyped and the non-stereotyped CLL clones. Of note, 
the median PB percentage and absolute count of stereotyped B-cell clones showed a tendency 
towards higher values than that of non-stereotyped B-cell clones: 45% vs. 37% of all white 
blood cells (P =0.1) and 11,336 clonal B-cells/μl vs. 7,408 clonal B-cells/μl (P =0.1), respectively 
(Table 18).  
Despite all the above similarities, non-stereotyped B-cell clones which were IGHV 
unmutated displayed significantly higher PB (clonal) B-cell counts than the IGHV mutated ones 
(14,076 cells/µl vs. 5,354 cells/µl, P =0.006) (Figure 11A). Likewise, the non-stereotyped B-cell 
clones which carried ≥2 cytogenetic alterations showed higher PB (clonal) B-cell counts than 
the the cytogenetically unaltered or minimally altered (isolated cytogenetic alteration) non-
stereotyped B-cell clones (17,310 cells/µl vs 4,841 cells/µl and 6,701 cells/µl, respectively; P 
≤0.007) (Figure 11B). In contrast, IGHV stereotyped B-cell clones did not show significant 
differences in their overall size when grouped according to their IGHV mutational status or to 
their cytogenetic profile (P >0.05; Figure 11). 
Similarly to what has been recently reported for multiple myeloma patients,501 29 of 
140 (21%) CLL and 10 of 41 (24%) MBLhigh cases, displayed MDS-associated immunophenotypic 
profiles on PB neutrophils (97%) and/or monocytes (46%). Most interestingly, 40% of all CLL 
and MBL cases carrying stereotyped B-cell clones showed MDS-associated phenotypic 
alterations on PB neutrophils and/or monocytes, a frequency which was significantly higher 
than that found among cases which had non-stereotyped B-cell clones (17%) (P =0.01) (Table 
18). 
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Figure 11. Number of clonal B-cells in the PB from IGHV stereotyped vs. non-stereotyped B-cell clones grouped 
according to their IGHV mutational status (panel A) and cytogenetic profile (panel B). Diagrams show the number of 
PB clonal B cells (x10
6
/L) with both stereotyped and non-stereotyped IGHV sequences according to their mutational 
status: unmutated (≤2% deviation from the germline sequence) vs. mutated (>2% deviation from the germline 
sequence) and the absence versus the presence of one or more than one cytogenetic abnormalities. Circles 
represent individual cases, and horizontal lines indicate median values. 
 
4.4. Discussion 
 
Despite increasing evidences about the potential occurrence of Ag encounter by the 
cell of origin in CLL exist,319 the precise B-cell scenario in which this event might occur, remains 
unknown. In order to gain insight into such potential scenario, here we investigated the 
molecular and biological features of stereotyped vs. non-stereotyped CLL and CLL-like MBL 
clones. Overall, stereotyped CLL and CLL-like MBL clones showed a unique IGHV profile, 
associated with higher VH1 gene usage (an IGHV subgroup that is particularly related with 
early stages in the evolution of the IGHV repertoire),40,502 longer HCDR3 sequences and 
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unmutated IGHV as compared to non-stereotyped clones. More interestingly, the overall size 
of the stereotyped B-cell clones in PB did not appear to be associated with the CLL-related 
cytogenetic profile of B-cells, whereas it did show a significant association with the presence of 
MDS-associated immunophenotypes on PB myeloid cells (neutrophils and monocytes).  
In recent years, immunophenotyping has been progressively introduced in clinical 
research and diagnostic laboratories for the identification of altered phenotypes in bone 
marrow precursors and myeloid (e.g. neutrophil, monocytic and erythroid lineage) cells, being 
currently considered in the WHO 2008 classification of hematological malignancies as a co-
criterion for the diagnosis of MDS.466 More recently, we have shown that altered MDS-like 
immunophenotypes are frequently observed on residual maturing neutrophils and monocytes 
(and to a lesser extent also on erythroid cells) from “de novo” AML and both MGUS and MM 
patients, where such aberrant myeloid phenotypes can be detected in >80% 503 and around 
15% 501 of de novo AML and MGUS/MM cases, respectively. Of note, in both groups of diseases 
(“de novo” AML and MGUS/MM), the MDS-associated phenotypes predicted for MDS-
associated cytogenetic changes (but not e.g. MGUS/MM-related genetic alterations) and the 
presence of an underlying clonal hematopoiesis.501 Based on these findings, we hypothesize 
that in those CLL and MBL cases in which we here found PB neutrophils and monocytes 
displaying the same MDS-associated phenotypes, an underlying clonal hematopoiesis, 
potentially associated with specific genetic changes that still remain to be identified, might 
also exist. Under these circumstances it could be speculated that, due to the close association 
between the presence of such MDS-associated phenotypes on myeloid cells and stereotyped 
B-cell clones, expansion of such stereotyped B-cell clones could more likely be favored by the 
altered local BM microenvironment than by chronic antigen stimulation outside the BM. This 
could also explain, at least in part, the greater rate of IGHV unmutated clones with longer 
HCDR3 sequences among stereotyped vs non-stereotyped cases. Similarly, it might also explain 
the lack of relationship observed between the presence and number of CLL-associated 
cytogenetic changes and the size of the stereotyped CLL and MBL PB clones, in contrast to 
what we observed among non-stereotyped cases. In line with these findings, it should be 
noted that within non-stereotyped cases, the presence and number of CLL-associated 
cytogenetic changes was significantly associated with the size of the B-cell clone in PB, only 
among those cases that did not show MDS-associated phenotypes on myeloid cells (data not 
shown). 
Altogether, our results support the notion that selective genetic and/or BM 
microenvironment forces may favor expansion of specific VDJ clones. This might occur already 
at the HSC level, particularly among IGHV stereotyped cases; such forces could initially lead to 
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the expansion of B-cell clones in an Ag-independent way, as recently proposed by Kikushige et 
al. 329. These early expansions would therefore, more likely translate into an oligoclonal MBLlow 
stable condition, in which clonality will not directly translate into malignancy;468,479 further 
clonal B-cell expansion might depend on additional micro-environmental factors (e.g. 
infections)204 and/or acquisition of specific (additional) genetic changes by the expanded B-
cells.468 Alternatively, chronic Ag-driven B-cell stimulation could act as the primary triggering 
factor in other cases (e.g. non-stereotyped B-cell clones from subjects who have a normal 
haematopoietic BM background/environment). However, due to the stable nature of most 
MBLlow clones, very long-term longitudinal studies are required to determine the exact 
pathways and factors involved in clonal CLL and CLL-like B-cell expansions potentially leading 
to neoplastic transformation.468 
In line with all the above, our study also revealed a greater VH1 and a lower VH3 gene 
usage in stereotyped vs. non-stereotyped B-cell clones. These findings would further support 
the existence of different ontogenic pathways for both categories of CLL-like and CLL clones.239 
VH3 genes belong to the ancestral phylogenetic clan III, which shows the greatest nucleotide 
conservation within the FR1 and FR3 intervals (versus IGHV1/5/7 and IGHV2/4/6 genes); 
because of this, usage of VH3 genes has been more frequently associated with the production 
of autoantibodies (e.g. anti-DNA antibodies) and direct FR3-ligand interaction with 
superantigens or self-antigens recognized in a pattern-specific way;40 this is further supported 
by the polyreactivity of some monoclonal antibodies produced by CLL cells247,318 which react 
with molecular structures present on apoptotic cells and bacteria.245,247 Fully in line with this 
hypothesis, we observed a lower incidence of multiclonality and a lower frequency of IGH 
mutated clones with longer HCDR3 sequences among stereotyped vs. non-stereotyped B-cell 
clones, pointing out the potential involvement of different types of BCR-triggers in stereotyped 
(e.g. survival promoting antigens like vimentin and calreticulin found on stromal cells504 or 
apoptotic cells245,246) vs. non-stereotyped clones (e.g. superantigens and autoantigens). Such 
hypothesis would be supported by recent observations which show that coexistence of 
phylogenetically-related B-cell clones that frequently share IGHV3 gene usage and that show 
both shorter HCDR3 sequences and a greater proportion of IGHV mutations and del(13q14.3), 
are more frequently seen in multiclonal MBL, CLL and other B-CLPD than in unrelated B-cell 
clones from monoclonal cases.499 Altogether these findings suggest that non-stereotyped B-cell 
clones with mostly mutated IGHV sequences and shorter HCDR3 sequences, could be more 
closely associated with chronic expansions driven by antigens in the periphery, whereas 
stereotyped B-cell clones with mostly unmutated IGHV sequences and longer HCDR3 
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sequences could derive from B-cells which are specifically selected in the bone marrow 
microenvironment. 
The association between stereotypy and MDS-associated immunophenotypic features 
of myeloid cells, further suggests the potential occurrence of increased cytokine-mediated 
intramedullary apoptosis reported to occur in specific subtypes of MDS.505 The potential 
contribution of intramedullary apoptosis to the expansion of stereotyped CLL and CLL-like MBL 
clones carrying unmutated IGHV sequences reactive against molecular structures present on 
apoptotic cells,245,247,296 would be in line with the highly-repetitive HCDR3 sequences of these 
stereotyped B-cell clones selected in such BM microenvironment; further investigations are 
required to confirm this hypothesis. 
In summary, in this study we report for the first time a significant association between 
stereotyped IGHV HCDR3 B-cell clones from both MBL subjects and CLL patients and 
coexistence of phenotypically altered (MDS-like) myeloid cells, suggesting that the emergence 
and/or expansion of CLL-like MBL and CLL clones in these cases could be favored by an 
underlying altered hematopoiesis; the precise significance of the MDS-like altered myeloid 
phenotypes, the potential underlying genetic lesions and the specific antigens involved, remain 
to be defined. 
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In general, detailed molecular analysis of the IGHV genes, has significantly contributed 
to unravel the pathogenesis of human B-CLPD. Thus, immunogenetic analysis of the clonogenic 
BCR offers valuable insight into both the ontogenesis of CLL and other B-CLPD and their 
precursor (e.g. MBL) states, and the potential involvement of Ag selection in the onset and 
development of the disease. In this regard, multiple studies have shown that CLL and other B-
CLPD exhibit a biased repertoire together with SHM patterns in their IGHV genes, both findings 
being generally considered as evidence for the involvement of a limited set of Ags and/or 
superantigens in the development of the disease. For CLL, the involvement of Ags in 
leukemogenesis is further supported by the identification of closely homologous Ag binding 
sites among unrelated cases (“stereotyped” BCR), which are characterized by a non-random 
combination of specific IGHV genes and homologous HCDR3, also associated in some 
instances, with a restricted selection of IGKV/IGLV light chains; of utmost relevance, such IGHV 
profiles are strongly associated with the clinical course of the disease. Despite all the above 
findings, at present it still remains unclear whether a single or multiple normal precursors are 
stimulated in parallel to evolve into CLL and at what stage(s) this potentially occurs. The 
recognition of MBL and particularly, the high frequency at which MBL cases show expansions 
of multiple B-cell clones, highlight a potential scenario where some individuals develop 
oligoclonal expansions of B-cells (e.g. CLL-like) from which only some will be selected to 
progress to overt disease. The specific driving forces involved in the origin, expansion, 
selection and malignant transformation of these B-cell clones, still remain largely unknown.  
In order to gain insight into the precise mechanisms leading to the development and 
progression of MBL into CLL and other B-CLPD, here we investigated the BCR features of a 
relatively large series of MBL and B-CLPD cases, particularly focusing on CLL-like MBLlow, CLL-
like MBLhigh and CLL subjects. For the purpose of the study we focused on three major goals: 1) 
the investigation of the potential associations between the specific IGHV repertoires and 
unique cytogenetic and mutational profiles of MBL vs. CLL cases; 2) the comparison of the 
immunogenetic, cytogenetic and hematological features of B-cell clones from monoclonal vs. 
multiclonal MBL, CLL and other B-CLPD, and; 3) the molecular and cytogenetic characteristics 
of MBL and CLL cases carrying stereotyped vs. non-stereotyped BCR. Based on the results of 
the work performed during this doctoral thesis, the following major conclusions can be drawn:  
 
‐ Regarding the potential existence of unique cytogenetic and mutational profiles associated 
with specific IGHV repertoires in MBL versus CLL: 
– MBLlow, MBLhigh and CLL B-cell clones display three major distinct, but partially 
overlapping, patterns of IGHV gene usage, IGHV mutational status and cytogenetic 
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alterations, suggesting that the combination of specific IGHV genes and IGHV 
mutational status of CLL-like B-cell clones may modulate the type of cytogenetic 
alterations acquired, their rate of acquisition and/or potentially also the distinct 
clinical behavior of such clones. 
 
‐ With respect to the phenotypic, cytogenetic and molecular characterization of expanded B-
cell clones from multiclonal versus monoclonal B-CLPD: 
– Multiclonal MBL, CLL and other B-CLPD display molecular, cytogenetic and 
hematological features which are typically associated with early MBL stages 
and/or initial phases of disease, at the same time they appear to more closely 
reflect an antigen-driven nature of MBL and B-CLPD with potential involvement of 
multiple and diverse antigenic determinants. 
 
‐ Regarding the molecular and cytogenetic characteristics of stereotyped CLL and CLL-like 
MBL clones and the potential coexistence of myelodysplasia-associated phenotypes on 
myeloid cells: 
– Stereotyped CLL and CLL-like MBL clones show unique IGHV profiles associated 
with unmutated IGHV sequences, longer HCDR3 and preferential usage of the VH1 
vs. VH3 genes; these BCR features may reflect a distinct origin for MBL and CLL B-
cells with stereotyped vs. non-stereotyped BCR. In line with this hypothesis, 
stereotyped CLL and CLL-like MBL B-cell clones more frequently showed 
myelodysplasia-associated immunophenotypes on PB myeloid cells. Altogether, 
these results point out the coexistence of an underlying altered hematopoiesis 
with potential involvement of HSC in the development and/or expansion of the CLL 
and CLL-like MBL B-cell clones from a significant fraction of cases carrying 
stereotyped BCR, the precise pathogenic role of such myelodysplasia-associated 
alterations of hematopoiesis deserving further investigations. 
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Supplemental Table 1. Informative parameters of the CLL-like/CLL B-cell clones included in the three 
major groups graphically visualized with APS view of the InfinicytTM software. 
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1 78multi_ MBLhigh_V4-34_M_0.xlsx 0 0 0 0 0 0 0 0 346 4-34 <98% 
 
1 79_ MBLhigh_V4-34_M_0.xlsx 0 0 0 0 0 0 0 0 1352 4-34 <98% 
 
1 80multi_ MBLhigh_V4-34_M_0.xlsx 0 0 0 0 0 0 0 0 2047 4-34 <98% 
 
1 81_ MBLhigh_V4-34_M_0.xlsx 0 0 0 0 0 0 0 0 2311 4-34 <98% 
 
1 95multi_ MBLhigh_V1-69_UM_0.xlsx 0 0 0 0 0 0 0 0 430 1-69 >98% 
 
1 96multi_ MBLhigh_V1-69_UM_0.xlsx 0 0 0 0 0 0 0 0 511 1-69 >98% 
 
1 49_ MBLhigh_V1-2_M_0.xlsx 0 0 0 0 0 0 0 0 999 1-2 <98% 
 
1 50_ MBLhigh_V1-2_M_0.xlsx 0 0 0 0 0 0 0 0 1454 1-2 <98% 
 
1 70_ MBLhigh_V3-7_M_0.xlsx 0 0 0 0 0 0 0 0 1264 3-7 <98% 
 
1 73_ MBLhigh_V3-30_M_0.xlsx 0 0 0 0 0 0 0 0 3986 3-30 <98% 
 
1 128multi_ MBLhigh_V3-30_M_del13q.xlsx 0 95 0 0 0 0 0 0 914 3-30 <98% 
 
1 57multi_ MBLhigh_V1-3_UM_0.xlsx 0 0 0 0 0 0 0 0 3458 1-3 >98% 
 
1 89_ MBLhigh_V3-48_UM_0.xlsx 0 0 0 0 0 0 0 0 1170 3-48 >98% 
 
1 63_ MBLhigh_V4-39_UM_0.xlsx 0 0 0 0 0 0 0 0 4594 4-39 >98% 
 
1 39_ MBLhigh_V5-51_UM_0.xlsx 0 0 0 0 0 0 0 0 2000 5-51 >98%  
1 31_CLL_V3-23_UM_0_A.xlsx 0 0 0 0 0 0 0 0 5200 3-23 >98%  
1 32multi_CLL_V3-23_M_0_A.xlsx 0 0 0 0 0 0 0 0 5680 3-23 <98%  
1 33_CLL_V3-23_M_0_A.xlsx 0 0 0 0 0 0 0 0 17488 3-23 <98%  
1 34_CLL_V3-23_M_0_A.xlsx 0 0 0 0 0 0 0 0 28710 3-23 <98%  
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Continuous parameters included for multivariate 
analysis based on PCA  
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1 47_CLL_V3-21_M_0_A.xlsx 0 0 0 0 0 0 0 0 37985 3-21 <98% A 
1 83_CLL_V4-34_M_0_A.xlsx 0 0 0 0 0 0 0 0 7103 4-34 <98% A 
1 84multi_CLL_V4-34_M_0_A.xlsx 0 0 0 0 0 0 0 0 7597 4-34 <98% A 
1 85_CLL_V4-34_M_0_A.xlsx 0 0 0 0 0 0 0 0 8653 4-34 <98% A 
1 130multi_CLL_V4-34_M_del13q_A.xlsx 0 96 0 0 0 0 0 0 8382 4-34 <98% A 
1 131multi_CLL_V4-34_M_del13q_A.xlsx 0 91 0 0 0 0 0 0 8398 4-34 <98% A 
1 132_CLL_V4-34_M_2del13q_A.xlsx 14 79 0 0 0 0 0 0 11523 4-34 <98% A 
1 37_SLL_V3-11_UM_0_A.xlsx 0 0 0 0 0 0 0 0 2404 3-11 >98% A 
1 38_CLL_V3-11_UM_0_A.xlsx 0 0 0 0 0 0 0 0 14076 3-11 >98% A 
1 98_CLL_V1-69_UM_del11q_A.xlsx 0 0 0 0 0 0 24 0 20880 1-69 >98% A 
1 56_CLL_V1-2_M_0_A.xlsx 0 0 0 0 0 0 0 0 9524 1-2 <98% A 
1 71_CLL_V3-7_M_t14q_del17p_A.xlsx 0 0 0 0 18 0 0 33 3055 3-7 <98% A 
1 58_CLL_V1-3_M_0_A.xlsx 0 0 0 0 0 0 0 0 7220 1-3 <98% A 
1 59multi_CLL_V1-3_M_0_A.xlsx 0 0 0 0 0 0 0 0 7833 1-3 <98% A 
1 61_CLL_V1-3_UM_0_A.xlsx 0 0 0 0 0 0 0 0 20229 1-3 >98% A 
1 92_CLL_V3-48_M_t14q_A.xlsx 0 0 0 0 22 0 0 0 64726 3-48 <98% A 
1 64multi_CLL_V4-39_UM_0_A.xlsx 0 0 0 0 0 0 0 0 6800 4-39 >98% A 
1 65_CLL_V4-39_UM_0_A.xlsx 0 0 0 0 0 0 0 0 17214 4-39 >98% A 
1 68multi_CLL_V4-39_UM_0_A.xlsx 0 0 0 0 0 0 0 0 71485 4-39 >98% A 
1 87_CLL_V4-34_M_0_B.xlsx 0 0 0 0 0 0 0 0 186012 4-34 <98% B 
1 133multi_CLL_V4-34_UM_del13q_C.xlsx 0 85 0 0 0 0 0 0 66142 4-34 >98% C 
1 53_CLL_V1-2_UM_0_B.xlsx 0 0 0 0 0 0 0 0 45081 1-2 >98% B 
1 54_CLL_V1-2_UM_0_B.xlsx 0 0 0 0 0 0 0 0 120102 1-2 >98% B 
1 74_SLL_V3-30_UM_0_B.xlsx 0 0 0 0 0 0 0 0 3509 3-30 >98% B 
1 76multi_CLL_V3-30_UM_0_B.xlsx 0 0 0 0 0 0 0 0 49600 3-30 >98% B 
1 129_CLL_V3-30_M_2del13q_C.xlsx 5 95 0 0 0 0 0 0 17175 3-30 <98% C 
1 66_CLL_V4-39_UM_0_B.xlsx 0 0 0 0 0 0 0 0 22704 4-39 >98% B 
2 24_ MBLlow_V3-23_M_2del13q.xlsx 86 0 86 0 0 0 0 0 1 3-23 <98%  
2 115_ MBLlow_V4-34_M_del13q.xlsx 96 0 0 0 0 0 0 0 26 4-34 <98%  
2 139_ MBLlow_V3-7_M_del13q 22 0 0 0 0 0 0 0 0.4 3-7 <98%  
2 141_ MBLlow_V3-48_M_del13q_tris12 19 0 0 41 0 0 0 0 0.57 3-48 <98%  
2 142_ MBLlow_V3-48_M_del13q 70 0 0 0 0 0 0 0 0.57 3-48 <98%  
2 29_ MBLhigh_V3-23_M_del13q.xlsx 21 0 0 0 0 0 0 0 4040 3-23 <98%  
2 101_ MBLhigh_V3-23_M_del13q.xlsx 88 0 0 0 0 0 0 0 3044 3-23 <98%  
2 116multi_ MBLhigh_V4-34_M_del13q.xlsx 83 0 0 0 0 0 0 0 551 4-34 <98%  
2 102multi_ MBLhigh_V3-11_M_del13q.xlsx 87 0 0 0 0 0 0 0 2692 3-11 <98%  
2 51_ MBLhigh_V1-2_M_del13q.xlsx 23 0 0 0 0 0 0 0 4623 1-2 <98%  
2 103_ MBLhigh_V1-2_M_2del13q.xlsx 96 0 96 0 0 0 0 0 4371 1-2 <98%  
2 107multi_ MBLhigh_V3-7_M_2del13q.xlsx 98 0 98 0 0 0 0 0 2750 3-7 <98%  
2 88multi_ MBLhigh_V3-48_M_del13q.xlsx 18 0 0 0 0 0 0 0 680 3-48 <98%  
2 62multi_ MBLhigh_V4-39_UM_2del13q.xlsx 15 0 15 0 0 0 0 0 3174 4-39 >98%  
2 118_CLL_V4-34_M_del13q_A.xlsx 99 0 0 0 0 0 0 0 13167 4-34 <98% A 
2 119_CLL_V4-34_M_2del13q_A.xlsx 97 0 95 0 0 0 0 0 105594 4-34 <98% A 
2 104_CLL_V1-2_UM_2del13q_A.xlsx 84 0 93 0 0 0 0 0 7683 1-2 >98% A 
2 111multi_CLL_V3-30_M_del13q_A.xlsx 80 0 0 0 0 0 0 0 7920 3-30 <98% A 
(Supplemental Table 1, continued) 
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Continuous parameters included for multivariate 
analysis based on PCA  
Groups ID P
e
rc
e
n
ta
ge
 o
f 
d
e
l(
13
q
1
4
.3
)+
 c
e
lls
 
P
e
rc
e
n
ta
ge
 o
f 
b
ia
lle
lic
 d
e
l(
1
3
q
1
4
.3
)+
 c
e
lls
 
P
e
rc
e
n
ta
ge
 o
f 
d
e
l(
13
q
1
4)
+
 c
e
lls
 
P
e
rc
e
n
ta
ge
 o
f 
tr
is
o
m
y 
12
+
 c
e
lls
 
P
e
rc
e
n
ta
ge
 o
f 
t(
1
4
q
3
2
)+
 c
e
lls
 
P
e
rc
e
n
ta
ge
 o
f 
d
e
l(
11
q
2
2
.3
)+
 c
e
lls
 
P
e
rc
e
n
ta
ge
 o
f 
d
e
l(
11
q
2
3
.3
)+
 c
e
lls
 
P
e
rc
e
n
ta
ge
 o
f 
d
e
l(
17
p
1
3
.1
)+
 c
e
lls
 
A
b
so
lu
te
 n
u
m
b
er
 o
f 
cl
o
n
al
 B
 c
e
lls
/µ
L 
IG
H
V
 g
e
n
e
 r
ep
e
rt
o
ir
e
 
IG
H
V
 m
u
ta
ti
o
n
al
 s
ta
tu
s*
 
B
in
e
t 
St
ag
e
**
 
2 112_CLL_V3-30_M_del13q_A.xlsx 53 0 0 0 0 0 0 0 13524 3-30 <98% A 
2 113_CLL_V3-30_UM_2del13q_del11q_A.xlsx 60 0 60 0 0 98 0 0 32063 3-30 >98% A 
2 114_CLL_V3-30_M_del13q_A.xlsx 88 0 0 0 0 0 0 0 33146 3-30 <98% A 
2 105_CLL_V1-3_UM_2del13q_t14q_del11q_A.xlsx 73 0 58 0 86 0 21 0 11419 1-3 >98% A 
2 123_CLL_V3-48_UM_2del13q_2del11q_A.xlsx 19 0 55 0 0 51 64 0 369289 3-48 >98% A 
2 45_CLL_V3-21_M_del13q_B.xlsx 0 0 61 0 0 0 0 0 5314 3-21 <98% B 
2 46multi_CLL_V3-21_M_del13q_C.xlsx 30 0 0 0 0 0 0 0 15309 3-21 <98% C 
2 97_CLL_V1-69_UM_del13q_del11q_B.xlsx 25 0 0 0 0 95 0 0 17445 1-69 >98% B 
2 125_CLL_V1-69_UM_2del13q_del17p_C.xlsx 91 0 93 0 0 0 0 44 23134 1-69 >98% C 
2 126_CLL_V1-69_M_del13q_C.xlsx 40 0 0 0 0 0 0 0 45737 1-69 <98% C 
2 110_CLL_V3-7_M_2del13q_B.xlsx 81 0 81 0 0 0 0 0 237817 3-7 <98% B 
2 120_CLL_V3-48_M_del13q_t14q_C.xlsx 64 0 0 0 19 0 0 0 16670 3-48 <98% C 
2 121_CLL_V3-48_M_2del13q_C.xlsx 77 0 66 0 0 0 0 0 26880 3-48 <98% C 
2 122multi_CLL_V3-48_M_2del13q_C.xlsx 87 0 95 0 0 0 0 0 27200 3-48 <98% C 
2 106_CLL_V4-39_M_2del13q_del11q_C.xlsx 51 0 47 0 0 68 0 0 190555 4-39 <98% C 
3 2_ MBLhigh_V3-23_M_tris12.xlsx 0 0 0 91 0 0 0 0 1358 3-23 <98% 
 
3 3multi_ MBLhigh_V3-23_UM_tris12.xlsx 0 0 0 87 0 0 0 0 3360 3-23 >98% 
 
3 4multi_ MBLhigh_V3-23_M_tris12_del11q.xlsx 0 0 0 95 0 93 0 0 3443 3-23 <98% 
 
3 5_ MBLhigh_V3-23_M_tris12_del11q.xlsx 0 0 0 93 0 20 0 0 4851 3-23 <98% 
 
3 19_ MBLhigh_V3-48_UM_tris12.xlsx 0 0 0 84 0 0 0 0 1661 3-48 >98% 
 
3 11multi_ MBLhigh_V4-39_UM_del13q.xlsx 0 0 0 93 0 0 0 0 700 4-39 >98% 
 
3 7multi_ MBLhigh_V5-51_UM_tris12_t14q.xlsx 0 0 0 76 52 0 0 0 1900 5-51 >98% 
 
3 8multi_ MBLhigh_V5-51_M_tris12.xlsx 0 0 0 93 0 0 0 0 2659 5-51 <98% 
 
3 10_CLL_V3-21_UM_tris12_A.xlsx 0 0 0 75 0 0 0 0 30739 3-21 >98% A 
3 17multi_CLL_V4-34_M_tris12_A.xlsx 0 0 0 75 0 0 0 0 5482 4-34 <98% A 
3 21_CLL_V1-69_UM_tris12_A.xlsx 0 0 0 87 0 0 0 0 14470 1-69 >98% A 
3 99_CLL_V1-69_UM_tris12_del11q_A.xlsx 0 0 0 33 0 24 0 0 30093 1-69 >98% A 
3 100_CLL_V1-69_UM_t14q_A.xlsx 0 0 0 0 91 0 0 0 75170 1-69 >98% A 
3 22_CLL_V1-69_UM_tris12_t14q_B.xlsx 0 0 0 73 82 0 0 0 46393 1-69 >98% B 
3 23_CLL_V1-69_UM_tris12_t14q_B.xlsx 0 0 0 97 30 0 0 0 119647 1-69 >98% B 
3 6_SLL_V3-11_UM_tris12_B.xlsx 0 0 0 84 0 0 0 0 2531 3-11 >98% B 
3 18_CLL_V4-34_UM_tris_t14q_C.xlsx 0 0 0 73 82 0 0 0 19568 4-34 >98% C 
3 13_CLL_V3-7_M_tris12_C.xlsx 0 0 0 78 0 0 0 0 9093 3-7 <98% C 
3 14_CLL_V3-7_M_tris12_C.xlsx 0 0 0 85 0 0 0 0 15257 3-7 <98% C 
3 15multi_CLL_V3-30_UM_tris12_del11q_B.xlsx 0 0 0 93 0 91 0 0 5412 3-30 >98% B 
3 20_CLL_V3-48_M_tris12_t14q_B.xlsx 0 0 0 82 91 0 0 0 10807 3-48 <98% B 
3 12_CLL_V4-39_UM_tris12_del17p_B.xlsx 0 0 0 80 0 0 0 35 22028 4-39 >98% B 
3 9_CLL_V5-51_UM_tris12_B.xlsx 0 0 0 76 0 0 0 0 175686 5-51 >98% B 
*The unmutated status of the IGHV genes (U) was defined as those with >98% identity with the most similar germline gene, 
while mutated one (M) was those in which CLL-like B cell clones displayed IGHV genes with <98% identity with the most 
similar germline gene. **only applicable to CLL cases. 
 
 
  
 
Supplemental Table 2.  IGHV sequences of CLL-like MBL and CLL B-cell clones analyzed by the IMGT-V-QUEST tool.  
B-cell clon from #case number 
V-GENE and 
allele 
Functionality 
% Identity  
V-REGION 
J-GENE and 
allele 
D-GENE and 
allele 
D-REGION 
reading 
frame 
CDR3 
length 
AA JUNCTION 
MBLlow from (monoclonal) #1 IGHV4-34*01 Productive 91.84% IGHJ4*02 IGHD2-15*01 2 20 CARGPPYCSGDSCSWGGILDYW 
MBLlow from (monoclonal) #2 IGHV3-23*01 Productive 100.00% IGHJ6*02 IGHD3-10*01 1 11 CANRGETRGMDVW 
MBLlow from (monoclonal) #3 IGHV3-7*01 Productive 96.39% IGHJ4*02 IGHD6-19*01 1 12 CVRDKYDSGSMDYW 
MBLlow from (monoclonal) #4 IGHV3-21*01 Productive 92.34% IGHJ6*02 IGHD6-25*01 1 20 CARHHPVRESSATGHYYGMDVW 
MBLlow from (monoclonal) #5 IGHV3-23*01 Productive 98.42% IGHJ6*02 IGHD5-12*01 1 11 CANRGETRGMDVW 
MBLlow from (monoclonal) #6 IGHV3-48*03 Productive 90.36% IGHJ3*02 IGHD5-12*01 3 12 CVRDGFHYYGFDIW 
MBLlow from (monoclonal) #7 IGHV3-23*01 Productive 95.98% IGHJ4*02 IGHD2-15*01 2 15 CAKHGSYSPDPYYFDYW 
MBLlow from (monoclonal) #8 IGHV1-8*01 Productive 97.86% IGHJ4*02 IGHD2-21*02 2 13 CARGLGSASQSRDSW 
MBLlow from (monoclonal) #9 IGHV4-34*01 Productive 96.57% IGHJ4*02 IGHD4-11*01 2 13 CARLGGDDSDYGFYW 
MBLlow from (monoclonal) #10 IGHV3-7*03 Productive 85.54% IGHJ4*03 IGHD3-3*01 2 15 CVRENEFWSGGWGLDGW 
MBLlow from (monoclonal) #11 IGHV3-23*01 Productive 99.6% IGHJ6*02 IGHD5-12*01 1 11 CANRGETRGMDVW 
MBLlow from (monoclonal) #12 IGHV3-30*02 Productive 88.54% IGHJ3*02 IGHD1-26*01 3 20 CANLGESRGGGSYPAPDTFDIW 
MBLlow from (monoclonal) #13 IGHV1-2*02 Productive 100.00% IGHJ4*02 IGHD6-19*01 3 13 CARLQWLGISHFDYW 
MBLlow from (multiclonal) #14A IGHV3-23*01 Productive 99.6% IGHJ6*02 IGHD5-12*01 1 11 CANRGETRGMDVW 
MBLlow from (multiclonal) #14B IGHV3-48*03 Productive 90.76% IGHJ3*02 IGHD5-12*01 3 12 CVRDGFHYYGFDIW 
MBLlow from (multiclonal) #15B IGHV3-23*01 Productive 97.99% IGHJ6*02 IGHD6-19*01 1 22 CANAPTPYSSGWNPWDYYYGMDVW 
MBLlow from (multiclonal) #16B IGHV3-11*03 Productive 96.79% IGHJ4*02 IGHD2-15*01 2 17 CAREEYCDGGTCYRLFDYW 
MBLlow from (multiclonal) #17A IGHV3-74*01 Productive 90.32% IGHJ4*02 IGHD3-10*01 2 14 CARDLDGSGSGVFDWW 
MBLlow from (multiclonal) #17B IGHV4-59*03 Productive 91.8% IGHJ6*01 IGHD3-10*01 2 15 CARGWRSTDSYYGMDVW 
MBLlow from (multiclonal) #18B IGHV5-a*01 Productive 100.00% IGHJ6*03 IGHD6-19*01 2 21 CARHVAVAGTTWGPYYYYYMDVW 
MBLlow from (multiclonal) #19B IGHV3-23*01 Productive 100.00% IGHJ4*02 IGHD2-2*01 2 15 CAKDHGEQFIGGCFDYW 
MBLlow from (multiclonal) #20B IGHV1-69*01 Productive 100.00% IGHJ3*02 IGHD3-3*01 2 22 CARDNPKYYDFWSGYYAPPAFDIW 
MBLlow from (multiclonal) #21C IGHV1-69*13 Productive 94.84% IGHJ4*02 IGHD4-11*01 2 15 CAREGKSRDNSNPFDYW 
MBLlow from (multiclonal) #22B IGHV3-21*04 Productive 94.98% IGHJ6*02 IGHD2-15*01 3 9 CARDANGMDVW 
MBLlow from (multiclonal) #23B IGHV4-34*01 Productive 96.68% IGHJ4*02 IGHD7-27*01 1 6 CAHLSGYW 
MBLlow from (multiclonal) #23C IGHV3-11*04 Productive 97.57% IGHJ6*03 IGHD2-21*01 2 18 CARKTCASITNYYYYYMDVW 
MBLlow from (multiclonal) #24B IGHV3-21*01 Productive 99.6% IGHJ4*02 IGHD6-13*01 2 11 CARVGAATGMDYW 
MBLhigh from (monoclonal) #25 IGHV3-23*01 Productive 94.76% IGHJ3*02 IGHD1-7*01 3 18 CAKDLPSTYNWNSGGAFDIW 
MBLhigh from (monoclonal) #26 IGHV3-23*01 Productive 90.36% IGHJ4*02 IGHD5-12*01 3 16 CTKDPRDTGYGGDAFDYW 
MBLhigh from (monoclonal) #27 IGHV3-23*01 Productive 99.58% IGHJ6*02 IGHD3-3*01 2 22 CAKDNKYYDFWSGYYPVGTGMDVW 
MBLhigh from (monoclonal) #28 IGHV3-53*01 Productive 92.31% IGHJ3*02 IGHD3-10*01 3 16 CARGPPQSRPVGDTFEIW 
1
6
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(Supplemental Table 2, continued)        
B-cell clon from #case number 
V-GENE and 
allele 
Functionality 
% Identity  
V-REGION 
J-GENE and 
allele 
D-GENE and 
allele 
D-REGION 
reading 
frame 
CDR3 
length 
AA JUNCTION 
MBLhigh from (monoclonal) #29 IGHV2-26*01 Productive 91.64% IGHJ4*03 IGHD5-18*01 3 15 CTRTRGYPYGDRYFDSW 
MBLhigh from (monoclonal) #30 IGHV1-2*02 Productive 94.44% IGHJ3*02 IGHD4-17*01 2 13 CARGLNTDYGAFDIW 
MBLhigh from (monoclonal) #31 IGHV1-2*02 Productive 91.88% IGHJ3*02 IGHD2-21*02 3 18 CARDRSVIVVTYILDAFDMW 
MBLhigh from (monoclonal) #32 IGHV3-23*01 Productive 91.97% IGHJ5*01 IGHD6-13*01 1 8 CSKGGWGDSW 
MBLhigh from (monoclonal) #33 IGHV3-74*01 Productive 94.51% IGHJ5*02 IGHD2-8*02 3 9 CARQLDMYSLW 
MBLhigh from (monoclonal) #34 IGHV4-34*01 Productive 92.68% IGHJ6*02 IGHD3-16*01 2 20 CVRGYPSDYTERRYYYYGLDVW 
MBLhigh from (monoclonal) #35 IGHV3-30*04 Productive 90.76% IGHJ3*02 IGHD2-2*01 2 18 CTRPHCSMSSCSWNDAFAIW 
MBLhigh from (monoclonal) #36 IGHV3-23*01 Productive 91.94% IGHJ3*02 IGHD3-22*01 2 14 CAKFYDDIQPNAFDIW 
MBLhigh from (monoclonal) #37 IGHV1-2*02 Productive 91.7% IGHJ4*02 IGHD5-18*01 3 15 CARDLEMRYSQGSFDSW 
MBLhigh from (monoclonal) #38 IGHV3-11*01 Productive 99.2% IGHJ6*02 IGHD3-3*01 2 23 CARDRRDDFWSGYRIYYYYYGMDVW 
MBLhigh from (monoclonal) #39 IGHV3-21*01 Productive 97.88% IGHJ6*02 IGHD1-26*01 3 9 CARDANGMDVW 
MBLhigh from (monoclonal) #40 IGHV3-7*03 Productive 97.19% IGHJ4*02 IGHD6-19*01 1 9 CARGGWYGDYW 
MBLhigh from (monoclonal) #41 IGHV4-39*01 Productive 100.00% IGHJ6*02 IGHD2-2*01 2 22 CARHRLGYCSSTSCYYYYYGMDVW 
MBLhigh from (monoclonal) #42 IGHV3-15*01 Productive 91.39% IGHJ4*02 IGHD2-8*01 3 12 CTTDSMVYVDMDYW 
MBLhigh from (monoclonal) #43 IGHV3-48*02 Productive 100.00% IGHJ6*02 IGHD2-2*01 3 23 CARDNTANDIVVVPADYYYYGMDVW 
MBLhigh from (monoclonal) #44 IGHV3-23*01 Productive 90.76% IGHJ3*02 IGHD4-17*01 3 17 CAKDRTLATVIQKDTFDIW 
MBLhigh from (monoclonal) #45 IGHV5-51*01 Productive 100.00% IGHJ6*02 IGHD3-3*01 2 19 CARRDFRGDFWSGYYYGMDVW 
MBLhigh from (monoclonal) #46 IGHV3-23*01 Productive 95.32% IGHJ6*02 IGHD2-2*01 2 14 CAFHCCRISCYGVDFW 
MBLhigh from (monoclonal) #47 IGHV4-34*01 Productive 93.67% IGHJ4*01 IGHD1-1*01 3 14 CARVIGDKGGYYLTYW 
MBLhigh from (monoclonal) #48 IGHV3-48*01 Productive 99.59% IGHJ6*02 IGHD3-3*01 2 20 CARSPGYDFWSGYPDYYGMDVW 
MBLhigh from (monoclonal) #49 IGHV1-2*02 Productive 96.02% IGHJ4*02 IGHD3-22*01 2 20 CARDLARYDSGGSYKRKMFDYW 
MBLhigh from (multiclonal) #50B IGHV3-11*03 Productive 95.32% IGHJ4*02 IGHD6-19*01 1 10 CAKVRSHYFDYW 
MBLhigh from (multiclonal) #51B IGHV3-21*04 Productive 96.65% IGHJ6*02 IGHD2-15*01 3 9 CARDANGMDVW 
MBLhigh from (multiclonal) #52B IGHV3-33*01 Productive 99.6% IGHJ4*02 IGHD3-9*01 1 21 CARDPRVLRYFDWLLSPPPFDYW 
MBLhigh from (multiclonal) #53A IGHV3-15*01 Productive 89.03% IGHJ4*02 IGHD2-21*01 2 12 CTTESGWYSASDHW 
MBLhigh from (multiclonal) #53B IGHV3-30*03 Productive 94.27% IGHJ4*02 IGHD2-15*01 2 18 CAKDTWGHCSGGFCSHFDSW 
MBLhigh from (multiclonal) #54B IGHV3-48*03 Productive 90.95% IGHJ3*02 IGHD3-3*01 2 20 CVRDDRSCSSNNCHALRSFDMW 
MBLhigh from (multiclonal) #55B IGHV3-53*01 Productive 92.55% IGHJ6*02 IGHD2-8*01 1 19 CATHPTNIYTRWPYVSDMDVW 
MBLhigh from (multiclonal) #56A IGHV3-23*01 Productive 100.00% IGHJ6*02 IGHD3-3*01 1 11 CAKDWESWGMDVW 
MBLhigh from (multiclonal) #57A IGHV4-39*01 Productive 100.00% IGHJ5*02 IGHD6-13*01 1 19 CASVQGYSSSWYGGDNWFDPW 
MBLhigh from (multiclonal) #57B IGHV3-23*01 Productive 100.00% IGHJ6*02 IGHD3-10*01 1 11 CANRGETRGMDVW 
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(Supplemental Table 2, continued)        
B-cell clon from #case number 
V-GENE and 
allele 
Functionality 
% Identity  
V-REGION 
J-GENE and 
allele 
D-GENE and 
allele 
D-REGION 
reading 
frame 
CDR3 
length 
AA JUNCTION 
MBLhigh from (multiclonal) #58A IGHV4-39*01 Productive 100.00% IGHJ5*02 IGHD3-3*01 2 20 CARHTSLYDFWSGYYRGWFDPW 
MBLhigh from (multiclonal) #58B IGHV1-69*01 Productive 100.00% IGHJ4*02 IGHD5-18*01 2 17 CAREAGSIQLWPPGFFDYW 
MBLhigh from (multiclonal) #59A IGHV3-7*01 Productive 93.57% IGHJ3*02 IGHD5-12*01 2 9 CARGRYVYDIW 
MBLhigh from (multiclonal) #60A IGHV4-34*01 Productive 96.48% IGHJ4*02 IGHD5-24*01 1 19 CARAEGQATLLSVWEYYFDSW 
MBLhigh from (multiclonal) #60B IGHV3-33*01 Productive 96.67% IGHJ2*01 IGHD6-19*01 1 17 CARDILITGGRGDWYFDLW 
MBLhigh from (multiclonal) #61B IGHV3-72*01 Productive 95.92% IGHJ5*02 IGHD2-2*01 2 13 CVRSSTGWTDWFDPW 
MBLhigh from (multiclonal) #62B IGHV4-34*01 Productive 96.81% IGHJ6*03 IGHD3-3*01 2 16 CARREDDNFWSGFYMDVW 
MBLhigh from (multiclonal) #63B IGHV3-23*01 Productive 95.16% IGHJ4*02 IGHD2-15*01 2 18 CAKLSTPCGGGSCYSSLDYW 
MBLhigh from (multiclonal) #64B IGHV4-34*01 Productive 95.12% IGHJ4*02 IGHD6-19*01 1 13 CARRDSSGWYYFDYW 
MBLhigh from (multiclonal) #65A IGHV5-51*01 Productive 92.2% IGHJ4*01 IGHD5-18*01 3 14 CGRRRTGYNDGEIDYW 
MBLhigh from (multiclonal) #65B IGHV4-30-4*01 Productive 97.81% IGHJ4*01 IGHD2-2*01 2 16 CARHPSCSRTSCYFFDYW 
MBLhigh from (multiclonal) #66A IGHV5-51*01 Productive 100.00% IGHJ4*02 IGHD3-3*01 2 21 CARHGTYYDFWSGYYLPGFFDYW 
MBLhigh from (multiclonal) #66B IGHV1-69*01 Productive 100.00% IGHJ6*02 IGHD6-13*01 1 26 CARQGAGSSWYGIVKGWFEYYYYGMDVW 
MBLhigh from (multiclonal) #66C IGHV3-33*01 Productive 98.81% IGHJ3*02 IGHD3-3*01 1 22 CARGNGGALRFLEWLLYHDAFDIW 
MBLhigh from (multiclonal) #67A IGHV1-3*01 Productive 97.96% IGHJ6*02 IGHD3-3*01 2 23 CARADGGYDFWSGYSTVNYYGMDVW 
MBLhigh from (multiclonal) #67B IGHV3-9*01 Productive 93.57% IGHJ4*02 IGHD1-26*01 3 14 CARVESGSYFWPSDYW 
CLL from (monoclonal) #68 IGHV3-23*01 Productive 93.57% IGHJ4*02 IGHD4-23*01 1 12 CAKGRQLWSYLDYW 
CLL from (monoclonal) #69 IGHV1-2*02 Productive 99.59% IGHJ3*02 IGHD5-12*01 3 12 CARDGDYFDAFDIW 
CLL from (monoclonal) #70 IGHV3-11*01 Productive 98.8% IGHJ4*02 IGHD3-3*01 2 22 CARDPRYYDFWSGYYLPDDKFDYW 
CLL from (monoclonal) #71 IGHV3-7*01 Productive 93.98% IGHJ4*02 - - 8 CASGSHVDYY (TRP 118 not identified)  
CLL from (monoclonal) #72 IGHV4-b*02 Productive 100.00% IGHJ4*02 IGHD5-18*01 2 13 CARSWIQLWSEFDYW 
CLL from (monoclonal) #73 IGHV4-4*02 Productive 91.57% IGHJ6*02 IGHD5-12*01 1 25 CARGSRNVDIVATITFIGFYYYGMDVW 
CLL from (monoclonal) #74 IGHV1-69*06 Productive 97.96% IGHJ6*03 IGHD3-3*01 2 24 CARAEQYYDFWSGHKGVDYYYYMDVW 
CLL from (monoclonal) #75 IGHV3-11*01 Productive 97.91% IGHJ4*02 IGHD3-10*01 2 16 CARGPDPYYYGSGTPSYW 
CLL from (monoclonal) #76 IGHV3-21*01 Productive 97.21% IGHJ5*02 IGHD3-9*01 1 22 CARDRRNGNFDWLEDPLYNWFDPW 
CLL from (monoclonal) #77 IGHV3-9*01 Productive 90.91% IGHJ6*02 IGHD4-23*01 1 16 CAKDRSNTWPLWGGMDVW 
CLL from (monoclonal) #78* IGHV1-2*02 Productive 99.57% IGHJ4*02 IGHD6-19*01 3 13 CARAQWLVLENFDYW 
CLL from (monoclonal) #79 IGHV4-34*01 Productive 85.43% IGHJ3*02 IGHD5-12*01 2 17 CARREEDWKRSGRDSFDIW 
CLL from (monoclonal) #80 IGHV1-69*01 Productive 95.1% IGHJ4*02 IGHD3-3*01 2 13 CAKGPYYDFWSGDYW 
CLL from (monoclonal) #81 IGHV4-39*01 Productive 99.21% IGHJ4*02 IGHD3-16*02 2 19 CARHTYYDYVWGSYRTPFDYW 
CLL from (monoclonal) #82 IGHV3-21*01 Productive 100.00% IGHJ4*02 IGHD2-2*02 2 21 CAREGGLGYCSSTSCYTTLFDYW 
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(Supplemental Table 2, continued)        
B-cell clon from #case number 
V-GENE and 
allele 
Functionality 
% Identity  
V-REGION 
J-GENE and 
allele 
D-GENE and 
allele 
D-REGION 
reading 
frame 
CDR3 
length 
AA JUNCTION 
CLL from (monoclonal) #83 IGHV3-72*01 Productive 89.41% IGHJ4*02 IGHD6-13*01 3 15 CVRSSMGAEQTIACDYW 
CLL from (monoclonal) #84 IGHV3-30*01 Productive 95.2% IGHJ4*02 IGHD6-19*01 1 15 CARDDYSSGVGTRLSYW 
CLL from (monoclonal) #85 IGHV4-4*03 Productive 92.77% IGHJ6*02 IGHD2-2*01 2 21 CARAPYCGSNTCYSYYYYGMDVW 
CLL from (monoclonal) #86 IGHV4-34*01 Productive 89.72% IGHJ6*02 IGHD2-15*01 2 24 CAGRFYCSGDTCHLPLYHYYYGLDVW 
CLL from (monoclonal) #87 IGHV3-23*01 Productive 94.78% IGHJ6*04 IGHD3-3*01 2 23 CARDLTHHNFWSAYYETSYCGMDVW 
CLL from (monoclonal) #88 IGHV3-48*02 Productive 95.58% IGHJ6*03 IGHD5-24*01 3 18 CARQGEDYNNRGYYCYMDVW 
CLL from (monoclonal) #89 IGHV1-2*02 Productive 98.29% IGHJ6*02 IGHD3-10*01 2 17 CARDPGGGDYYYYYGMDVW 
CLL from (monoclonal) #90 IGHV4-39*01 Productive 92.97% IGHJ4*02 IGHD6-13*01 3 10 CARHEQQLADYW 
CLL from (monoclonal) #91 IGHV4-34*01 Productive 95.98% IGHJ6*02 IGHD4-23*01 3 20 CARGYGSTGETRRYYYYGMDVW 
CLL from (monoclonal) #92 IGHV4-59*01 Productive 100.00% IGHJ4*02 IGHD3-3*01 2 19 CARVVHYLDFWSGYTYYFDYW 
CLL from (monoclonal) #93 IGHV3-64*01 Productive 95.58% IGHJ6*02 IGHD6-19*01 2 9 CAVDRTGMDVW 
CLL from (monoclonal) #94 IGHV6-1*01 Productive 92.19% IGHJ4*02 IGHD6-19*01 1 18 CARSPSRYSNGWYERDFDCW 
CLL from (monoclonal) #95 IGHV1-69*01 Productive 100.00% IGHJ6*02 IGHD6-19*01 2 21 CAREVVYGVAGTYYYYYYGMDVW 
CLL from (monoclonal) #96 IGHV4-34*08 Productive 85.96% IGHJ4*02 IGHD3-22*01 2 13 CARGFHWGGYYLDFW 
CLL from (monoclonal) #97 IGHV3-23*01 Productive 94.4% IGHJ4*02 IGHD2-15*01 2 18 CAKLSTPCGGGSCYSSLDYW 
CLL from (monoclonal) #98 IGHV1-8*01 Productive 87.5% IGHJ6*02 IGHD3-3*01 2 21 CARGPSYYDFWSGPFDNYGMDVW 
CLL from (monoclonal) #99* IGHV1-2*02 Productive 100.00% IGHJ4*02 IGHD6-19*01 3 13 CARAQWLVLENFDYW 
CLL from (monoclonal) #100 IGHV3-7*01 Productive 94.38% IGHJ3*01 IGHD3-16*01 1 16 CASALRYLPYADTAFDLW 
CLL from (monoclonal) #101 IGHV3-7*03 Productive 85.77% IGHJ4*03 IGHD3-3*01 2 15 CVRENEFWSGGWGLDGW 
CLL from (monoclonal) #102 IGHV1-69*13 Productive 99.59% IGHJ6*02 IGHD3-3*01 3 22 CATTTITIFGVVTVYYYYYGMDVW 
CLL from (monoclonal) #103 IGHV4-34*01 Productive 100.00% IGHJ4*02 IGHD3-10*01 2 20 CARGLIGAYGSGSYYPFPFDYW 
CLL from (monoclonal) #104 IGHV1-69*01 Productive 100.00% IGHJ6*02 IGHD3-3*01 2 23 CARADGGYDFWSGYSTVNYYGMDVW 
CLL from (monoclonal) #105 IGHV3-48*03 Productive 91.06% IGHJ3*02 IGHD5-12*01 3 12 CVRDGFHYYGFDIW 
CLL from (monoclonal) #106 IGHV3-30*03 Productive 97.93% IGHJ6*03 IGHD3-3*01 2 30 CAKDQEQGPRPRYYDFWSAPPPWYYYYYMDVW 
CLL from (monoclonal) #107 IGHV1-69*01 Productive 98.29% IGHJ5*02 IGHD3-3*01 2 15 CATDKKYYDFWSGYYLW 
CLL from (monoclonal) #108 IGHV4-59*02 Productive 91.5% IGHJ4*02 IGHD1-14*01 3 13 CARHLRNDKYYLDFW 
CLL from (monoclonal) #109 IGHV3-48*03 Productive 100.00% IGHJ6*02 IGHD3-3*01 2 21 CARDYDFWSGYYSYYYYYGMDVW 
CLL from (monoclonal) #110 IGHV5-51*01 Productive 99.6% IGHJ6*03 IGHD2-2*01 2 23 CARYCSSTSCMTGTMGYYYYYMDVW 
CLL from (monoclonal) #111 IGHV3-48*02 Productive 92.34% IGHJ4*02 IGHD6-13*01 1 14 CARDLGGNSWPTFDFW 
CLL from (monoclonal) #112 IGHV3-30*03 Productive 89.56% IGHJ6*02 IGHD6-19*01 2 19 CAKIGMAGDFLEFRYYGMDVW 
CLL from (monoclonal) #113 IGHV1-3*01 Productive 99.18% IGHJ6*02 IGHD3-22*01 2 25 CARDLTYYYDSSGYYYFNYYYYGMDVW 
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(Supplemental Table 2, continued)        
B-cell clon from #case number 
V-GENE and 
allele 
Functionality 
% Identity  
V-REGION 
J-GENE and 
allele 
D-GENE and 
allele 
D-REGION 
reading 
frame 
CDR3 
length 
AA JUNCTION 
CLL from (monoclonal) #114 IGHV3-7*03 Productive 85.54% IGHJ4*03 IGHD3-3*01 2 15 CVRENEFWSGGWGLDGW 
CLL from (monoclonal) #115 IGHV4-59*01 Productive 91.94% IGHJ4*02 IGHD6-19*01 1 14 CARGPDISGWNGLDYW 
CLL from (monoclonal) #116 IGHV4-34*01 Productive 91.46% IGHJ5*02 IGHD6-13*01 3 13 CATNSRESQGWFDPW 
CLL from (monoclonal) #117 IGHV3-15*01 Productive 91.32% IGHJ6*02 IGHD2-15*01 2 23 CVTGPGYCSGGGCSSRGYYYGMDVW 
CLL from (monoclonal) #118 IGHV3-30*04 Productive 100.00% IGHJ6*02 IGHD3-3*01 2 22 CARDLKTAYYDFWSGYYGDGMDVW 
CLL from (monoclonal) #119 IGHV3-9*01 Productive 98.8% IGHJ6*02 IGHD3-3*01 2 26 CAKDKYYDFWSGYSHLGVLYYYYGMDVW 
CLL from (monoclonal) #120 IGHV1-3*01 Productive 97.94% IGHJ6*02 IGHD3-3*01 2 23 CARADGGYDFWSGYSTVNYYGMDVW 
CLL from (monoclonal) #121 IGHV1-18*01 Productive 100.00% IGHJ6*02 IGHD2-15*01 3 9 CARDANGMDVW 
CLL from (monoclonal) #122 IGHV1-69*01 Productive 100.00% IGHJ3*02 IGHD3-16*02 2 21 CARGGNYDYIWGSYRPNDAFDIW 
CLL from (monoclonal) #123 IGHV1-69*02 Productive 100.00% IGHJ6*03 IGHD2-15*01 3 22 CARSQAHIVVVVAATYYYYYMDVW 
CLL from (monoclonal) #124 IGHV1-18*01 Productive 100.00% IGHJ4*02 IGHD7-27*01 3 13 CARKNWGPDYYFDYW 
CLL from (monoclonal) #125 IGHV4-39*01 Productive 100.00% IGHJ6*01 IGHD2-2*01 2 22 CARHRLGYCSSTSCYYYYYGMDVW 
CLL from (monoclonal) #126 IGHV1-69*01 Productive 98.76% IGHJ1*01 IGHD3-22*01 2 22 CARGSSTYYYDSSVYGVAEYFQHW 
CLL from (monoclonal) #127 IGHV3-30*03 Productive 98.39% IGHJ4*02 IGHD3-22*01 2 21 CARGPNVSHTYYYDNSGSHFDYW 
CLL from (monoclonal) #128 IGHV3-74*01 Productive 92.98% IGHJ4*02 IGHD2-2*01 3 15 CARVDIEVDGGGHFDNW 
CLL from (monoclonal) #129 IGHV1-2*02 Productive 96.97% IGHJ4*02 IGHD2-8*01 1 15 CGRDVELRYWQGYFDLW 
CLL from (monoclonal) #130 IGHV1-18*01 Productive 100.00% IGHJ6*02 IGHD6-13*01 1 19 CARDLSLSSNWFTPPYGMDVW 
CLL from (monoclonal) #131 IGHV1-2*02 Productive 100.00% IGHJ5*01 IGHD3-3*01 2 32 CARAPRGDYDTEAGGAYSYGLEVWRLRRNRFDSW 
CLL from (monoclonal) #132 IGHV4-39*07 Productive 100.00% IGHJ6*02 IGHD2-2*01 2 22 CARDRLGYCSSTSCYLYYYGMDVW 
CLL from (monoclonal) #133 IGHV4-b*01 Productive 94.14% IGHJ1*01 IGHD2-15*01 2 20 CARLPHCTASRCYGGGRYVDQW 
CLL from (monoclonal) #134 IGHV1-18*01 Productive 99.57% IGHJ6*02 IGHD3-9*01 2 20 CARGAYYDILTGYRYYYGMDVW 
CLL from (monoclonal) #135 IGHV4-34*01 Productive 95.49% IGHJ4*02 IGHD2-15*01 2 11 CARGSAGSRLDYW 
CLL from (monoclonal) #136 IGHV3-21*01 Productive 94.63% IGHJ6*02 - - 9 RTKDANGMDVW (2nd-CYS 104 not identified) 
CLL from (monoclonal) #137 IGHV3-7*01 Productive 95.98% IGHJ4*02 IGHD2-2*01 2 16 CGSQCSTTSCPSSISEYW 
CLL from (monoclonal) #138 IGHV1-69*01 Productive 100.00% IGHJ6*03 IGHD7-27*01 3 21 CARDTGLMTNWGYYYYYYYMDVW 
CLL from (monoclonal) #139 IGHV3-7*03 Productive 92.59% IGHJ4*02 IGHD3-22*01 2 15 CARVSDETTGYGNFDYW 
CLL from (monoclonal) #140 IGHV4-b*01 Productive 99.59% IGHJ4*02 IGHD5-18*01 2 13 CARAWIQLWSDFDYW 
CLL from (monoclonal) #141 IGHV4-34*01 Productive 99.19% IGHJ6*02 IGHD2-2*01 3 21 CARADLLVVPAAIYYYYYGMDVW 
CLL from (monoclonal) #142 IGHV3-48*03 Productive 91.13% IGHJ6*02 IGHD6-19*01 1 8 CSRRGRLDIW 
CLL from (monoclonal) #143 IGHV3-30*03 Productive 96.37% IGHJ4*02 IGHD3-10*01 2 19 CANRGDTSGLGTCCQGIGDSW 
CLL from (monoclonal) #144 IGHV4-61*02 Productive 91.63% IGHJ5*02 IGHD5-12*01 3 14 CAKRYGDHGEGWFDPW 
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(Supplemental Table 2, continued)        
B-cell clon from #case number 
V-GENE and 
allele 
Functionality 
% Identity  
V-REGION 
J-GENE and 
allele 
D-GENE and 
allele 
D-REGION 
reading 
frame 
CDR3 
length 
AA JUNCTION 
CLL from (monoclonal) #145 IGHV3-30*01 Productive 93.15% IGHJ4*02 IGHD3-10*01 3 17 CASGSMIGGVILPPGFDYW 
CLL from (monoclonal) #146 IGHV3-53*01 Productive 100.00% IGHJ6*02 IGHD3-22*01 2 25 CAREGYYDSSGYSEAPHYYYYYGMDVW 
CLL from (monoclonal) #147 IGHV2-70*11 Productive 96.21% IGHJ4*02 IGHD1-20*01 3 14 CARMQHRYHWNDSDSW 
CLL from (monoclonal) #148 IGHV1-3*01 Productive 90.2% IGHJ5*01 IGHD3-9*01 1 19 CARGIRYSGWLLYGSDWYDSW 
CLL from (monoclonal) #149 IGHV3-23*01 Productive 99.58% IGHJ6*02 IGHD5-12*01 1 11 CANRGETRGMDVW 
CLL from (monoclonal) #150 IGHV4-39*01 Productive 100.00% IGHJ5*02 IGHD6-13*01 1 18 CATQTGYSSSWYAVNWFDPW 
CLL from (monoclonal) #151 IGHV1-24*01 Productive 100.00% IGHJ6*02 IGHD3-9*01 2 24 CATDGYDILTGYYKGPGAYYYGMDVW 
CLL from (monoclonal) #152 IGHV3-48*03 Productive 99.16% IGHJ3*02 IGHD5-12*01 3 12 CARDGFHYYGFDIW 
CLL from (monoclonal) #153 IGHV4-61*02 Productive 92.65% IGHJ4*02 IGHD7-27*01 3 12 CARDNWGFEGFDSW 
CLL from (monoclonal) #154 IGHV3-74*01 Productive 93.15% IGHJ3*01 IGHD4-23*01 3 14 CARGHKVVNPGSFDLW 
CLL from (multiclonal) #155A IGHV4-34*01 Productive 93.06% IGHJ4*02 IGHD3-3*01 3 11 CARPNVGAVFVFW 
CLL from (multiclonal) #156A IGHV4-34*01 Productive 96.69% IGHJ2*01 IGHD4-23*01 2 13 CARAGGYSDWYFDLW 
CLL from (multiclonal) #157A IGHV3-9*01 Productive 100.00% IGHJ3*02 IGHD3-3*01 2 19 CAKDRYYDFWSGYYTAAFDIW 
CLL from (multiclonal) #158A IGHV4-39*01 Productive 98.47% IGHJ6*02 IGHD3-3*01 1 18 CGILGEWLSFYFFFYGMDVW 
CLL from (multiclonal) #159A IGHV3-30-3*01 Productive 91.13% IGHJ4*02 IGHD5-12*01 3 16 CARGKGRNSGYDYLLHYW 
CLL from (multiclonal) #160A IGHV1-3*01 Productive 94.03% IGHJ5*02 IGHD5-18*01 1 19 CARDRVVIIPDTTTINWFDPW 
CLL from (multiclonal) #161A IGHV3-48*02 Productive 96.34% IGHJ4*02 IGHD4-17*01 2 12 CARSSGDDSLIDYW 
CLL from (multiclonal) #162A IGHV4-34*01 Productive 97.56% IGHJ6*02 IGHD3-10*01 2 17 CARGFDYYGSGSANGLDVW 
CLL from (multiclonal) #163A IGHV1-46*01 Productive 100.00% IGHJ4*01 IGHD3-3*01 2 21 CARAHYYDFWSGYVYPRLAFDYW 
CLL from (multiclonal) #164A IGHV3-53*01 Productive 100.00% IGHJ6*02 IGHD3-22*01 2 25 CAREGYYDSSGYSEAPHYYYYYGMDVW 
CLL from (multiclonal) #165A IGHV1-3*01 Productive 96.2% IGHJ3*01 IGHD1-26*01 3 17 CARGLRSGTFYGADAFDFW 
CLL from (multiclonal) #165B IGHV4-34*01 Productive 92.93% IGHJ3*02 IGHD2-15*01 3 26 TARGGLFVETEIAGVGYRSGTGTLFDSW 
(2nd-CYS 104 not identified) 
CLL from (multiclonal) #166A IGHV3-33*01 Productive 91.5% IGHJ6*02 IGHD3-10*01 2 18 CARDDNRDGSGNYKGGMDFW 
CLL from (multiclonal) #166B IGHV3-21*01 Productive 94.8% IGHJ4*02 IGHD4-23*01 2 13 CARDLDGGNSVFDYW 
CLL from (multiclonal) #167A IGHV3-52*01(P) Productive** 96.06% IGHJ3*02 IGHD2-21*02 2 19 CMTVLWANRGGDCPGDAFDIW 
CLL from (multiclonal) #168A IGHV4-34*01 Productive 98.78% IGHJ4*02 IGHD1-26*01 3 17 CARGPDRLYSGSYTRFDYW 
CLL from (multiclonal) #169A IGHV3-48*02 Productive 93.6% IGHJ4*02 IGHD3-10*01 1 12 CVRELWFGNGGDYW 
CLL from (multiclonal) #170A IGHV3-30*03 Productive 99.22% IGHJ6*02 IGHD3-9*01 1 25 CAKYGGVKLRYFDWLLYGDYYYGMDVW 
CLL from (multiclonal) #171A IGHV3-33*01 Productive 99.61% IGHJ5*02 IGHD1-26*01 2 12 CARGELLHNWFDPW 
CLL from (multiclonal) #171B IGHV3-23*01 Productive 99.18% IGHJ3*02 IGHD5-12*01 3 12 CAKDGFPYYGFDIW 
CLL from (multiclonal) #172A IGHV2-26*01 Productive 91.91% IGHJ5*02 IGHD3-3*01 2 22 CAGTNIPRQFDFWSGSSPNWFDPW 
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(Supplemental Table 2, continued)        
B-cell clon from #case number 
V-GENE and 
allele 
Functionality 
% Identity  
V-REGION 
J-GENE and 
allele 
D-GENE and 
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D-REGION 
reading 
frame 
CDR3 
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AA JUNCTION 
CLL from (multiclonal) #173A IGHV3-30*03 Productive 99.6% IGHJ6*02 IGHD3-9*01 1 25 CAKYGGVKLRYFDWLLYGDYYYGMDVW 
CLL from (multiclonal) #174A IGHV4-39*01 Productive 98.76% IGHJ3*01 IGHD1-14*01 3 17 CASHRNTQTYNNRAAFDVW 
CLL from (multiclonal) #175A IGHV5-51*01 Productive 100.00% IGHJ4*02 IGHD2-15*01 2 19 CARIPVAGYCRGGSCYPFDYW 
CLL from (multiclonal) #175B IGHV4-34*01 Productive 99.16% IGHJ4*02 IGHD3-10*01 2 14 CARTKTYGSGPPGKYW 
CLL from (multiclonal) #176A IGHV4-34*01 Productive 99.59% IGHJ4*02 IGHD3-10*01 2 15 CARGLYYYGSGVYFDYW 
*B-cell clones from #78 and #99 corresponded to the same untreated CLL patient at recruitment and after 1-year evaluation, respectively; **however the closest V is a pseudogene. 
Grey shadowed cells highlight those CDR3 of the IGHV genes identical or highly homologous. Scripts in cells indicate IMGT/JunctionAnalysis giving no results for that JUNCTION. 
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            SUPPORTING INFORMATION 
Supplemental Table 3. Diagnosis, differential immunophenotypic/IGHV features and cytogenetic 
alterations of the coexisting aberrant B-cell populations from multiclonal MBL, CLL and other B-
CLPD cases (n=41). 
Case 
ID 
Phenotype of population 1  
(% from WBC; compatible 
diagnosis) 
V(D)J rearrangement-MS† 
iFISH 
Phenotype of population 2  
(% from WBC; compatible 
diagnosis) 
V(D)J rearrangement-MS† 
iFISH* 
1 FSC/SSClo CD19++ CD5+ CD20lo 
(62.9%; CLL) 
V3-30(D3-9)J6-UM 
ND FSC/SSCint CD19+hi CD5- CD20+ 
(4.1%; Non-CLL-like MBLhigh MZL) 
V1-2(D5-5)J4-UM 
ND 
2¶ FSC/SSClolo FMC7lo CD23+ CD5+ 
CD43lo CD11clo (33%; CLL) 
V3-30(D3-9)J6-UM 
+12 (93%) 
del(11q22.3) (91%) 
FSC/SSClolo FMC7lo CD23+ CD5+ 
CD43+ CD11c+ (21%;  CLL-like 
MBLhigh) 
V3-23(D2-15)J4-M 
+12 (95%) 
del(11q22.3) (93%) 
3 FSC/SSClo CD19+ lo CD5+ CD79blo 
FMC7- (26.5%; CLL) 
V1-3(D1-26)J3-M 
ND FSC/SSCint CD19lo+ CD5het CD79b- 
FMC7+ (25.7%; CLL) 
V4-34(D2-15)J3-M 
ND 
4 FSC/SSCintlo CD20lo CD79bloCD5+ 
(20.6%; CLL) 
V3-53(D3-22)J6-UM 
+12 (49%) 
polysomy 
FSC/SSClolo CD20lo CD79bloCD5+ 
(0.6%; CLL-like MBLlow) 
V1-69(D3-3)J3-UM 
NDª 
5 FSC/SSCloloCD20lo CD5+ CD43+ 
CD23+ (44.2%; CLL) 
V4-34(D3-3)J4-M 
biallelic 
del(13q14.3) (99%)  
FSC/SSClohiCD20+ CD5- CD43- 
CD23- (1.4%; Non-CLL-like MBLlow 
MZL) 
V1-8(D3-3)J5-UM 
ND 
6 FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (33%; CLL) 
V4-34(D4-23)J2-M 
del(13q14.3) (96%) FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (10.6%; CLL-likeMBLhigh) 
V3-11(D6-19)J4-M 
del(13q14.3) (96%) 
7 FSC/SSCloCD19+ lo CD20lo CD5+ 
(34.6%; CLL) 
V4-39(D3-3)J6-UM 
ND  FSC/SSCloCD19+ lo CD20lo CD5+ 
(9.4%; CLL-likeMBLhigh) 
V3-33(D3-9)J4-M 
ND  
8 FSC/SSClo CD19lo CD43- CD5+ 
CD25+ IgM+ CD27+ CD11c+/het 
(50.2% CLL) 
V1-3(D5-5)J5-M 
ND FSC/SSClo CD19+ CD43+ CD5hi 
CD25hi IgMhi CD27hi CD11c+ (5% 
CLL-like MBLhigh) 
V3-53(D2-8)J6-M 
ND 
9 FSC/SSClo+ CD5+ CD20lo CD43- 
(12.6%; CLL-like MBLhigh) 
V3-23(D5-12)J6-UM 
+12 (87%) FSC/SSClo+ CD5+ CD20lo CD43+ 
(3%; CLL-like MBLhigh) 
V4-39(D6-13)J5-UM 
+12 (93%) 
10 FSC/SSClolo CD22lo CD23+ CD5+ 
(54.6%; CLL) 
Not found 
del(13q14.3) (96%) FSC/SSClolo CD22lo CD23+ CD5+ 
(4.1%; CLL-like MBLhigh) 
V3-72(D2-2)J5-M 
ND 
11¶ FSC/SSClo CD19+ lo CD5+ CD79blo 
FMC7- (0.6%; CLL-like MBLlow) 
V3-23(D5-12)J6-UM 
ND FSC/SSClo CD19+ + CD5+ CD79blo 
FMC7- (1.6%; CLL-like MBLlow) 
V3-48(D5-12)J6-M 
del(13q14.3)(19%) 
+12 (41%) 
12 FSC/SSCloCD19+lo CD5+ CD20lo 
(89%; CLL) 
V4-39(D1-7)J3-UM 
ND FSC/SSCloCD19+ lo CD5+ CD20lo 
(0.1%; CLL-like MBLlow) 
V3-21(D6-13)J4-UM 
ND 
13 FSC/SSCloCD19+ lo CD20lo FMC7- 
CD5+ (49.9%; CLL) 
V5-51(D2-15)J4-UM 
ND FSC/SSCloCD19+ lo CD20lo FMC7- 
CD5+ (40.8%; CLL) 
V4-34(D3-10)J4-UM 
ND 
14¶ FSC/SSClo+d CD20lo CD5+ CD22lo 
CD23+ FMC7- (84%; CLL) 
V4-34(D1-26)J4-UM 
biallelic 
del(13q14.3) 
(85%); 
 
FSC/SSCloloCD20lo/het CD5+ CD22lo 
CD23+ FMC7- (0.7%;  CLL-like 
MBLhigh) 
V4-34(D3-3)J6-M 
del(13q14.3) (83%) 
15¶ FSC/SSCloCD19lo+ CD5- (11%; 
CLL-like MBLhi) 
V3-23(D3-22)J6-UM 
ND FSC/SSCloCD19+ loCD5+ (1.1%; 
CLL-like MBLlow) 
V3-11(D2-15)J4-M 
NDª 
16¶ FSC/SSChi CD19loCD38++CD10+ 
cBcl2+ sIg- c+ 
(20.6%;  Non-CLL FL) 
V3-11(D1-1)J3-M 
t(14q32)(95%); 
t(14;18) (96%);  
+18q21 (95%)  
+8q24 (92%) 
FSC/SSClo CD19+CD38-CD10-+ 
(2.5%;  Non-CLL FL) 
V3-23(D5-12)J6-UM 
t(14;18) (90%);  
+8q21 (90%)  
+18q21 (87%) 
17 FSC/SSCloCD19+ + CD5+ CD20lo 
CD11c- (59.3%; CLL) 
V1-46(D3-3)J4-UM 
ND FSC/SSClo CD19+ Ig- CD5- CD20hi 
CD11chi (0.5%;  Non-CLL-like 
MBLlow MZL) 
V3-53(D1-26)J4-M 
ND 
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   SUPPORTING INFORMATION 
(Supplemental Table 3, continued) 
Case 
ID 
Phenotype of population 1  
(% from WBC; compatible 
diagnosis) 
V(D)J rearrangement-MS† 
iFISH 
Phenotype of population 2  
(% from WBC; compatible 
diagnosis) 
V(D)J rearrangement-MS† 
iFISH* 
18¶ FSC/SSCloCD19+ CD5+ lo (15.6%; 
CLL-like MBLhigh) 
V3-15(D3-3)J4-M 
ND FSC/SSCloCD19+ CD5+ lo (10.1%; 
CLL-like MBLhigh) 
V3-30(D5-12)J4-M 
+12 (19%);  
del(13q14.3) (32%) 
19¶ FSC/SSCloCD19+lo CD20lo CD5+ 
(44%; CLL) 
V3-30(D5-12)J4-M 
del(13q14.3) (80%) FSC/SSCloCD19+ loCD20lo CD5+ 
(0.3%; CLL-like MBLlow) 
V3-23(D6-19)J6-UM 
biallelic 
del(13q14.3) (73%) 
20 FSC/SSCloCD19+ loCD20lo CD5+ 
(35.6%; CLL) 
V4-34(D3-10)J6-M 
+12 (75%);  
 
FSC/SSCloCD19+ lo CD20lo CD5+ 
(0.5%; CLL-like MBLlow) 
V5-a(D6-19)J6-UM 
NDª 
 
21 FSC/SSClohi FMC7+ CD5- CD23- 
CD43- (5.2%; Non-CLLMZL) 
V4-61(D7-27)J4-M 
ND FSC/SSClolo FMC7- CD5+ CD23+ 
CD43+ (2.3%;  CLL-like MBLlow) 
V3-21(D2-2)J6-M 
ND 
22 FSC/SSClo+ CD5+ CD20lo CD79blo 
(6.4%; CLL-like MBLlow) 
V3-74(D3-10)J4-M 
NDª FSC/SSCloloCD5+ CD20lo CD79b- 
(0.6%; CLL-like MBLlow) 
V4-59(D3-10)J6-M 
ND 
23 FSC/SSCloCD19+ lo CD22lo CD23+ 
CD5+ (11.5%; CLL-like MBLhigh) 
V4-34(D5-24)J4-M 
ND FSC/SSCloCD19+ lo CD22lo CD23+ 
CD5+ (3.8%; CLL-like MBLhigh) 
V3-33(D6-19)J2-M 
 ND 
24 FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (21.1%;  CLL-like MBLhigh) 
V5-51(D5-5)J4-M 
+12 (93%) FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (8.7%; CLL-like MBLhigh) 
V4-30-4(D2-2)J4-M 
ND 
25 FSC/SSCloCD19+ lo CD5het CD20lo 
(17.8%;  CLL-like MBLhigh) 
V5-51(D3-3)J4-UM 
+12(76%);  t(14q32) 
(52%) 
FSC/SSCloCD19+ lo CD5lo CD20lo 
(2.6%;  CLL-like MBLhigh) 
V1-69(D6-13)J6-UM 
ND 
26 FSC/SSClo+ CD5+ CD20lo CD43+ 
(23%; CLL-like MBLhigh) 
V4-39(D3-3)J5-UM 
del(13q14) (15%);  
del(13q14.3) (15%) 
FSC/SSClolo CD5+ CD20lo CD43- 
(3.7%; CLL-like MBLhigh) 
V1-69(D5-5)J4-UM 
ND 
27¶ FSC/SSCloloCD20lo CD79blo CD5+ 
(10%; CLL-like MBLhigh) 
V3-7(D5-12)J3-M 
del(13q14) (98%);  
del(13q14.3) (98%) 
FSC/SSCloloCD20lo CD79blo CD5+ 
(0.6%; CLL-like MBLlow) 
V3-23(D6-6)J4-M 
ND 
28 FSC/SSCloCD19+ + CD5+ CD20lo 
CD22- (68%; CLL) 
V3-48(D4-17)J4-M 
del(13q14) (95%);  
del(13q14.3) (87%) 
FSC/SSCloCD19+  + CD11c+ 
CD5het CD20hi CD22+ (1.1%; Non-
CLL-like MBLhigh MZL) 
V1-69(D6-6)J4-M 
ND 
29¶ FSC/SSClolo CD19lo, CD20lo 
CD79b- CD43+ (36.4%; CLL) 
V3-48(D3-10)J4-M 
ND FSC/SSClohi CD19+, CD20hi 
CD79b+ CD43- (16.7%; Non-CLL 
MALT) 
V3-15(D4-17)J4-M 
del(17p13) (91%) 
30 FSC/SSCloloFMC7lo CD5+ CD79b- 
CD23+ CD43+ (33.7%; CLL) 
V4-34(D3-10)J4-UM 
t(14q32) (98%)  FSC/SSClo+ CD5- CD11c- 
FMC7hiCD79bhet CD23- CD43- 
(8.4%; Non-CLL MALT) 
V3-15(D6-6)J6-M 
ND 
31¶ FSC/SSCintlo CD23+ CD5+ CD11c+ 
(24%; CLL) 
V3-33(D2-15)J5-UM 
ND FSC/SSClolo CD5+ CD23het CD11clo 
(20%; CLL) 
V3-23(D5-12)J3-M 
ND 
32¶ FSC/SSCintCD19+ + CD20+ CD5- 
(17.7% Non-CLL MZL) 
V4-39(D6-19)J4-M 
ND FSC/SSCloCD19+ lo CD5+ CD20lo 
(3.2%;  CLL-like MBLhigh) 
V4-34(D6-19)J4-M 
ND 
33 FSC/SSCloCD19+dlo CD5+ CD20lo  
(65.3%; CLL) 
V2-26(D3-3)J5-M 
del(13q14.3) (81%) FSC/SSCloCD19hi+ CD5+ CD20hi 
(12.5%; Non-CLL MZL) 
V3-53(D2-15)J2-M 
t(14q32) (28%)  
34¶ FSC/SSClo+ CD19+ CD20hi CD22+ 
CD38- CD11c- CD25+ (65.8%; 
Non-CLL MALT) 
V3-7(D2-21)J4-M 
ND FSC/SSClo+ CD19+ CD20hi CD22+ 
CD38- CD11c- CD25+ (13.2%; 
Non-CLL MALT) 
V3-23(D2-2)J2-M 
ND 
35¶ FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (55.3%; CLL) 
V3-9(D3-3)J3-UM 
ND FSC/SSClolo CD20lo FMC7- CD5+ 
CD23+ (9.8%;  CLL-likeMBLhigh) 
V3-21(D2-2)J6-M 
ND 
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            SUPPORTING INFORMATION 
(Supplemental Table 3, continued) 
Case 
ID 
Phenotype of population 1  
(% from WBC; compatible 
diagnosis) 
V(D)J rearrangement-MS† 
iFISH 
Phenotype of population 2  
(% from WBC; compatible 
diagnosis) 
V(D)J rearrangement-MS† 
iFISH* 
36 FSC/SSCinthiCD5+ CD11c+ FMC7lo 
(46%; Non-CLL MZL) 
V1-2(D6-6)J5-UM 
ND FSC/SSClohi CD5- CD11c- FMC7hi 
(40.9%; Non-CLL MALT) 
V3-48(D1-26)J4-UM 
ND 
37¶ FSC/SSChi CD103+ CD25+ CD11c+ 
(21%; Non-CLL HCL) 
V3-30(D3-3)J5-UM 
NA FSC/SSCloloCD5+ (0.8%; CLL-like 
MBLlow) 
V3-11(D4-17)J6-M 
NDª 
38¶ FSC/SSCloCD19lo+ CD5+ CD20+ 
CD23- (38.6%; Non-CLL MZL) 
V3-21(D6-13)J6-UM 
+3q27 (89%) FSC/SSCloCD19hilo CD5+ CD20lo 
CD23+ (6.3%; CLL-likeMBLhigh) 
V3-48(D3-3)J3-M 
del(13q14.3) (18%) 
39 FSC/SSClolo CD19+, CD20lo 
CD79b- CD43+ (24%; CLL-like 
MBLhigh) 
V1-3(D3-3)J6-UM 
ND FSC/SSClolo CD19+ CD20lo FMC7- 
CD5+ CD23+ (14%; CLL-like 
MBLhigh) 
V3-9(D1-26)J4-M 
del(13q14.3) (65%); 
t(14q32) (31%) 
40¶ FSC/SSCloloCD20lo CD5+ CD22lo 
CD23+ FMC7- (46.7%; CLL) 
V3-33(D3-10)J6-M 
biallelic 
del(13q14.3) (95%)  
FSC/SSCloloCD20lo/het CD5+ 
CD22lo CD23+ FMC7- (43.1%; CLL) 
V3-21(D4-23)J4-M 
del(13q14.3) (30%) 
41 FSC/SSCintlo CD5+ CD19+ CD11c- 
(87.1%; Non-CLL MCL) 
V3-21(D3-3)J6-UM 
t(11;14) (97%) FSC/SSClo+ CD11chi CD19hi 
(1.3%; Non-CLL-like MBLlow MZL) 
V4-34/D3-10/J5-M 
ND 
CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; HCL, hairy cell leukemia; LPL, lymphoplasmacytic 
lymphoma; MZL, marginal zone lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MALT, B-cell 
lymphoma of mucosa-associated lymphoid tissue. + indicates antigen expression at normal levels; -, absence of 
expression; het, heterogeneous antigen expression; hi, high antigen expression; lo, low antigen expression; int, 
intermediate scatter; c, cytoplasmatic antigen expression. 
†
MS, mutational status (UM, unmutated; M, mutated), 
*FISH was performed on interphase nuclei from FACS-purified cells; ND: no chromosomal alterations detected by 
iFISH for the probes studied; NA: not analyzed. An additional B-cell clone (population 3) was detected by interphase 
FISH in case 2 (FSC/SSC
lo

lo
 CD23
lo
 CD5
lo
 CD43
lo
 CD11c
lo
; 0.7%, CLL-like MBL
low
; ND
a
), case 25 (FSC/SSC
lo
CD19+ + 
CD5
hi
 CD20
lo
; 2.4%, CLL-like MBL
high
; +12(66%)) and case 37 (FSC/SSC
lo

lo
 CD5+; 0.2%, CLL-like MBL
low
; NDª)
a
The 
percentage of B-cells from this subpopulation was very low and only allowed analysis for some iFISH probes (13q14, 
13q14.3, 17p13.1 and 11q22.3). Genetic abnormalities present in one population were always evaluated also in the 
other coexisting population. 
¶Cases whose clones had IGHV aa sequences phylogenetically closer than those found in the rest of multiclonal 
cases. 
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   SUPPORTING INFORMATION 
Supplemental Table 4. Peripheral blood B-cell counts and BCR features of multiclonal versus 
monoclonal CLL-like and non-CLL-like B-cell clones. 
 CLL-like B-cells Non-CLL-like B-cells 
 
Multiclonal B-cells 
n=66 clones 
Monoclonal B-cells 
n=128 clones 
Multiclonal B-cells 
n=19 clones 
Monoclonal B-cells 
n=15 clones 
N. of PB clonal B cells (x10
6
/L)* 2,675 (0.6-71,485)a 10,956 (0.1-369,288) 4,375 (85-156,168) 4,771 (54-41,221) 
% of PB clonal B cells from WBC* 13% (0.1%-89%)a 45% (0.001%-97%) 13% (0.5%-87%) 41% (1%-73%) 
MBL
low
 B-cell clones 14/66 (21%)a 13/128 (10%) 3/19 (16%) 2/15 (13%) 
MBL
high
 B-cell clones 26/66 (39%)a 26/128 (20%) 2/19 (10%) 2/15 (13%) 
CLL B-cell clones 26/66 (39%)a 89/128 (69%) NA NA 
CLL-stage A clones 12/66 (18%)a 53/128 (41%) NA NA 
CLL-stage B/C clones 8/66 (12%)a 36/128 (28%) NA NA 
Non-CLL B-cell clones NA NA 14/19 (74%) 11/15 (73%) 
IGHV mutated B-cell clones 40/66 (61%) 76/124 (61%) 11/19 (58%) 8/15 (53%) 
% alignment of IGHV aa 
sequences between coexisting  
B-cell clones 
51% (38%-79%) NA 62% (46%-76%)# NA 
% alignment of IGHV aa 
sequences between each B-cell 
clone and the other clones 
52% (31%-100%)a 50% (29%-100%) 51% (32%-89%)a 49% (33%-86%) 
Results expressed as number of B-cell clones and percentage between brackets or as *median value (range). 
PB, peripheral blood; WBC, white blood cells; CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; 
MBL
low
, low count monoclonal B-cell lymphocytosis; IGHV, immunoglobulin heavy chain variable region genes; 
CLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MBL
high
, clinical monoclonal B-cell 
lymphocytosis; aa, amino acids. NA, not appropriate.
#
Both coexisting B-cell clones showed Non-CLL-like 
phenotype (n=4 cases) or the majority B-cell clone showed Non-CLL-like phenotype (n=4 cases). 
a
Statistically 
significant differences (P <0.05) found between clones from multiclonal vs. monoclonal cases. 
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            SUPPORTING INFORMATION 
Supplemental Table 5. Cytogenetic features of non-CLL like B-cell clones from monoclonal cases. 
Clone type Type of cytogenetic changes / % aberrant B-cells analyzed by iFISH 
Non-CLL-like MBL
high 
(MZL) trisomy 12
+
 (80%); and  t(14q32)
+
 (35%) 
Non-CLL (FL) del(13q14.3)
+
 (18%); 3 copies of IGH gene (85%)*
 
Non-CLL (FL) t(14;18)
+
 (89%); and t(8;14)
+
 (78%); polysomy 
Non-CLL (MCL) t(11;14)
+ 
(93%) 
Non-CLL (MALT) t(14q32)
+ 
(94%) 
Non-CLL (MZL) t(14q32)
+
 (94%); 3 and 4 copies of IGH gene (53% and 37%, respectively) 
Only cytogenetically altered clones are shown; cytogenetically non-altered clones from monoclonal cases included non-CLL MZL (n=5; 2 
MBLlow, 1 MBLhigh and 2 MZL), MALT-lymphoma (n=1), MCL (n=1), DLBCL (n=1) and LPL (n=1). CLL, chronic lymphocytic leukemia/small 
lymphocytic lymphoma; MBL, monoclonal B-cell lymphocytosis; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; LPL, 
lymphoplasmacytic lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone B-cell lymphoma; MALT, B-cell lymphoma of mucosa-
associated lymphoid tissue; * t(14;18)+ by molecular studies; ND, not detected ; NA, not analyzed. 
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   SUPPORTING INFORMATION 
Supplemental Table 6.  Monoclonal cases with B-cell clones sharing HCDR3 sequences of the 
same length (± 1 amino acid) and belonging to identical or evolutionary highly-related VH 
families. 
Monoclonal Case 
 ID 
VH families RDCH3 
htgnel 
aa composition of HCDR3 (% homology)# 
149 V3-48 8 _WIDRGRLRSC_ 
(25) 
158 V3-11 8 _WYDGSYFRAC_ 
66 V3-7 9 _WIDRYVYARGC_ 
(44) 
136 V3-7 9 _WYDGWYGARGC_ 
113 V3-74 9 _WRQLDMYSLAC_ 
(11) 
121 V3-64 9 _WVDRTGMDVAC_ 
92 V3-23 12 _WYLDGRQLWSYAKC_ 
(33) 
153 V3-23 12 _WIFDDGFTKDVAKC_ 
16 V1-2 13 _WIFDGLNTDYGAARC_ 
(31) 
18 V1-2 13 _WYFDAQWLVLENARC_ 
201 V4-34 13 _WFLDRGFHWGGYYAC_ 
(23) 
206 V4-34 13 _WPFDTNSRESQGWAC_ 
190 V4-34 14 _WYDIRYYDFSAPAPAC_ 
(29) 
214 V4-34 14 _WYTLIGDKGGYYVRAC_ 
205 V4-59 14 _WYLDNGGWPDISARGC_ 
(50) 
218 V4-61 14 _WPGWFDDHGEGRYAKC_ 
124 V3-23 14 _WDIQPNAFIKFYDDAC_ 
(29) 
145 V3-23 14 _WDFSCYGVIFHCCRAC_ 
24 V1-2 15 _WSFDSQGSRDLEMRYAC_ 
(60) 
35 V1-2 15 _WYFDLQGWRDVELRYGC_ 
125 V3-7 16 _WLDFTARYLPYADLASAC_ 
(31) 
147 V3-7 16 _WYESSISTTSCPSCQSGC_ 
105 V3-23 16 _WYFDADGYGGTPRDKDTC_ 
(35) 
142 V3-23 17 _WIFDTDVIQKTRTLAKDAC_ 
142 V3-23 17 _WFDIRTLATVIQKDTAKDC_ 
(35) 
104 V3-23 18 _WFDILPSTYNWNSGGAAKDC_ 
151 V3-30 17 _WDYFILPPGVGGIASGSMC_ 
(18) 
120 V3-30 18 _WAIFSWNDACSSMTRPHCSC_ 
132 V3-30 19 _WVGMDEFRYYLDFGMAGKIAC_ 
(37) 
150 V3-30 19 _WSDGGIGTCCQGLDTSGNRAC_ 
96 V3-21 20 _WYYGMDVATGHSHHPVRESRAC_ 
(45) 
155 V3-48 20 _WYYGMDVGYPDSSPGYDFWARC_ 
196 V4-34 20 _WVLDYYGYYTERRYYPSDVRGC_ 
(40) 
202 V4-34 20 _WYFDPFPYYGSGSYLIGAARGC_ 
198 V4-34 20 _WVMDYYGYYRRTEGSTGYARGC_ (50) 
202 V4-34 20 _WYFDPFPYYGSGSAYGLIARGC_  
155 V3-48 20 _WYYGMDVPDYDFWSGYSPGARC_ (71) 
130 V3-48 21 _WYYGMDVYSYYYYDFWSGYDARC_  
96 V3-21 20 _WVMDYGYGHTASHHPVRESARC_ (35) 
114 V3-21 21 _WYFDTTLYSCTSSEGGLGYCARC_  
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            SUPPORTING INFORMATION 
(Supplemental Table 6, continued) 
Monoclonal Case 
ID 
VH families RDCH3 
htgnel 
aa composition of HCDR3 (% homology)# 
130 V3-48 21 _WVMDGYYYYYSYGYWSFYDARDC_ 
(48) 
114 V3-21 21 _WYFDTTLYSTSCSCLGYGGAREC_ 
22 V1-69 21 _WMDVGYYYYYYTGVAGVVYAREC_ 
(67) 
39 V1-69 21 _WGYYYYYYYMDVLMTNWGTARDC_ 
22 V1-69 21 _WMDVYYYYYGGTYAVGYEVVARC_ 
(48) 
31 V1-69 21 _WFDIARPNDGSYWIDYYGGNARC_ 
31 V1-69 21 _WFDIRPNDAYSWGNYDYIGGARC_ 
(43) 
39 V1-69 21 _WMDVYYYYYYYWGLMTNGDTARC_ 
143 V3-30 21 _WYFDSHGTYYYDNSHGPNVSARC_ 
(28) 
138 V3-30 22 _WVMDDGGDFWSGYYYDLKTAYARC_ 
114 V3-21 21 _WYFDTTLCYSSTSCLGYGGAREC_ 
(42) 
110 V3-21 22 _WPFDNWYLEDPLNFDWGRRNARDC_ 
114 V3-21 21 _WYFDTTLCYSSTSCGYLGGEARC_ 
(42) 
157 V3-21 22 _WVMDYYYGIYMEGLSAWLLRARGC_ 
110 V3-21 22 _WPDNWFYPLDEWLRNGNFDRDARC_ 
(36) 
157 V3-21 22 _WVDYYYGMYGIELMWLLSARGARC_ 
110 V3-21 22 _WPFDYNWLLEDPWDFNGNRRARDC_ 
(41) 
93 V3-11 22 _WYFDPDDKLSGYYFWYYDRPARDC_ 
157 V3-21 22 _WVMDYYGYYIGGRLSAWLLMEARC_ 
(32) 
93 V3-11 22 _WYFDLPDDKGYYDPRYYDFWSARC_ 
26 V1-69 22 _WDVMGYYYYTVYITIFGVVTTTAC_ 
(32) 
34 V1-69 22 _WQHYFGVAESVYSTYYYDSSRGAC_ 
26 V1-69 22 _WYYGMDVYYYTVVVFGTTTITIAC_ 
(50) 
27 V1-69 23 _WYYGMDVNTVYSGSWDFRADGGYAC_ 
34 V1-69 22 _WEYFQHAGVYYYDSSVYGSSTARC_ 
(23) 
27 V1-69 23 _WNYYGMDVVSTYDFWSGYADGGARC_ 
129 V3-11 23 _WYYYYGMDVRRDDFWSGYRIYARDC_ 
(48) 
141 V3-48 23 _WYYYYGMDVNTANDIVVVPADARDC_ 
27 V1-69 23 _WMDVGYYNVYSTYDFWSGGGARADC_ 
(69) 
15 V1-69 24 _WMDVYYYYDVHKGYDFWSGQYARAEC_ 
Amino acids with an analogous side-chain polarity (highlighted in gray): L,F; A,V; I,L; K,R; L,V;  L,M; L,C; T,S; A,I; 
D,E; I,M; V,C; L,F; M,F; I,V; H,Y; I,C; F,W. #Number of aa with an analogous side-chain polarity (excluding the 
delineating C_ and _W positions)/HCDR3 length*100. 
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   SUPPORTING INFORMATION 
Supplemental Table 7. Haematological features of B-CLPD cases who received chemotherapy. 
 No. of case Abs. No. Clonal B-cells (x106/L) Binet Stage MAP 
Monoclonal Subjects 33 12 640 A Yes 
 34 23 134 C No 
 35 5 314 B No 
 36 44 428 B Yes 
 37 18 600 B Yes 
 38 29 376 B Yes 
Multiclonal Subjects 5 
Clone A: 11 724 
Clone B: 2 078 
B Yes 
 26 
Clone A: 49 600 
Clone B: 350 
B Yes 
 39 
Clone A: 5 438 
Clone B: 158 
C No 
 40* 
Clone A, HCL: 1 029 
Clone B, CLL-like MBLlow: 39 
Clone C, CLL-like MBLlow: 10 
- No 
*This case corresponded to a hairy cell leukemia patient. Gray shadowed clonal B-cells represent multiclonal B-CLPD cases with 
stereotyped CLL-like B-cell clones. CLL, chronic lymphocytic leukemia; MBL, monoclonal B-cell lymphocytosis; HCL, hairy cell 
leukemia; B-CLPD, B-cell chronic lymphoproliferative disorders; MAP, myelodysplasia-associated phenotype; -, not applicable. 
 
 
 
 
